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ABSTRACT 
CARLOS M. GONZÁLEZ: Viral Modulators of KSHV Lytic Replication 
(Under the direction of Blossom Damania) 
 
Kaposi’s Sarcoma and the B-cell derived primary effusion lymphoma and 
multicentric Castleman’s Disease are all outcomes of infection with Kaposi’s Sarcoma–
associated Herpesvirus (KSHV). A predominantly latent virus, KSHV also requires a 
subpopulation of cells to undergo lytic reactivation in order to generate an environment 
conducive to neoplastic growth. The replication and transcription activator (RTA, Orf50) is 
necessary and sufficient to initiate the lytic cascade. We have studied two modulators of lytic 
replication encoded by KSHV Orf49 and Orf64 that support RTA during lytic reactivation. 
KSHV Orf49 lies adjacent to and in the opposite strand as Orf50. Upon ectopic 
expression, Orf49 was found to encode a 30 kDa protein that localized to the cytoplasm and 
nucleus. The Orf49 transcript displayed early lytic kinetics and was shown to enhance RTA-
mediated transactivation of lytic promoters including vGPCR, K8 and Orf57. Orf49 induced 
c-Jun, JNK and p38 kinase activation. Pharmacologic inhibition demonstrated that activation 
of the c-Jun and p38 signaling pathways are required for the completion of the lytic cycle, 
underscoring the importance of KSHV Orf49 during lytic replication. 
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KSHV Orf64 encodes a large, 2636 amino acid tegument protein. We have found that 
Orf64 encodes deubiquitinase (DUB) activity in its amino-terminal 200 amino acids in vitro 
and in vivo. Whereas all other herpesviral DUBs cleave Lysine 48 (K48)-linked ubiquitin, 
KSHV Orf64 was capable of cleaving both K48 and K63-linked ubiquitin chains. Cleavage 
of K63-linked ubiquitin is associated with functional regulation whereas K48-ubiquitination 
leads to proteosomal degradation. Mutation of a cysteine residue at amino acid position 29 in 
the catalytic core of the DUB ablated DUB activity. Orf64 also synergized with RTA to 
augment transcription from RTA-responsive promoters. These data suggest that the 
deubiquitination function of Orf64 may play an important role in viral replication. 
The role of NFκB pathway activation on KSHV pathogenesis in unclear. Various 
members of this pathway are regulated by ubiquitination and represent potential targets of 
Orf64. Reactivating KSHV-293 cells selectively activated the canonical NFκB pathway. We 
discovered that Orf64 induced degradation of IκBα and IKKγ suggesting that it can induce 
the canonical pathway, highlighting the multiple roles and functions of Orf64. 
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Kaposi’s Sarcoma 
Austro-Hungarian physician Moritz Kaposi worked for two years in the University of 
Vienna’s syphilis clinic before deciding to change to dermatology. In the General Hospital’s 
School of Dermatology and during the years 1868 and 1871 he treated 5 patients, all male 
and over 40 years of age, for what he called “idiopathisches multiples pigmentsarcoma der 
haut” or ‘idiopathic multiple pigmented sarcoma of the skin (26). In his seminal 1872 paper 
he described the lesions as “Nodules the size of peas or hazelnuts, brown-red to blue-red in 
colour. They are either isolated or form groups; in the latter case, the central nodules of a 
plaque retrogress and generate a pitted, dark-pigmented depression.” He notes that the lesions 
typically appear first on the feet and hands and later appear on the upper extremities, trunk, 
and face. “…Finally, identical nodules appear on the mucous linings of the larynx, trachea, 
stomach, intestines and liver. The disease is rapidly lethal, within two or three years.” Dr. 
Kaposi determined it to be a systemic disease based on the simultaneous appearance of 
nodules on both feet and hands. The disease is now known as Kaposi’s sarcoma or KS. 
The KS lesion is composed mostly of proliferating spindle cells and is highly 
vascularized. The cellular lineage of these spindle cells is now thought to be endothelial or 
vascular endothelial in origin (55, 60, 127, 131). However, the lesion itself is complex and 
includes other cell types such as macrophages and inflammatory cells.  
The clinical course of disease exhibits a wide spectrum which ranges from slow and 
indolent to rapid and fulminant with metastatic dissemination. Tissues involved include the 
skin (limbs, trunk and face), gastrointestinal tract (17, 29, 138) or respiratory tract (95, 114) . 
Today, the range of disease is classified as four distinct clinical types of Kaposi’s sarcoma. 
Classic KS affects older men of Jewish and Mediterrenian backgrounds and represents the 
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type observed by Dr. Kaposi. The disease is mostly indolent, slow and characterized by 
lymphedema, and venous stasis followed by painful swelling of the hands and feet in the 
latter stages. Secondary malignancies develop in nearly thirty percent of Classic KS patients 
(56). 
The second clinical type known as ‘Endemic KS’ mostly involves younger men and 
boys from tropical and southern Africa. Endemic KS presents with a far more aggressive 
disease and is associated with a high fatality rate (146). It also results in a widely varied 
neoplastic disease across central Africa and is characterized by involvement of multifocal 
mucocutaneous, lymphatic and visceral tissues (142, 147). Aggressive endemic forms of KS 
have been documented in children from central Africa (9, 166). A known risk factor for the 
Endemic subtype of KS is exposure to high levels of iron (167). Iron-rich soils in central 
Africa tightly correlate with a much higher incidence of endemic KS and the appearance of 
KS in the feet and lower legs, the areas in regular direct constant contact with the soil (167). 
Iatrogenic or post-transplant KS is characterized by the onset of KS after solid organ 
transplants. Up to forty-five percent of patients will develop KS in the viscera in an average 
of 30 months post-transplantation (122). The development of post-transplant KS carries a 
poor prognosis (63, 122). Treatment includes altering or discontinuing the immuno-
suppresive therapy and chemotherapeutics like paclitaxel (Taxol) (59, 120).  
The advent of the AIDS epidemic also brought a sharp increase of KS cases 
particularly among HIV-infected homosexual men. The fourth and most widespread form of 
the disease is knows as Epidemic or AIDS-related KS. Epidemic KS is the most prevalent 
neoplasia in the HIV-positive population and is now recognized as an AIDS-defining illness, 
particularly in homosexual men. Up to fifteen percent of HIV-positive homosexual males 
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will develop AIDS-related KS (16). Epidemic KS is also the most aggressive form of KS, 
achieving a high degree of occurrence in heterosexual adults in developing nations like 
Africa and lower occurrence in children (16).  
Kaposi’s Sarcoma-Associated Herpesvirus 
The exponential increase in KS cases during the 1980s suggested that KS could be 
transmitted by an infectious agent. Bacterial (74), chemical (115) as well as viral (71-73, 119, 
152) culprits were considered including human cytomegalovirus (hCMV) and HIV. 
 Identification of the actual infectious agent was first accurately reported by Chang, et 
al in 1994 (41). Using representational difference analysis they found herpes-like sequences 
in KS biopsies that were specific to KS tumors when compared to normal tissues. The 
sequences were most closely related to Herpesvirus Saimiri (HVS) a gammaherpesvirus that 
induces lymphoma in New World monkeys and less so to Epstein-Barr Virus (EBV). Based 
on the limited homology to herpesviruses the authors proposed that the causative agent of KS 
represented a herpesvirus that was related, but distinct, from previously known herpesviruses. 
This etiologic agent of KS was named Kaposi’s Sarcoma Associated Herpesvirus, or human 
herpesvirus eight (HHV8). 
KSHV-related diseases   
KSHV has since been shown to be present in all forms of KS lesions (21). More 
recently KSHV has also been implicated as the etiologic agent of two lymphoproliferative 
diseases; Primary Effusion Lymphoma (PEL) and Multicentric Castleman’s Disease (MCD).  
Primary Effusion lymphoma or body cavity-based lymphomas (BCBL) have been 
shown to be ninety-eight percent infected with KSHV (39). EBV is usually also present 
although co-infection is not essential and the role of EBV in the development of PEL is not 
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clear (34). PEL is a non-Hodgkin’s, diffuse-large B-cell lymphoma of clonal origin. It is 
characterized by liquid growth in the visceral cavities of the pleura, peritoneum and 
pericardium. An HIV-positive status and homosexual behaviors are two prominent risk 
factors. Upon development of PEL most patients face a negative prognosis, with a mean 
survival time between three to six months post-diagnosis (42). 
Multicentric Castleman’s Disease (MCD) is a multifocal hyperplasia of polyclonal 
origin that is clinically characterized by systemic manifestations. These include fever, 
weakness, generalized lymphadenopathy, and hyper-gamma-globulinemia which are due in 
part to raised serum concentrations of interleukin 6 (75, 117). Exacerbation of the disease 
correlates with an increase in KSHV viral loads in peripheral blood mononuclear cells 
(PBMCs). Patients also suffer from cytopenias, rashes, and recurrent infections and some 
have been reported to develop non-Hodgkin lymphoma.  KSHV-associated MCD is in most 
cases refractory to corticosteroids and chemotherapy. The resistance of MCD to systemic 
treatments makes MCD potentially lethal. 
Epidemiology 
KSHV seroprevalence varies widely and is not as widespread as that of other herpesviruses. 
In African regions where KSHV is endemic, fifty to seventy percent of individuals may be positive 
(76, 135). The incidence of KS roughly correlates with seroprevalence of the disease. However, gross 
disparities between seroprevalence and incidence in certain populations point to the importance of 
other potential aggravating factors in the progression from KSHV infection to KS (148). 
Although there are data documenting the sexual, horizontal, and parental transmission 
of KSHV, evidence defining the mode of KSHV transmission has thus far been elusive. Men 
who have sex with men have a markedly increased prevalence of infections which further 
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increases with the number of male partners (35, 38). Pre-existing sexually transmitted 
diseases (STDs) and intravenous drug use increase the likelyhood of infection. The risk of 
developing KS is also significantly increased with HIV co-infection (109). These data 
suggest that sexual transmission may be a viable route of infection. However, heterosexual 
couples have a low degree of prevalence (143) that is thought to be due to KSHV being 
poorly infectious (25, 78). Interestingly, saliva seems to be a more infectious body fluid than 
semen. KSHV viral load in semen from HIV-positive or HIV-negative patients is low (84) 
while viral loads in saliva can be quite high (121). Moreover, transmission via salivary 
secretions has been documented (154). 
 Areas with endemic KSHV produce cases where virus shedding occurs from the 
oropharynx of immunocompetent and immunocompromised men and women alike (36, 37, 
151). In these areas transfusion recipients show an increased risk of KSHV transmission (33, 
83). In addition, transmission of KSHV through solid organ transplants has also been 
documented (12, 106). Transmission through exposure to saliva has been shown between 
mother and child, and between siblings (108, 125).  
Disease Manifestations of Human Herpesviruses  
Herpesviruses are enveloped DNA viruses with large coding capacities ranging from 
100 to over 200 open reading frames. These viruses establish slow-progressing, life-long 
infections in their host, thus their name herpes from the Greek herpein meaning “to creep”. 
Herpesviruses have been classified into three families, Alpha, Beta and Gamma (Fig. 1). The 
Alpha Herpesviruses include herpes simplex type-1 (HSV-1), herpes simplex type-2 (HSV-2) 
and Varicella zoster virus (VZV). HSV-1 and HSV-2 are responsible for herpetic lesions of 
the oral mucosa and genitalia, respectively. Varicella zoster is the etiologic agent of chicken  
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Figure 1. Classification of herpesviruses. A phylogenetic tree depicting the alpha, beta, and 
gamma subfamilies of herpesviruses. The phylogram is unrooted and was constructed by 
parsimony analysis using the viral DNA polymerase gene and the neighbor-joining method. 
The scale shown below the tree represents number of amino acid changes. (Taken from 
Damania and Jung (46).) 
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pox as well as shingles, which is associated with reactivation of VZV. The prototype for 
alpha-herpesviruses, HSV-1, infects epithelial cells on the mouth and lips and travels to the 
dorsal root ganglion where it can establish a latent infection. From there it periodically 
reactivates and infects innervated epithelial cells. 
Human Cytomegalovirus or HCMV causes disease in small children, unborn babies 
and transplant recipients. HCMV belongs to the beta family of herpesviruses as does HHV-6 
and HHV-7. HCMV infection is a leading cause of birth defects and a major cause of 
morbidity and mortality in immune-compromised individuals (48, 66). HCMV prevalence 
can be found world-wide. Disease manifestations in immune-compromised patients include 
infectious mononucleosis, pneumonia, hepatitis, CNS involvement (Guillain-Barré 
syndrome) aseptic meningitis, and immunologic abnormalities. In contrast, the immune-
competent host has a mostly asymptomatic infection.  
Gamma-herpesviruses are further classified into two subclasses, the genus 
lymphocryptovirus (Gamma-1) and the genus rhadinovirus (Gamma-2). While KSHV 
belongs to the rhadinovirus or gamma-2 grouping of herpesviruses, Epstein-Barr Virus 
(EBV) is the archetypal lymphocryptovirus and can be found world-wide. EBV can cause a 
wide range of B-cell lymphoproliferative disorders, including Burkitt lymphoma (BL), 
classic Hodgkin lymphoma (HL), and lymphomas arising in immune-compromised 
individuals (post-transplantation and HIV-associated lymphoproliferative disorders (49, 161).  
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Lifecycle of Herpesviruses: Latency and Lytic replication 
 Herpesviruses are distinguished from other viruses by their inherent ability to exist in 
bimodal replicative states. The herpesviral characteristic state is that of latency which 
alternates with the state of productive lytic replication. Herpesviral infection of the host cell 
is initiated by specific interactions between viral envelope proteins and cell surface receptors 
as well as non-specific binding to heparin sulfate moieties. In the case of KSHV, integrin 
alpha3beta5 has been identified as a cellular receptor (3). The initial binding of virus to 
receptor triggers fusion of the viral and plasma membranes which liberates the virion into the 
cytoplasm. Once inside the cell, the virion proteins are shed allowing the linear viral genome 
to circularize and travel to the nucleus. After nuclear entry the viral genome can go into 
either lytic replication or latency.  
Lytic Replication  
Productive lytic replication is characterized by replication of viral genomes, followed 
by assembly and release of viral progeny resulting in cell lysis. However, these processes 
occur in a succession of steps dictated by a highly-coordinated set of transcriptional waves 
known as immediate early (IE), early (E) and late (L). The temporal regulation of 
transcription ensures that the IE, E, and L proteins required at each step are available when 
needed. Moreover, uncontrolled expression of all viral ORFs would be massively inefficient 
and counterproductive to viral replication and survival.  
The initial or IE class of transcription is limited to viral proteins that transactivate 
other viral promoters thereby setting the stage for the next wave of cellular and viral 
transcription. Early genes are mostly involved in viral DNA replication and include the six 
conserved core replication proteins: DNA polymerase, processivity factor, helicase, primase, 
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primase-associated factor, and a ssDNA binding protein. These in addition to the IE protein 
KSHV RTA and K8 are required for the replication of the viral genome from two distinct 
origins of lytic replication (ori-lyt) (AuCoin-04Virol). The protein complexes formed on 
these ori-lyts mediate replication via the rolling circle mode characteristic of herpesviruses. 
After the onset of viral DNA replication, the L genes are transcribed which code for 
the structural components of progeny virions. Once L proteins have been expressed the 
nascent virions are assembled in the nucleus, and start to egress. During egress the capsids 
will acquire an array of viral and host proteins known as the tegument, which decorate the 
outer capsid. The capsid and tegument then acquire an outer membrane embedded with viral 
glycoproteins. Mature virions reach the plasma membrane and are released to infect 
neighboring cells.  
Latency 
The latent state is defined by the expression of a very limited complement of viral 
proteins. This small group of viral gene products protects the virus from antigen presentation 
and the immune response, while also stimulating cell cycle progression. Latency transcripts 
include LANA, viral cyclin (vCyclin), a viral FLICE inhibitor (vFLIP), viral interferon 
regulatory factors 1 and 3 (vIRF-1 and vIRF-3) in endothelial and B cells, respectively (57, 
126), K15 (140), kaposin or K12 (132), and the viral microRNAs (31). The viral genome 
persists as a circle termed an episome which is tethered to the host chromosome. The latency-
associated nuclear antigen (LANA) binds the viral genome at its terminal repeats (10) and the 
host chromosome (124) via histones H2A/H2B (11). This two-fold interaction of LANA with 
the viral TR and the host chromosome ensures that the viral episome segregates to daughter 
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cells after mitosis. During latency the viral genome is replicated by the cellular machinery 
and LANA is essential in this respect as well (141).  
Reactivation 
Certain stimuli can trigger latent cells to undergo reactivation. Reactivation generally 
results in the viral genome entering the lytic phase of replication, although at time this may 
be abortive rather than complete replication. Latency allows for viral persistence and evasion 
of immune surveillance, but reactivation is viral replication and dissemination to new cells 
and tissues. Although latent virus can be reactivated in vitro by phorbol esters (TPA) (105) or 
histone de-acetylase (HDAC) inhibitors (N-butyrate), the in vivo factors that act as triggers of 
reactivation remain elusive. Reactivation is enhanced by immune-deficiencies and hypoxia 
may be another such factor. Expression of the lytic switch protein, RTA, is induced under 
hypoxic conditions (30, 47, 81). This finding correlates very well with the fact that classic 
KS develops first in the feet and hands, sites where older patients frequently show poor 
circulation. Solid tumors also face the prospect of hypoxia as the tumor grows and requires 
more nutrients and oxygen. It is possible that in this scenario hypoxia induces reactivation of 
some KSHV-infected cells and may contribute to the neoplastic process.  
The Viral Genome  
The KSHV genome resembles a typical herpesvirus genome in its large size of nearly 
140-150 kilobase pairs (kb). However, unlike most herpesviruses there is a single unique-
long region and no unique-short region. The unique-long region is flanked by 20-35 kb of 
terminal repeat (TR) sequences. The terminal repeats consist of high G+C content, 801 bp 
repeats (130). Conserved, core replication genes are concentrated towards the center of the 
genome where there is less recombination-mediated variability. Less conserved and unique 
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genes tend to be located towards the ends where rates of recombination are higher (Fig. 2). 
There are close to eighty open reading frames encoded by KSHV. The functions for most 
ORFs have been predicted from sequence homology to proteins from other herpesviruses and 
most ORFs have had some empirically-confirmed function. Still, some ORFs remain to be 
functionally described. The KSHV genome includes core herpesviral genes, KSHV-specific 
genes and genes that are homologous to cellular gene. These viral homologs have most likely 
been “stolen” from the host in what is referred to as “molecular piracy” (111). The virus has 
altered these genes in order to subvert host control mechanisms and thus modify the cellular 
environment to suit its particular needs. Cellular homologs in KSHV include a viral cyclin 
(vCyclin), viral FLICE inhibitor (vFLIP), viral bcl-2 (vbcl-2), viral IL-6 (vIL-6), four viral 
IRFs (vIRFs), two viral MIPs (vMIP1 and 2), and a constitutively active G protein-coupled 
receptor (vGPCR). They mediate viral-induced disruption of cell cycle progression and 
cellular signaling pathways, and can also down-modulate the immune response. 
Model Systems  
Early in vitro studies of KSHV have been carried out in a variety of cell lines 
originating from PEL malignancies. PEL-derived B-cell lines maintain the viral episome 
indefinitely and are one hundred percent infected with KSHV (8, 21, 32, 68, 82, 91). The 
establishment of these cell lines requires transformation for in vitro adaptation. In these cells 
latency is the norm. However, a small subset of cells (about five percent) 
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spontaneously enter productive lytic replication. Lytic reactivation can be induced in these 
cell lines by ectopic expression of RTA or chemical treatments such as phobol ester or 
HDAC inhibitors (104, 128). The proportion of cells that are induced is nonetheless quite 
low, peaking at twenty percent. Thus, the study of KSHV reactivation and pathogenesis in 
this system has been performed in the presence of a high degree of background latency. 
Likewise, the study of latency is hampered by the small degree of spontaneous lytic 
reactivation that occurs with these cell lines. Moreover, because they are already 
transformed, this system cannot help to delineate the mechanism of KSHV-induced 
transformation. 
Endothelial cells (EC), believed to be the primary target of de novo infection and the 
precursors of spindle cells, have been shown to be infected and transformed by KSHV in 
vitro (7, 65). These cells also displayed the classic markers of KS and the development of the 
characteristic spindle cell morphology.  However, immortalized ECs as well as primary ECs 
infected in vitro quickly switch to a latent state and shed the viral episome making this 
system inadequate for the study of lytic replication and transformation. B-cell lines either 
established or primary can be infected in vitro but cannot maintain the episome after 
extended passages (13, 18). Intriguingly, cell lines established from KS lesions are also 
unable to maintain the viral episome (5, 6, 14, 98, 144).  
 Limits in existing cell culture systems have hampered the study of viral replication 
and transformation. The development of a bacterial artificial chromosome (BAC) system for 
KSHV (163) has proved to be useful in allowing the study of individual ORFs in the context 
of the whole viral genome (94, 159, 160). In addition, this system makes possible the 
engineering of viral genomes that generate live recombinant viruses. With live recombinant 
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viruses we are now able to explore the contributions of individual genes to the biology of the 
entire virus.  
Previously, studies of individual ORFs were limited to cloning and over-expressing 
ORFs in the absence of the viral genome. This approach can delineate the effects of 
individual proteins only if they are capable of acting in the absence of other viral proteins. 
Cooperative actions of several ORFs or all ORFs encoded by the viral genome are 
cumbersome and inefficient to study this way. Moreover, since these experiments are also 
confined to tissue culture systems, these types of experiments cannot predict how the gene or 
genes under study will affect host pathogenesis. 
 Model animal systems for KSHV are lacking. The extent of animal use for KSHV 
research has been limited to recombinant inbred mice. Xenograft injection of KSHV infected 
B-cells (BCBL-1 or BCP-1) into NOD/SCID and PEL cells into C.B.17 SCID mice (21, 45, 
123, 145) have been documented. In addition, human cells or tissues have been 
transplantated into mice and have been shown to develop human, KSHV-specific antibodies 
and identified CD34+ hematopoietic progenitor cells (HPC) as a possible reservoir for KSHV 
infection (44, 58, 67, 118, 158). Daily systemic treatment with Azidothymidine (AZT) and 
IFN-alpha curtailed viral replication and increased mean survival times in these animals. 
 Other animal studies have managed to recapitulate several key features of the KS 
tumor. Normal mouse bone marrow-derived endothelial cells (mECs) transfected with the 
KSHV BAC were injected into nude mice. The xenograft generated vascularized spindle cell 
sarcomas which result in KS-like tumors with overexpression of VEGF and Angiopoietin 
ligands and receptors. In spite of this, the infection was nonproductive and reverted to 
nontumorgenicity once the viral genome was lost (113).  
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Finally, although progress has been made in the in vitro and in vivo fronts, we are still 
lacking a robust animal model system for the study of KSHV-induced tumorgenesis. Mice, in 
addition to being inbred and thus not representative of a heterogeneous human population, 
are only distantly related to humans. A better, more closely related animal system like non-
human primate would be best, although significantly more costly. 
RRV 
Another member of the gamma-2 or rhadinovirus sub-family is Rhesus monkey 
rhadinovirus (RRV). Immunocompromised rhesus macaques infected with RRV develop 
diseases that resemble KSHV-associated multicentric Castleman's disease and non-Hodgkin's 
lymphoma. Rhesus macaques are naturally infected with RRV.  
In 1997, the New England Primate Research Center (NEPRC) and the Oregon 
Regional Primate Research Center (ORPRC) practically simultaneously reported the 
discovery of two distinct strains of a monkey rhadinovirus termed rhesus monkey 
rhadinovirus or RRV (strains H26-95 and 17577, respectively) (15, 53). The H26-95 strain 
was isolated from primary rhesus fibroblasts exhibiting cytopathic effects (CPE) after co-
culture with PBMCs from healthy rhesus macaques. Strain 17577 was isolated from an SIV-
infected macaque presenting with a lymphoproliferative disease. Both strains were fully 
sequenced less than three years after their discovery (4, 136). 
In culture, rhesus fibroblast (RhF) infection with RRV is completely lytic. After de 
novo infection, the virus is replicated and progeny virus is released until every cell in culture 
is killed. RRV infection generates CPE and is susceptible to plaque assays since it kills RhF. 
Virus production and titers are high compared to other gamma-herpesviruses reaching up to 
106-107 plaque forming units (PFU) per ml. The high rate of lytic replication also allows the 
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manipulation of the viral genome and establishment of different assays to measure viral 
replication (54). The advent of BAC-assisted RRV genome (61) now allows more convenient 
manipulation of the viral genome for further study. 
As discussed previously, efforts to investigate KSHV pathogenesis have been 
hampered by the virus’ slow growth kinetics, limited infectivity in cell culture and lack of an 
animal model. RRV, in contrast can grow to high titers in cell culture of RhF and naturally 
infects rhesus macaques. Moreover, The RRV genome shows a high degree of homology and 
colinearity with the KSHV genome (Fig. 3.). Every gene in RRV is represented in KSHV. 
Finally, SIV plus RRV co-infection recapitulates the lymphoproliferative diseases seen in 
AIDS patients. Taken together these finding indicate that RRV provides a suitable animal 
system for the study of KSHV pathogenesis. 
KSHV viral proteins involved in the modulation of the lytic cycle 
KSHV RTA/Orf50 
The KSHV RTA/ORF50 encodes a replication and transcription activator. The RTA 
protein is one of several core herpesviral proteins that is conserved across the 
gammaherpesviridae. The importance of this protein for the virus is evidenced in the high 
degree of homology between related viruses. The degree of conservation is such that RTA 
protein from KSHV can induce RRV RTA-responsive promoters and vice-versa making 
them functionally interchangeable.  
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The RTA protein is multifunctional and is termed the lytic switch protein due to its 
ability to single-handedly induce the lytic replication cycle (105, 149). Indeed, RTA has been 
shown to be necessary and sufficient for lytic induction. Recently, a KSHV-BAC 
recombinant virus lacking ORF50 (BAC36Δ50) was reported to be tightly latent (159).  
The ability of RTA to single-handedly activate the entire lytic cascade depends on 
two separate mechanisms. RTA can directly bind promoters through RTA-responsive 
elements (RREs) to induce transcription from them (101, 103). This is true for Orf57 (MTA), 
K8 (K-bZIP, ZTA)  (103), K12 (kaposin), and polyandelytated nuclear RNA (Pan) (40). In 
all cases electrophoretic mobility shift assays (EMSA) have shown that transcription from 
these promoters requires direct binding by RTA. A second mechanism of transcriptional 
activation involves binding to cellular components. RTA can bind to recombination signal-
binding protein Jkappa (RBP-Jk). RBP-Jk binding sites in the targeted promoters recruit an 
RTA-RBP-Jk complex to the promoter where RTA can induce transcription (100). Another 
cellular RTA binding partner is the transcription factor CCAAT/enhancer-binding protein-
alpha (CEPB-α). Similar to RBP-Jk, CEPB-α binds both K8 and RTA and upregulates 
transcription from the RTA, Orf57 and K8 promoters. Again, EMSA studies showed that 
CEPB-α recruits RTA and K8 to CEPB-α-binding sites in these promoters and that binding 
is required for optimal induction (156). Additional binding partners of RTA during 
transcriptional activation include Oct-1, Sp-1, c-Jun, and CREB-binding protein (CBP) (79, 
133, 162). Other promoters induced by RTA include K1, ORF6, ORF9, vIL-6, K5, K9, 
Orf59, thymidine kinase (TK), vGPCR, K14, LANA and ORF50 (24, 50, 80, 87, 96, 104, 
105, 110, 133). 
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KSHV ORF49 
ORF49 is an open reading frame in the RTA locus that is encoded on the 
complementary strand. It is flanked by a short exon and the second long exon encoding the 
RTA gene. The ORF49 gene shows limited sequence homology to the EBV BRRF1 gene. 
The EBV BRRF1 is also contained within the EBV RTA homolog, BRLF-1 locus. These loci 
are collinear and are subject to a splicing event resulting in the removal of the ORF49 and 
BRRF-1 sequences from the ORF50 and BRLF-1 transcripts, respectively (104, 105, 137) 
(Fig. 4.). The BRRF-1transcript was detected in Raji and Akata cells treated with TPA/Na-
butyrate or anti-IgG respectively. The BRRF-1 protein was found predominantly in the 
nucleus of transfected cells. 
KSHV ORF64 
The gene encoded by KSHV ORF64 is predicted to be a large tegument protein due 
to homology to other herpesviruses. It is conserved across the alpha, beta and 
gammaherpesviridae and is considered a core herpesviral protein. The ORF64 gene is the 
longest single sequence in the genome with close to 8kb of coding sequence. The predicted 
molecular weight of this protein is approximately 300kDa. Thus far, one study used yeast-
two-hybrid and co-immunoprecipitations (co-IP) to show that ORF64 interacts with itself, 
with ORFs21, 45, and 63 plus glycoproteins gB, gH, and gM (129). These data echo the 
findings of Zhu et al (165) where ORF64 was found to be tightly associated with the viral 
capsid. Interestingly, this group found ORF64 to be sensitive to protease 
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 treatment of the virion. This finding suggests that ORF64 is in contact with the capsid and 
the envelope of KSHV virions where it is exposed to protease and bind glycoproteins. The 
significance of these findings is currently under investigation. 
ORF64 and its homologues in all the herpesviruses have predicted deubiquitinase 
(DUB) domains encoded in their N-termini. DUB activity has now been identified in several 
herpesviruses (134). In Herpes Simplex virus-1 (HSV-1), and Pseudorabies virus (PRV) (α-
subfamily) the UL36 gene encodes a multifunctional, large tegument protein that are DUBs. 
In human Cytomegalovirus (β-subfamily), the homologous UL48 protein also encodes DUB 
activity (155). 
Although the targets of the herpesviral deubiquitinases remain to be discovered, 
studies of HSV-1 mutants have implicated the HSV DUB in virion transport through 
microtubules (139), release of the viral genome into the nucleus (1, 89), tegumentation and 
envelopment (52) as well as virion egress (112). A DUB-null mutant of HSV UL36 
displayed a 3-log decrease in titers and a 50% reduction of egressing capsids from neurons 
(97) suggesting that DUB activity plays an important role in lytic replication. Null mutations 
for PRV UL36 have been shown to be lethal in vitro (107) and delay neuroinvasion in the 
mouse model (23). Moreover, specifically mutating the DUB catalytic domain reduces titer 
and plaque size (22). Finally, it was recently shown that a DUB mutant of Marek’s disease 
virus was severely impaired in its ability to induce lymphomagenesis (86). 
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The NFκB pathway 
  Nuclear factor (NF)-κB is an evolutionarily conserved signaling molecule that  
plays a central role in the regulation of a variety of cellular processes including the immune 
system (70) (99) (19). The NF-κB family is made up of p50/p105 (NF-κB1), p52/p100 (NF-
κB2), p65 (RelA), RelB, and c-Rel. In their steady state they form homo- or heterodimers in 
the cytoplasm. The inhibitor of κB (IκB) proteins binds to and prevents NF-κB translocation 
to the nucleus. Signaling through NF-κB follows two parallel pathways, the canonical or 
non-canonical (19). Pro-inflammatory cytokines, pathogens or antigenic peptides can activate 
this pathway. Once induced, the classical pathway activates the β subunit of the IκB kinase 
(IKK) complex, which can phosphorylate IκB proteins and trigger their ubiquitination and 
degradation.  
The non-canonical or alternative pathway, is induced by activation of the α subunit 
(IKKα), which in turn phosphorylates p100. IκB proteins are phosphorylated and 
subsequently ubiquitinated through lysine 48 (K48) by the Skp1–Cullin1– F-box (SCF)/-
transducin repeat-containing protein (TrCP) E3-ligase complex.  
Poly-ubiquitination targets IκB molecules for processing by the preteosome into p50, 
p65 and c-Rel. The resulting subunits form NF-κB heterodimers that translocate to the 
nucleus. Once in the nucleus, the heterodimers bind to NF-κB-responsive promoters of target 
genes.  
There are seven members of the IκB family: IκBα, IκBβ, IκBγ, IκBε, BCL-3, p100 
and p105 (19). IκB degradation is induced by phosphorylated and thus activated, IKK 
complex. The IKK complex includes two kinase subunits, IKKα (IKK1) and IKKβ (IKK2), 
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and IKKγ, or NEMO (NF-κB essential modifier), a regulatory subunit (19, 69). IKKγ, 
considered the ‘molecular switch of NF-κB activation’, has been shown to be non-
destructively regulated through ubiquitination through different lysine residues (2, 85, 164). 
The TNF receptor (TNFR)-associated factor 6 (TRAF-6) is a lysine-63 (K63)-specific 
E3 ligase which is required for IKK complex function in in vitro assays (43). TRAF-6 
mediated ubiquitination of IKKγ is essential for IL-1 receptor (IL-1R) and Toll-like receptor 
(TLR) signaling (51, 90). TRAF-2 is another K63-specific E3 ligase that mediates 
polyubiquitination of RIP (receptor-interacting protein) (157) which plays a pivotal role in 
receptor complex formation after TNF-α-stimulation. TRAF2/TRAF5 doubly deficient mice 
(150) display marked inhibition of NF-κB activation during TNF receptor (TNFR) induction. 
Thus, TRAFs 2 and 5 could function in TNF signaling as analogs to TRAF6 during IL-1 
activation. IL-1 induction causes TRAF6 binding to TGF-β-activated kinase 1 (TAK1) which 
activates the NFκ-B pathway (116). TAK1 kinase activity is regulated by TAK1-binding 
(TAB) proteins TAB2 and TAB3. TABs recognize proteins ubiquitinated by TRAF2 and 
TRAF6 (90). 
CYLD is a cellular, K63-specific DUB capable of inhibiting NF-κB signaling (28, 93, 
153). Mutations in the CYLD gene result in an autosomal-dominant disease familial 
cylindromatosis. The disease is characterized by benign tumors arising from hair follicles or 
eccrine gland cell types. NF-κB activation induces CYLD expression which inhibits IKK 
activity (88). The mechanism of NF-κB signaling inhibition by CYLD involves the cleavage 
of K63-linked Ub chains from TRAF2, TRAF6 and IKKγ.  
Another cellular DUB that interferes with TNF-α-induced NF-κB responses is A20 
(20). A20 inhibits IKK activation by cleaving K63-linked ubiquitin chains from RIP and 
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TRAF6. The deubiquitination of RIP and TRAF6 block signaling to NF-κB (20, 157). A 
K48-specific Ub E3 ligase is also encoded by A20. The E3 module can catalyze the K48-
linked poly-ubiquitination of RIP (157). Cezanne is another DUB that may regulate TRAF6 
(62). Cezanne blocks NF-κB signaling possibly through IKK deubiquitination. 
 Various conflicting data on the effects of KSHV infection on the NF-κB activation 
have been reported. Inhibition of NF-κB with Bay 11-7082 (Bay-11) increased levels of lytic 
reactivation in PEL cells (27). Additionally, activation of KSHV lytic promoters is countered 
by p65 expression. In latently infected cells v-FLIP expression is high and has been shown to 
induce NF-κB activation (64) (102). In contrast, treatment of PEL cells with Bay-11 results 
in an induction of apoptosis and suggests that NF- B activity is required for PEL cell survival 
(92). Moreover, inhibition of the NFκB pathway in human fibroblasts does not increase lytic 
reactivation and activated NFκB has been reported during lytic replication in vous cell types 
(77). 
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OBJECTIVES 
1) Characterization of KSHV ORF49 
There have been no previous studies on KSHV ORF49 or its role in the viral life 
cycle. The initial study of KSHV ORF49 aimed to characterize both transcript and 
protein. The kinetics of KSHV Orf49 transcription and the 5’ and 3’ ends of the 
transcript (RACE) were identified. The properties and function of the encoded 
protein were investigated as well as the contribution to lytic replication. 
2) Characterization of KSHV ORF64 
KSHV ORF64 has been shown to be present in the tegument of virions and to 
associate with several tegument and glycoproteins but has not been ascribed a 
function. We aimed to identify potential roles of KSHV ORF64 in the viral life 
cycle. DUB enzymatic activity was identified in the N-terminus of KSHV ORF64 
by a number of different assays. The role of virus-encoded DUB activity in the 
context of lytic replication was assessed. 
3) KSHV ORF64 DUB activity and signaling 
The robust DUB activity encoded by KSHV Orf64 suggests a large pool of 
potential protein targets of Orf64-mediated deubiquitination. Since several 
signaling pathways pertinent to viral infection are regulated through 
ubiquitination, we have tried to identify potential targets of the KSHV-encoded 
DUB. 
 
 
 
27 
 
 
REFERENCES 
 
1. Abaitua, F., and P. O'Hare. 2008. Identification of a highly conserved, 
functional nuclear localization signal within the N-terminal region of herpes 
simplex virus type 1 VP1-2 tegument protein. J Virol 82:5234-44. 
2. Abbott, D. W., A. Wilkins, J. M. Asara, and L. C. Cantley. 2004. The 
Crohn's disease protein, NOD2, requires RIP2 in order to induce 
ubiquitinylation of a novel site on NEMO. Curr Biol 14:2217-27. 
3. Akula, S. M., N. P. Pramod, F. Z. Wang, and B. Chandran. 2002. Integrin 
alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-
associated herpesvirus (KSHV/HHV-8) entry into the target cells. Cell 
108:407-19. 
4. Alexander, L., L. Denekamp, A. Knapp, M. R. Auerbach, B. Damania, 
and R. C. Desrosiers. 2000. The primary sequence of rhesus monkey 
rhadinovirus isolate 26-95: sequence similarities to Kaposi's sarcoma-
associated herpesvirus and rhesus monkey rhadinovirus isolate 17577. J Virol 
74:3388-98. 
5. Aluigi, M. G., A. Albini, S. Carlone, L. Repetto, R. De Marchi, A. Icardi, 
M. Moro, D. Noonan, and R. Benelli. 1996. KSHV sequences in biopsies 
and cultured spindle cells of epidemic, iatrogenic and Mediterranean forms of 
Kaposi's sarcoma. Res Virol 147:267-75. 
6. Ambroziak, J. A., D. J. Blackbourn, B. G. Herndier, R. G. Glogau, J. H. 
Gullett, A. R. McDonald, E. T. Lennette, and J. A. Levy. 1995. Herpes-like 
sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science 
268:582-3. 
7. An, F. Q., H. M. Folarin, N. Compitello, J. Roth, S. L. Gerson, K. R. 
McCrae, F. D. Fakhari, D. P. Dittmer, and R. Renne. 2006. Long-term-
infected telomerase-immortalized endothelial cells: a model for Kaposi's 
sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 80:4833-
46. 
8. Arvanitakis, L., E. A. Mesri, R. G. Nador, J. W. Said, A. S. Asch, D. M. 
Knowles, and E. Cesarman. 1996. Establishment and characterization of a 
primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring 
kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of 
Epstein-Barr virus. Blood 88:2648-54. 
9. Athale, U. H., P. S. Patil, C. Chintu, and B. Elem. 1995. Influence of HIV 
epidemic on the incidence of Kaposi's sarcoma in Zambian children. J Acquir 
Immune Defic Syndr Hum Retrovirol 8:96-100. 
28 
 
10. Ballestas, M. E., and K. M. Kaye. 2001. Kaposi's sarcoma-associated 
herpesvirus latency-associated nuclear antigen 1 mediates episome persistence 
through cis-acting terminal repeat (TR) sequence and specifically binds TR 
DNA. J Virol 75:3250-8. 
11. Barbera, A. J., J. V. Chodaparambil, B. Kelley-Clarke, V. Joukov, J. C. 
Walter, K. Luger, and K. M. Kaye. 2006. The nucleosomal surface as a 
docking station for Kaposi's sarcoma herpesvirus LANA. Science 311:856-61. 
12. Barozzi, P., M. Luppi, F. Facchetti, C. Mecucci, M. Alu, R. Sarid, V. 
Rasini, L. Ravazzini, E. Rossi, S. Festa, B. Crescenzi, D. G. Wolf, T. F. 
Schulz, and G. Torelli. 2003. Post-transplant Kaposi sarcoma originates from 
the seeding of donor-derived progenitors. Nat Med 9:554-61. 
13. Bechtel, J. T., Y. Liang, J. Hvidding, and D. Ganem. 2003. Host range of 
Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol 77:6474-81. 
14. Benelli, R., A. Albini, C. Parravicini, S. Carlone, L. Repetto, G. 
Tambussi, and A. Lazzarin. 1996. Isolation of spindle-shaped cell 
populations from primary cultures of Kaposi's sarcoma of different stage. 
Cancer Lett 100:125-32. 
15. Bergquam, E. P., N. Avery, S. M. Shiigi, M. K. Axthelm, and S. W. Wong. 
1999. Rhesus rhadinovirus establishes a latent infection in B lymphocytes in 
vivo. J Virol 73:7874-6. 
16. Biggar, R. J., and C. S. Rabkin. 1996. The epidemiology of AIDS--related 
neoplasms. Hematol Oncol Clin North Am 10:997-1010. 
17. Birch, N. H. 1967. A case of Kaposi's Sarcoma of the small intestine. East 
Afr Med J 44:343-5. 
18. Blackbourn, D. J., E. Lennette, B. Klencke, A. Moses, B. Chandran, M. 
Weinstein, R. G. Glogau, M. H. Witte, D. L. Way, T. Kutzkey, B. 
Herndier, and J. A. Levy. 2000. The restricted cellular host range of human 
herpesvirus 8. Aids 14:1123-33. 
19. Bonizzi, G., and M. Karin. 2004. The two NF-kappaB activation pathways 
and their role in innate and adaptive immunity. Trends Immunol 25:280-8. 
20. Boone, D. L., E. E. Turer, E. G. Lee, R. C. Ahmad, M. T. Wheeler, C. 
Tsui, P. Hurley, M. Chien, S. Chai, O. Hitotsumatsu, E. McNally, C. 
Pickart, and A. Ma. 2004. The ubiquitin-modifying enzyme A20 is required 
for termination of Toll-like receptor responses. Nat Immunol 5:1052-60. 
21. Boshoff, C., S. J. Gao, L. E. Healy, S. Matthews, A. J. Thomas, L. 
Coignet, R. A. Warnke, J. A. Strauchen, E. Matutes, O. W. Kamel, P. S. 
Moore, R. A. Weiss, and Y. Chang. 1998. Establishing a KSHV+ cell line 
29 
 
(BCP-1) from peripheral blood and characterizing its growth in Nod/SCID 
mice. Blood 91:1671-9. 
22. Bottcher, S., H. Granzow, C. Maresch, B. Mohl, B. G. Klupp, and T. C. 
Mettenleiter. 2007. Identification of functional domains within the essential 
large tegument protein pUL36 of pseudorabies virus. J Virol 81:13403-11. 
23. Bottcher, S., C. Maresch, H. Granzow, B. G. Klupp, J. P. Teifke, and T. 
C. Mettenleiter. 2008. Mutagenesis of the active-site cysteine in the 
ubiquitin-specific protease contained in large tegument protein pUL36 of 
pseudorabies virus impairs viral replication in vitro and neuroinvasion in vivo. 
J Virol 82:6009-16. 
24. Bowser, B. S., S. M. DeWire, and B. Damania. 2002. Transcriptional 
regulation of the K1 gene product of Kaposi's sarcoma-associated herpesvirus. 
J Virol 76:12574-83. 
25. Brambilla, L., V. Boneschi, S. Ferrucci, M. Taglioni, and E. Berti. 2000. 
Human herpesvirus-8 infection among heterosexual partners of patients with 
classical Kaposi's sarcoma. Br J Dermatol 143:1021-5. 
26. Braun, M. 1982. Classics in Oncology. Idiopathic multiple pigmented 
sarcoma of the skin by Kaposi. CA Cancer J Clin 32:340-7. 
27. Brown, H. J., M. J. Song, H. Deng, T. T. Wu, G. Cheng, and R. Sun. 2003. 
NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol 77:8532-40. 
28. Brummelkamp, T. R., S. M. Nijman, A. M. Dirac, and R. Bernards. 2003. 
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating 
NF-kappaB. Nature 424:797-801. 
29. Bryk, D., J. Farman, S. Dallemand, M. A. Meyers, and A. Wecksell. 1978. 
Kaposi's sarcoma of the intestinal tract: roentgen manifestations. Gastrointest 
Radiol 3:425-30. 
30. Cai, Q., K. Lan, S. C. Verma, H. Si, D. Lin, and E. S. Robertson. 2006. 
Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with 
HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control 
under low oxygen conditions. J Virol 80:7965-75. 
31. Cai, X., S. Lu, Z. Zhang, C. M. Gonzalez, B. Damania, and B. R. Cullen. 
2005. Kaposi's sarcoma-associated herpesvirus expresses an array of viral 
microRNAs in latently infected cells. Proc Natl Acad Sci U S A 102:5570-5. 
32. Cannon, J. S., D. Ciufo, A. L. Hawkins, C. A. Griffin, M. J. Borowitz, G. 
S. Hayward, and R. F. Ambinder. 2000. A new primary effusion 
lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma 
herpesvirus-containing supernatant. J Virol 74:10187-93. 
30 
 
33. Cannon, M. J., S. C. Dollard, D. K. Smith, R. S. Klein, P. Schuman, J. D. 
Rich, D. Vlahov, and P. E. Pellett. 2001. Blood-borne and sexual 
transmission of human herpesvirus 8 in women with or at risk for human 
immunodeficiency virus infection. N Engl J Med 344:637-43. 
34. Carbone, A., G. Gaidano, A. Gloghini, L. M. Larocca, D. Capello, V. 
Canzonieri, A. Antinori, U. Tirelli, B. Falini, and R. Dalla-Favera. 1998. 
Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-
encoded latent membrane protein-1 identifies distinct histogenetic subsets of 
acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. 
Blood 91:747-55. 
35. Casper, C., D. Carrell, K. G. Miller, F. D. Judson, A. S. Meier, J. S. Pauk, 
R. A. Morrow, L. Corey, A. Wald, and C. Celum. 2006. HIV 
serodiscordant sex partners and the prevalence of human herpesvirus 8 
infection among HIV negative men who have sex with men: baseline data 
from the EXPLORE Study. Sex Transm Infect 82:229-35. 
36. Casper, C., E. Krantz, S. Selke, S. R. Kuntz, J. Wang, M. L. Huang, J. S. 
Pauk, L. Corey, and A. Wald. 2007. Frequent and asymptomatic 
oropharyngeal shedding of human herpesvirus 8 among immunocompetent 
men. J Infect Dis 195:30-6. 
37. Casper, C., M. Redman, M. L. Huang, J. Pauk, T. M. Lampinen, S. E. 
Hawes, C. W. Critchlow, R. A. Morrow, L. Corey, N. Kiviat, and A. 
Wald. 2004. HIV infection and human herpesvirus-8 oral shedding among 
men who have sex with men. J Acquir Immune Defic Syndr 35:233-8. 
38. Casper, C., A. Wald, J. Pauk, S. R. Tabet, L. Corey, and C. L. Celum. 
2002. Correlates of prevalent and incident Kaposi's sarcoma-associated 
herpesvirus infection in men who have sex with men. J Infect Dis 185:990-3. 
39. Cesarman, E., Y. Chang, P. S. Moore, J. W. Said, and D. M. Knowles. 
1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-
related body-cavity-based lymphomas. N Engl J Med 332:1186-91. 
40. Chang, P. J., D. Shedd, L. Gradoville, M. S. Cho, L. W. Chen, J. Chang, 
and G. Miller. 2002. Open reading frame 50 protein of Kaposi's sarcoma-
associated herpesvirus directly activates the viral PAN and K12 genes by 
binding to related response elements. J Virol 76:3168-78. 
41. Chang, Y., E. Cesarman, M. S. Pessin, F. Lee, J. Culpepper, D. M. 
Knowles, and P. S. Moore. 1994. Identification of herpesvirus-like DNA 
sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-9. 
42. Chen, Y. B., A. Rahemtullah, and E. Hochberg. 2007. Primary effusion 
lymphoma. Oncologist 12:569-76. 
31 
 
43. Chen, Z. J., L. Parent, and T. Maniatis. 1996. Site-specific phosphorylation 
of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. 
Cell 84:853-62. 
44. Chronowski, G. M., C. S. Ha, R. B. Wilder, F. Cabanillas, J. Manning, 
and J. D. Cox. 2001. Treatment of unicentric and multicentric Castleman 
disease and the role of radiotherapy. Cancer 92:670-6. 
45. D'Agostino, G., E. Arico, L. Santodonato, M. Venditti, P. Sestili, L. 
Masuelli, A. Coletti, A. Modesti, G. Picchio, D. E. Mosier, M. Ferrantini, 
and F. Belardelli. 1999. Type I consensus IFN (IFN-con1) gene transfer into 
KSHV/HHV-8-infected BCBL-1 cells causes inhibition of viral lytic cycle 
activation via induction of apoptosis and abrogates tumorigenicity in sCID 
mice. J Interferon Cytokine Res 19:1305-16. 
46. Damania, B., and J. U. Jung. 2001. Comparative analysis of the 
transforming mechanisms of Epstein-Barr virus, Kaposi's sarcoma-associated 
herpesvirus, and Herpesvirus saimiri. Adv Cancer Res 80:51-82. 
47. Davis, D. A., A. S. Rinderknecht, J. P. Zoeteweij, Y. Aoki, E. L. Read-
Connole, G. Tosato, A. Blauvelt, and R. Yarchoan. 2001. Hypoxia induces 
lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 97:3244-50. 
48. de Jong, M. D., G. J. Galasso, B. Gazzard, P. D. Griffiths, D. A. Jabs, E. 
R. Kern, and S. A. Spector. 1998. Summary of the II International 
Symposium on Cytomegalovirus. Antiviral Res 39:141-62. 
49. Delecluse, H. J., R. Feederle, B. O'Sullivan, and P. Taniere. 2007. Epstein 
Barr virus-associated tumours: an update for the attention of the working 
pathologist. J Clin Pathol 60:1358-64. 
50. Deng, H., J. T. Chu, M. B. Rettig, O. Martinez-Maza, and R. Sun. 2002. 
Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-
regulates human interleukin-6 gene expression. Blood 100:1919-21. 
51. Deng, L., C. Wang, E. Spencer, L. Yang, A. Braun, J. You, C. Slaughter, 
C. Pickart, and Z. J. Chen. 2000. Activation of the IkappaB kinase complex 
by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a 
unique polyubiquitin chain. Cell 103:351-61. 
52. Desai, P. J. 2000. A null mutation in the UL36 gene of herpes simplex virus 
type 1 results in accumulation of unenveloped DNA-filled capsids in the 
cytoplasm of infected cells. J Virol 74:11608-18. 
53. Desrosiers, R. C., V. G. Sasseville, S. C. Czajak, X. Zhang, K. G. 
Mansfield, A. Kaur, R. P. Johnson, A. A. Lackner, and J. U. Jung. 1997. 
A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-
associated herpesvirus. J Virol 71:9764-9. 
32 
 
54. DeWire, S. M., E. S. Money, S. P. Krall, and B. Damania. 2003. Rhesus 
monkey rhadinovirus (RRV): construction of a RRV-GFP recombinant virus 
and development of assays to assess viral replication. Virology 312:122-34. 
55. Dictor, M. 1997. Human herpesvirus 8 and Kaposi's sarcoma. Semin Cutan 
Med Surg 16:181-7. 
56. DiGiovanna, J. J., and B. Safai. 1981. Kaposi's sarcoma. Retrospective 
study of 90 cases with particular emphasis on the familial occurrence, ethnic 
background and prevalence of other diseases. Am J Med 71:779-83. 
57. Dittmer, D., M. Lagunoff, R. Renne, K. Staskus, A. Haase, and D. 
Ganem. 1998. A cluster of latently expressed genes in Kaposi's sarcoma-
associated herpesvirus. J Virol 72:8309-15. 
58. Dittmer, D., C. Stoddart, R. Renne, V. Linquist-Stepps, M. E. Moreno, C. 
Bare, J. M. McCune, and D. Ganem. 1999. Experimental transmission of 
Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) to SCID-hu 
Thy/Liv mice. J Exp Med 190:1857-68. 
59. Duman, S., H. Toz, G. Asci, S. Alper, M. Ozkahya, I. Unal, A. Celik, E. 
Ok, and A. Basci. 2002. Successful treatment of post-transplant Kaposi's 
sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 
17:892-6. 
60. Dupin, N., C. Fisher, P. Kellam, S. Ariad, M. Tulliez, N. Franck, E. van 
Marck, D. Salmon, I. Gorin, J. P. Escande, R. A. Weiss, K. Alitalo, and C. 
Boshoff. 1999. Distribution of human herpesvirus-8 latently infected cells in 
Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion 
lymphoma. Proc Natl Acad Sci U S A 96:4546-51. 
61. Estep, R. D., M. F. Powers, B. K. Yen, H. Li, and S. W. Wong. 2007. 
Construction of an infectious rhesus rhadinovirus bacterial artificial 
chromosome for the analysis of Kaposi's sarcoma-associated herpesvirus-
related disease development. J Virol 81:2957-69. 
62. Evans, P. C., E. R. Taylor, J. Coadwell, K. Heyninck, R. Beyaert, and P. 
J. Kilshaw. 2001. Isolation and characterization of two novel A20-like 
proteins. Biochem J 357:617-23. 
63. Farge, D., C. Lebbe, Z. Marjanovic, P. Tuppin, C. Mouquet, M. N. 
Peraldi, P. Lang, C. Hiesse, C. Antoine, C. Legendre, J. Bedrossian, M. F. 
Gagnadoux, C. Loirat, C. Pellet, J. Sheldon, J. L. Golmard, F. Agbalika, 
and T. F. Schulz. 1999. Human herpes virus-8 and other risk factors for 
Kaposi's sarcoma in kidney transplant recipients. Groupe Cooperatif de 
Transplantation d' Ile de France (GCIF). Transplantation 67:1236-42. 
33 
 
64. Field, N., W. Low, M. Daniels, S. Howell, L. Daviet, C. Boshoff, and M. 
Collins. 2003. KSHV vFLIP binds to IKK-gamma to activate IKK. J Cell Sci 
116:3721-8. 
65. Flore, O., S. Rafii, S. Ely, J. J. O'Leary, E. M. Hyjek, and E. Cesarman. 
1998. Transformation of primary human endothelial cells by Kaposi's 
sarcoma-associated herpesvirus. Nature 394:588-92. 
66. Forbes, B. A. 1989. Acquisition of cytomegalovirus infection: an update. Clin 
Microbiol Rev 2:204-16. 
67. Foreman, K. E., J. Friborg, B. Chandran, H. Katano, T. Sata, M. 
Mercader, G. J. Nabel, and B. J. Nickoloff. 2001. Injection of human 
herpesvirus-8 in human skin engrafted on SCID mice induces Kaposi's 
sarcoma-like lesions. J Dermatol Sci 26:182-93. 
68. Gaidano, G., K. Cechova, Y. Chang, P. S. Moore, D. M. Knowles, and R. 
Dalla-Favera. 1996. Establishment of AIDS-related lymphoma cell lines 
from lymphomatous effusions. Leukemia 10:1237-40. 
69. Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-kappaB puzzle. 
Cell 109 Suppl:S81-96. 
70. Ghosh, S., M. J. May, and E. B. Kopp. 1998. NF-kappa B and Rel proteins: 
evolutionarily conserved mediators of immune responses. Annu Rev Immunol 
16:225-60. 
71. Giraldo, G., and E. Beth. 1972. [Kaposi's sarcoma: presence of herpes type 
virus in tissue culture in 5 different cases. A possible new model in the study 
of viruses associated with human tumors]. C R Acad Sci Hebd Seances Acad 
Sci D 275:289-92. 
72. Giraldo, G., E. Beth, W. Henle, G. Henle, V. Mike, B. Safai, J. M. 
Huraux, J. McHardy, and G. deThe. 1978. Antibody patterns to 
herpesviruses in Kaposi's sarcoma. II. Serological association of American 
Kaposi's sarcoma with cytomegalovirus. Int J Cancer 22:126-31. 
73. Glaser, R., L. Geder, S. St Jeor, S. Michelson-Fiske, and F. Haguenau. 
1977. Partial characterization of a herpes-type virus (K9V) derived from 
Kaposi's sarcoma. J Natl Cancer Inst 59:55-60. 
74. Gougerot, H., and J. Hewit. 1950. [Unna-Kaposi's acrosarcoma ameliorated 
by massive doses of penicillin.]. Bull Soc Fr Dermatol Syphiligr 57:502-3. 
75. Grandadam, M., N. Dupin, V. Calvez, I. Gorin, L. Blum, S. Kernbaum, 
D. Sicard, Y. Buisson, H. Agut, J. P. Escande, and J. M. Huraux. 1997. 
Exacerbations of clinical symptoms in human immunodeficiency virus type 1-
infected patients with multicentric Castleman's disease are associated with a 
34 
 
high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood 
mononuclear cells. J Infect Dis 175:1198-201. 
76. Grossman, Z., J. Iscovich, F. Schwartz, E. Azizi, A. Klepfish, A. 
Schattner, and R. Sarid. 2002. Absence of Kaposi sarcoma among Ethiopian 
immigrants to Israel despite high seroprevalence of human herpesvirus 8. 
Mayo Clin Proc 77:905-9. 
77. Grossmann, C., and D. Ganem. 2008. Effects of NFkappaB activation on 
KSHV latency and lytic reactivation are complex and context-dependent. 
Virology 375:94-102. 
78. Guttman-Yassky, E., Z. Kra-Oz, J. Dubnov, R. Friedman-Birnbaum, I. 
Segal, N. Zaltzman, T. Roth, F. Schwartz, S. Linn, D. Rozenman, M. 
David, M. Silbermann, M. Barchana, R. Bergman, and R. Sarid. 2005. 
Infection with Kaposi's sarcoma-associated herpesvirus among families of 
patients with classic Kaposi's sarcoma. Arch Dermatol 141:1429-34. 
79. Gwack, Y., H. Byun, S. Hwang, C. Lim, and J. Choe. 2001. CREB-binding 
protein and histone deacetylase regulate the transcriptional activity of Kaposi's 
sarcoma-associated herpesvirus open reading frame 50. J Virol 75:1909-17. 
80. Haque, M., J. Chen, K. Ueda, Y. Mori, K. Nakano, Y. Hirata, S. 
Kanamori, Y. Uchiyama, R. Inagi, T. Okuno, and K. Yamanishi. 2000. 
Identification and analysis of the K5 gene of Kaposi's sarcoma-associated 
herpesvirus. J Virol 74:2867-75. 
81. Haque, M., D. A. Davis, V. Wang, I. Widmer, and R. Yarchoan. 2003. 
Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains 
hypoxia response elements: relevance to lytic induction by hypoxia. J Virol 
77:6761-8. 
82. Herndier, B. G., L. D. Kaplan, and M. S. McGrath. 1994. Pathogenesis of 
AIDS lymphomas. Aids 8:1025-49. 
83. Hladik, W., S. C. Dollard, J. Mermin, A. L. Fowlkes, R. Downing, M. M. 
Amin, F. Banage, E. Nzaro, P. Kataaha, T. J. Dondero, P. E. Pellett, and 
E. M. Lackritz. 2006. Transmission of human herpesvirus 8 by blood 
transfusion. N Engl J Med 355:1331-8. 
84. Howard, M. R., D. Whitby, G. Bahadur, F. Suggett, C. Boshoff, M. 
Tenant-Flowers, T. F. Schulz, S. Kirk, S. Matthews, I. V. Weller, R. S. 
Tedder, and R. A. Weiss. 1997. Detection of human herpesvirus 8 DNA in 
semen from HIV-infected individuals but not healthy semen donors. Aids 
11:F15-9. 
85. Huang, T. T., S. M. Wuerzberger-Davis, Z. H. Wu, and S. Miyamoto. 
2003. Sequential modification of NEMO/IKKgamma by SUMO-1 and 
35 
 
ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 115:565-
76. 
86. Jarosinski, K., L. Kattenhorn, B. Kaufer, H. Ploegh, and N. Osterrieder. 
2007. A herpesvirus ubiquitin-specific protease is critical for efficient T cell 
lymphoma formation. Proc Natl Acad Sci U S A 104:20025-30. 
87. Jeong, J., J. Papin, and D. Dittmer. 2001. Differential regulation of the 
overlapping Kaposi's sarcoma-associated herpesvirus vGCR (orf74) and 
LANA (orf73) promoters. J Virol 75:1798-807. 
88. Jono, H., J. H. Lim, L. F. Chen, H. Xu, E. Trompouki, Z. K. Pan, G. 
Mosialos, and J. D. Li. 2004. NF-kappaB is essential for induction of CYLD, 
the negative regulator of NF-kappaB: evidence for a novel inducible 
autoregulatory feedback pathway. J Biol Chem 279:36171-4. 
89. Jovasevic, V., L. Liang, and B. Roizman. 2008. Proteolytic cleavage of 
VP1-2 is required for release of herpes simplex virus 1 DNA into the nucleus. 
J Virol 82:3311-9. 
90. Kanayama, A., R. B. Seth, L. Sun, C. K. Ea, M. Hong, A. Shaito, Y. H. 
Chiu, L. Deng, and Z. J. Chen. 2004. TAB2 and TAB3 activate the NF-
kappaB pathway through binding to polyubiquitin chains. Mol Cell 15:535-
48. 
91. Katano, H., Y. Hoshino, Y. Morishita, T. Nakamura, H. Satoh, A. 
Iwamoto, B. Herndier, and S. Mori. 1999. Establishing and characterizing a 
CD30-positive cell line harboring HHV-8 from a primary effusion lymphoma. 
J Med Virol 58:394-401. 
92. Keller, S. A., E. J. Schattner, and E. Cesarman. 2000. Inhibition of NF-
kappaB induces apoptosis of KSHV-infected primary effusion lymphoma 
cells. Blood 96:2537-42. 
93. Kovalenko, A., C. Chable-Bessia, G. Cantarella, A. Israel, D. Wallach, 
and G. Courtois. 2003. The tumour suppressor CYLD negatively regulates 
NF-kappaB signalling by deubiquitination. Nature 424:801-5. 
94. Krishnan, H. H., N. Sharma-Walia, L. Zeng, S. J. Gao, and B. Chandran. 
2005. Envelope glycoprotein gB of Kaposi's sarcoma-associated herpesvirus 
is essential for egress from infected cells. J Virol 79:10952-67. 
95. Kurgan, J. 1972. [Disseminated pulmonary lesions in the course of Kaposi's 
sarcoma]. Gruzlica 40:751-4. 
96. Lan, K., D. A. Kuppers, S. C. Verma, N. Sharma, M. Murakami, and E. 
S. Robertson. 2005. Induction of Kaposi's sarcoma-associated herpesvirus 
latency-associated nuclear antigen by the lytic transactivator RTA: a novel 
mechanism for establishment of latency. J Virol 79:7453-65. 
36 
 
97. Lee, J. I., G. W. Luxton, and G. A. Smith. 2006. Identification of an 
essential domain in the herpesvirus VP1/2 tegument protein: the carboxy 
terminus directs incorporation into capsid assemblons. J Virol 80:12086-94. 
98. Li, J. J., Y. Q. Huang, C. J. Cockerell, and A. E. Friedman-Kien. 1996. 
Localization of human herpes-like virus type 8 in vascular endothelial cells 
and perivascular spindle-shaped cells of Kaposi's sarcoma lesions by in situ 
hybridization. Am J Pathol 148:1741-8. 
99. Li, Q., and I. M. Verma. 2002. NF-kappaB regulation in the immune system. 
Nat Rev Immunol 2:725-34. 
100. Liang, Y., and D. Ganem. 2004. RBP-J (CSL) is essential for activation of 
the K14/vGPCR promoter of Kaposi's sarcoma-associated herpesvirus by the 
lytic switch protein RTA. J Virol 78:6818-26. 
101. Liao, W., Y. Tang, Y. L. Kuo, B. Y. Liu, C. J. Xu, and C. Z. Giam. 2003. 
Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 transcriptional 
activator Rta is an oligomeric DNA-binding protein that interacts with tandem 
arrays of phased A/T-trinucleotide motifs. J Virol 77:9399-411. 
102. Liu, L., M. T. Eby, N. Rathore, S. K. Sinha, A. Kumar, and P. M. 
Chaudhary. 2002. The human herpes virus 8-encoded viral FLICE inhibitory 
protein physically associates with and persistently activates the Ikappa B 
kinase complex. J Biol Chem 277:13745-51. 
103. Lukac, D. M., L. Garibyan, J. R. Kirshner, D. Palmeri, and D. Ganem. 
2001. DNA binding by Kaposi's sarcoma-associated herpesvirus lytic switch 
protein is necessary for transcriptional activation of two viral delayed early 
promoters. J Virol 75:6786-99. 
104. Lukac, D. M., J. R. Kirshner, and D. Ganem. 1999. Transcriptional 
activation by the product of open reading frame 50 of Kaposi's sarcoma-
associated herpesvirus is required for lytic viral reactivation in B cells. J Virol 
73:9348-61. 
105. Lukac, D. M., R. Renne, J. R. Kirshner, and D. Ganem. 1998. Reactivation 
of Kaposi's sarcoma-associated herpesvirus infection from latency by 
expression of the ORF 50 transactivator, a homolog of the EBV R protein. 
Virology 252:304-12. 
106. Luppi, M., P. Barozzi, G. Santagostino, R. Trovato, T. F. Schulz, R. 
Marasca, D. Bottalico, L. Bignardi, and G. Torelli. 2000. Molecular 
evidence of organ-related transmission of Kaposi sarcoma-associated 
herpesvirus or human herpesvirus-8 in transplant patients. Blood 96:3279-81. 
107. Luxton, G. W., J. I. Lee, S. Haverlock-Moyns, J. M. Schober, and G. A. 
Smith. 2006. The pseudorabies virus VP1/2 tegument protein is required for 
intracellular capsid transport. J Virol 80:201-9. 
37 
 
108. Lyall, E. G., G. S. Patton, J. Sheldon, C. Stainsby, J. Mullen, S. O'Shea, 
N. A. Smith, A. De Ruiter, M. O. McClure, and T. F. Schulz. 1999. 
Evidence for horizontal and not vertical transmission of human herpesvirus 8 
in children born to human immunodeficiency virus-infected mothers. Pediatr 
Infect Dis J 18:795-9. 
109. Martin, J. N., D. E. Ganem, D. H. Osmond, K. A. Page-Shafer, D. 
Macrae, and D. H. Kedes. 1998. Sexual transmission and the natural history 
of human herpesvirus 8 infection. N Engl J Med 338:948-54. 
110. Matsumura, S., Y. Fujita, E. Gomez, N. Tanese, and A. C. Wilson. 2005. 
Activation of the Kaposi's sarcoma-associated herpesvirus major latency locus 
by the lytic switch protein RTA (ORF50). J Virol 79:8493-505. 
111. Moore, P. S., and Y. Chang. 1998. Antiviral activity of tumor-suppressor 
pathways: clues from molecular piracy by KSHV. Trends Genet 14:144-50. 
112. Morrison, E. E., A. J. Stevenson, Y. F. Wang, and D. M. Meredith. 1998. 
Differences in the intracellular localization and fate of herpes simplex virus 
tegument proteins early in the infection of Vero cells. J Gen Virol 79 ( Pt 
10):2517-28. 
113. Mutlu, A. D., L. E. Cavallin, L. Vincent, C. Chiozzini, P. Eroles, E. M. 
Duran, Z. Asgari, A. T. Hooper, K. M. La Perle, C. Hilsher, S. J. Gao, D. 
P. Dittmer, S. Rafii, and E. A. Mesri. 2007. In vivo-restricted and reversible 
malignancy induced by human herpesvirus-8 KSHV: a cell and animal model 
of virally induced Kaposi's sarcoma. Cancer Cell 11:245-58. 
114. Nash, G., and S. Fligiel. 1984. Kaposi's sarcoma presenting as pulmonary 
disease in the acquired immunodeficiency syndrome: diagnosis by lung 
biopsy. Hum Pathol 15:999-1001. 
115. Newell, G. R., S. C. Adams, P. W. Mansell, and E. M. Hersh. 1984. 
Toxicity, immunosuppressive effects and carcinogenic potential of volatile 
nitrites: possible relationship to Kaposi's sarcoma. Pharmacotherapy 4:284-91. 
116. Ninomiya-Tsuji, J., K. Kishimoto, A. Hiyama, J. Inoue, Z. Cao, and K. 
Matsumoto. 1999. The kinase TAK1 can activate the NIK-I kappaB as well 
as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398:252-6. 
117. Oksenhendler, E., M. Duarte, J. Soulier, P. Cacoub, Y. Welker, J. 
Cadranel, D. Cazals-Hatem, B. Autran, J. P. Clauvel, and M. Raphael. 
1996. Multicentric Castleman's disease in HIV infection: a clinical and 
pathological study of 20 patients. Aids 10:61-7. 
118. Parsons, C. H., L. A. Adang, J. Overdevest, C. M. O'Connor, J. R. 
Taylor, Jr., D. Camerini, and D. H. Kedes. 2006. KSHV targets multiple 
leukocyte lineages during long-term productive infection in NOD/SCID mice. 
J Clin Invest 116:1963-73. 
38 
 
119. Pastinszky, I. 1950. [Herpetic virus in the pathogenesis of Kaposi's disease 
and differential diagnosis.]. Borgyogy Venerol Sz 4:146-55. 
120. Patel, N., M. Salifu, N. Sumrani, D. Distant, J. Hong, M. Markell, and A. 
S. Braverman. 2002. Successful treatment of post-renal transplant Kaposi's 
sarcoma with paclitaxel. Am J Transplant 2:877-9. 
121. Pauk, J., M. L. Huang, S. J. Brodie, A. Wald, D. M. Koelle, T. Schacker, 
C. Celum, S. Selke, and L. Corey. 2000. Mucosal shedding of human 
herpesvirus 8 in men. N Engl J Med 343:1369-77. 
122. Penn, I. 1997. Kaposi's sarcoma in transplant recipients. Transplantation 
64:669-73. 
123. Picchio, G. R., R. E. Sabbe, R. J. Gulizia, M. McGrath, B. G. Herndier, 
and D. E. Mosier. 1997. The KSHV/HHV8-infected BCBL-1 lymphoma line 
causes tumors in SCID mice but fails to transmit virus to a human peripheral 
blood mononuclear cell graft. Virology 238:22-9. 
124. Piolot, T., M. Tramier, M. Coppey, J. C. Nicolas, and V. Marechal. 2001. 
Close but distinct regions of human herpesvirus 8 latency-associated nuclear 
antigen 1 are responsible for nuclear targeting and binding to human mitotic 
chromosomes. J Virol 75:3948-59. 
125. Plancoulaine, S., L. Abel, M. van Beveren, D. A. Tregouet, M. Joubert, P. 
Tortevoye, G. de The, and A. Gessain. 2000. Human herpesvirus 8 
transmission from mother to child and between siblings in an endemic 
population. Lancet 356:1062-5. 
126. Rainbow, L., G. M. Platt, G. R. Simpson, R. Sarid, S. J. Gao, H. Stoiber, 
C. S. Herrington, P. S. Moore, and T. F. Schulz. 1997. The 222- to 234-
kilodalton latent nuclear protein (LNA) of Kaposi's sarcoma-associated 
herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of 
the latency-associated nuclear antigen. J Virol 71:5915-21. 
127. Regezi, J. A., L. A. MacPhail, T. E. Daniels, Y. G. DeSouza, J. S. 
Greenspan, and D. Greenspan. 1993. Human immunodeficiency virus-
associated oral Kaposi's sarcoma. A heterogeneous cell population dominated 
by spindle-shaped endothelial cells. Am J Pathol 143:240-9. 
128. Renne, R., W. Zhong, B. Herndier, M. McGrath, N. Abbey, D. Kedes, and 
D. Ganem. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus 
(human herpesvirus 8) in culture. Nat Med 2:342-6. 
129. Rozen, R., N. Sathish, Y. Li, and Y. Yuan. 2008. Virion-wide protein 
interactions of Kaposi's sarcoma-associated herpesvirus. J Virol 82:4742-50. 
130. Russo, J. J., R. A. Bohenzky, M. C. Chien, J. Chen, M. Yan, D. 
Maddalena, J. P. Parry, D. Peruzzi, I. S. Edelman, Y. Chang, and P. S. 
39 
 
Moore. 1996. Nucleotide sequence of the Kaposi sarcoma-associated 
herpesvirus (HHV8). Proc Natl Acad Sci U S A 93:14862-7. 
131. Rutgers, J. L., R. Wieczorek, F. Bonetti, K. L. Kaplan, D. N. Posnett, A. 
E. Friedman-Kien, and D. M. Knowles, 2nd. 1986. The expression of 
endothelial cell surface antigens by AIDS-associated Kaposi's sarcoma. 
Evidence for a vascular endothelial cell origin. Am J Pathol 122:493-9. 
132. Sadler, R., L. Wu, B. Forghani, R. Renne, W. Zhong, B. Herndier, and D. 
Ganem. 1999. A complex translational program generates multiple novel 
proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-
associated herpesvirus. J Virol 73:5722-30. 
133. Sakakibara, S., K. Ueda, J. Chen, T. Okuno, and K. Yamanishi. 2001. 
Octamer-binding sequence is a key element for the autoregulation of Kaposi's 
sarcoma-associated herpesvirus ORF50/Lyta gene expression. J Virol 
75:6894-900. 
134. Schlieker, C., G. A. Korbel, L. M. Kattenhorn, and H. L. Ploegh. 2005. A 
deubiquitinating activity is conserved in the large tegument protein of the 
herpesviridae. J Virol 79:15582-5. 
135. Schulz, T. F. 1999. Epidemiology of Kaposi's sarcoma-associated 
herpesvirus/human herpesvirus 8. Adv Cancer Res 76:121-60. 
136. Searles, R. P., E. P. Bergquam, M. K. Axthelm, and S. W. Wong. 1999. 
Sequence and genomic analysis of a Rhesus macaque rhadinovirus with 
similarity to Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8. J 
Virol 73:3040-53. 
137. Segouffin-Cariou, C., G. Farjot, A. Sergeant, and H. Gruffat. 2000. 
Characterization of the epstein-barr virus BRRF1 gene, located between early 
genes BZLF1 and BRLF1. J Gen Virol 81:1791-9. 
138. Sengupta, P., and M. M. Das. 1978. Kaposi's sarcoma of small intestine. J 
Indian Med Assoc 71:120-2. 
139. Shanda, S. K., and D. W. Wilson. 2008. UL36p is required for efficient 
transport of membrane-associated herpes simplex virus type 1 along 
microtubules. J Virol 82:7388-94. 
140. Sharp, T. V., H. W. Wang, A. Koumi, D. Hollyman, Y. Endo, H. Ye, M. 
Q. Du, and C. Boshoff. 2002. K15 protein of Kaposi's sarcoma-associated 
herpesvirus is latently expressed and binds to HAX-1, a protein with 
antiapoptotic function. J Virol 76:802-16. 
141. Shinohara, H., M. Fukushi, M. Higuchi, M. Oie, O. Hoshi, T. Ushiki, J. 
Hayashi, and M. Fujii. 2002. Chromosome binding site of latency-associated 
nuclear antigen of Kaposi's sarcoma-associated herpesvirus is essential for 
40 
 
persistent episome maintenance and is functionally replaced by histone H1. J 
Virol 76:12917-24. 
142. Slavin, G., H. M. Cameron, C. Forbes, and R. M. Mitchell. 1970. Kaposi's 
sarcoma in East African children: a report of 51 cases. J Pathol 100:187-99. 
143. Smith, N. A., C. A. Sabin, R. Gopal, D. Bourboulia, W. Labbet, C. 
Boshoff, D. Barlow, B. Band, B. S. Peters, A. de Ruiter, D. W. Brown, R. 
A. Weiss, J. M. Best, and D. Whitby. 1999. Serologic evidence of human 
herpesvirus 8 transmission by homosexual but not heterosexual sex. J Infect 
Dis 180:600-6. 
144. Staskus, K. A., W. Zhong, K. Gebhard, B. Herndier, H. Wang, R. Renne, 
J. Beneke, J. Pudney, D. J. Anderson, D. Ganem, and A. T. Haase. 1997. 
Kaposi's sarcoma-associated herpesvirus gene expression in endothelial 
(spindle) tumor cells. J Virol 71:715-9. 
145. Staudt, M. R., Y. Kanan, J. H. Jeong, J. F. Papin, R. Hines-Boykin, and 
D. P. Dittmer. 2004. The tumor microenvironment controls primary effusion 
lymphoma growth in vivo. Cancer Res 64:4790-9. 
146. Stein, M. E., J. Lachter, D. Spencer, L. Margolius, and W. R. Bezwoda. 
1996. Variants of Kaposi's sarcoma in Southern Africa. A retrospective 
analysis (1980-1992). Acta Oncol 35:193-9. 
147. Stein, M. E., D. Spencer, A. Kantor, P. Ruff, N. Haim, and W. R. 
Bezwoda. 1994. Epidemic AIDS-related Kaposi's sarcoma in southern Africa: 
experience at the Johannesburg General Hospital (1980-1990). Trans R Soc 
Trop Med Hyg 88:434-6. 
148. Sullivan, R. J., L. Pantanowitz, C. Casper, J. Stebbing, and B. J. Dezube. 
2008. HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi 
sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion 
lymphoma, and multicentric Castleman disease. Clin Infect Dis 47:1209-15. 
149. Sun, R., S. F. Lin, L. Gradoville, Y. Yuan, F. Zhu, and G. Miller. 1998. A 
viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated 
herpesvirus. Proc Natl Acad Sci U S A 95:10866-71. 
150. Tada, K., T. Okazaki, S. Sakon, T. Kobarai, K. Kurosawa, S. Yamaoka, 
H. Hashimoto, T. W. Mak, H. Yagita, K. Okumura, W. C. Yeh, and H. 
Nakano. 2001. Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-
induced NF-kappa B activation and protection from cell death. J Biol Chem 
276:36530-4. 
151. Taylor, M. M., B. Chohan, L. Lavreys, W. Hassan, M. L. Huang, L. 
Corey, R. Ashley Morrow, B. A. Richardson, K. Mandaliya, J. Ndinya-
Achola, J. Bwayo, and J. Kreiss. 2004. Shedding of human herpesvirus 8 in 
41 
 
oral and genital secretions from HIV-1-seropositive and -seronegative Kenyan 
women. J Infect Dis 190:484-8. 
152. Thiers, H., D. Colomb, J. Fayolle, D. Germain, G. Moulin, and A. 
Chassard. 1958. [Two cases of Kaposi-Juliusberg varioliform pustulosis 
caused by a virus of herpetic type.]. Lyon Med 90:838-9. 
153. Trompouki, E., E. Hatzivassiliou, T. Tsichritzis, H. Farmer, A. Ashworth, 
and G. Mosialos. 2003. CYLD is a deubiquitinating enzyme that negatively 
regulates NF-kappaB activation by TNFR family members. Nature 424:793-6. 
154. Vieira, J., M. L. Huang, D. M. Koelle, and L. Corey. 1997. Transmissible 
Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of 
men with a history of Kaposi's sarcoma. J Virol 71:7083-7. 
155. Wang, J., A. N. Loveland, L. M. Kattenhorn, H. L. Ploegh, and W. 
Gibson. 2006. High-molecular-weight protein (pUL48) of human 
cytomegalovirus is a competent deubiquitinating protease: mutant viruses 
altered in its active-site cysteine or histidine are viable. J Virol 80:6003-12. 
156. Wang, S. E., F. Y. Wu, M. Fujimuro, J. Zong, S. D. Hayward, and G. S. 
Hayward. 2003. Role of CCAAT/enhancer-binding protein alpha 
(C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus 
(KSHV) lytic-cycle replication-associated protein (RAP) promoter in 
cooperation with the KSHV replication and transcription activator (RTA) and 
RAP. J Virol 77:600-23. 
157. Wertz, I. E., K. M. O'Rourke, H. Zhou, M. Eby, L. Aravind, S. Seshagiri, 
P. Wu, C. Wiesmann, R. Baker, D. L. Boone, A. Ma, E. V. Koonin, and V. 
M. Dixit. 2004. De-ubiquitination and ubiquitin ligase domains of A20 
downregulate NF-kappaB signalling. Nature 430:694-9. 
158. Wu, W., J. Vieira, N. Fiore, P. Banerjee, M. Sieburg, R. Rochford, W. 
Harrington, Jr., and G. Feuer. 2006. KSHV/HHV-8 infection of human 
hematopoietic progenitor (CD34+) cells: persistence of infection during 
hematopoiesis in vitro and in vivo. Blood 108:141-51. 
159. Xu, Y., D. P. AuCoin, A. R. Huete, S. A. Cei, L. J. Hanson, and G. S. Pari. 
2005. A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 
ORF50 deletion mutant is defective for reactivation of latent virus and DNA 
replication. J Virol 79:3479-87. 
160. Ye, F. C., F. C. Zhou, S. M. Yoo, J. P. Xie, P. J. Browning, and S. J. Gao. 
2004. Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear 
antigen leads to abortive episome persistence. J Virol 78:11121-9. 
161. Young, L. S., and A. B. Rickinson. 2004. Epstein-Barr virus: 40 years on. 
Nat Rev Cancer 4:757-68. 
42 
 
162. Zhang, L., J. Chiu, and J. C. Lin. 1998. Activation of human herpesvirus 8 
(HHV-8) thymidine kinase (TK) TATAA-less promoter by HHV-8 ORF50 
gene product is SP1 dependent. DNA Cell Biol 17:735-42. 
163. Zhou, F. C., Y. J. Zhang, J. H. Deng, X. P. Wang, H. Y. Pan, E. Hettler, 
and S. J. Gao. 2002. Efficient infection by a recombinant Kaposi's sarcoma-
associated herpesvirus cloned in a bacterial artificial chromosome: application 
for genetic analysis. J Virol 76:6185-96. 
164. Zhou, H., I. Wertz, K. O'Rourke, M. Ultsch, S. Seshagiri, M. Eby, W. 
Xiao, and V. M. Dixit. 2004. Bcl10 activates the NF-kappaB pathway 
through ubiquitination of NEMO. Nature 427:167-71. 
165. Zhu, F. X., J. M. Chong, L. Wu, and Y. Yuan. 2005. Virion proteins of 
Kaposi's sarcoma-associated herpesvirus. J Virol 79:800-11. 
166. Ziegler, J. L., and E. Katongole-Mbidde. 1996. Kaposi's sarcoma in 
childhood: an analysis of 100 cases from Uganda and relationship to HIV 
infection. Int J Cancer 65:200-3. 
167. Ziegler, J. L., T. Simonart, and R. Snoeck. 2001. Kaposi's sarcoma, 
oncogenic viruses, and iron. J Clin Virol 20:127-30. 
 
 
   
CHAPTER TWO 
 
IDENTIFICATION AND CHARACTERIZATION OF THE KSHV ORF49 PROTEIN 
 
Carlos M. Gonzalez1,2, Emily L. Wong1,3, Brian S. Bowser1,2, Gregory K. Hong1,2, 
Shannon Kenney1,3 and  Blossom Damania1, 2* 
 
Copyright © American Society for Microbiology, Journal of Virology (2006), 
Mar;80(6):3062-70. 
 
 
 
 
 
 
 
44 
 
 ABSTRACT  
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s 
sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman’s disease 
(MCD). KS is the most common neoplasm among HIV-positive individuals. Like other 
herpesviruses, KSHV is able to establish a predominantly latent, life-long infection in its 
host. The KSHV lytic cycle can be triggered by a number of stimuli that induce the 
expression of the key lytic switch protein, the replication and transcription activator (RTA) 
encoded by Orf50. The expression of Rta is necessary and sufficient to trigger the full lytic 
program resulting in the ordered expression of viral proteins, release of viral progeny and 
host cell death. We have characterized an unknown open reading frame, Orf49, which lies 
adjacent and in the opposite orientation to Orf50. Orf49 is expressed during the KSHV lytic 
cycle and shows early transcription kinetics.  
We have mapped the 5’ and 3’ ends of the unspliced Orf49 transcript, which encodes 
a 30kD protein that is localized to both the nucleus and the cytoplasm.  Interestingly, we 
found that Orf49 was able to cooperate with Rta to activate several KSHV lytic promoters 
containing AP-1 sites. The Orf49-encoded protein was also able to induce transcriptional 
activation through c-Jun but not ATF1, ATF2, or CREB transcription factors. We found that 
Orf49 could induce phosphorylation and activation of the transcription factor, c-Jun, the Jun 
N-terminal kinase (JNK) and p38. Our data suggests that Orf49 functions to activate the JNK 
and p38 pathways during the KSHV lytic cycle. 
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INTRODUCTION 
Kaposi’s Sarcoma-associated Herpesvirus (KSHV) is etiologically linked to Kaposi’s 
sarcoma (KS) (12, 17, 25) primary effusion lymphoma (PEL) and multicentric Castleman’s 
disease (MCD) (3, 4).  KS is the leading neoplasm in HIV- positive individuals. KSHV is the 
most recently described human herpes virus, identified in 1994 by Chang et al.(6) via 
representational difference analysis (RDA). A member of the gamma-subfamily of herpes 
viruses, KSHV is also the only known human rhadinovirus. Like other herpesviruses, KSHV 
can establish both latent and lytic infection in its host. The lytic program can be triggered by 
a number of stimuli that induce the expression of the lytic switch protein, the replication and 
transcription activator (RTA) encoded by Orf50 (38). The expression of RTA is necessary 
and sufficient to trigger the full lytic program (21, 22) resulting in the ordered expression of 
all viral proteins, release of viral progeny and host cell death. RTA/Orf50 initiates the lytic 
cascade by inducing the transcriptional activation of viral promoters like PAN, ORF6 (single 
stranded DNA binding protein), K1, K2 (vIL-6), K5, K6 (vMIP-1), K8 (MTA), K9 (vIRF), 
ORF57 (MTA), ORF50 (RTA), thymidine kinase, K12 (kaposin), K14 (vOX-2), and ORF74 
(vGPCR) (5, 7, 9, 10, 16, 20, 21, 33, 37, 39, 44).  
This wide range of promoter activation occurs through sequence-specific binding of 
Orf50 to DNA via RTA responsive elements (RREs) (5, 9, 20, 37) and binding to cellular 
transcription factors like C/EBP-α and RBPJ-κ (19, 41). Another protein expressed in the 
lytic cascade is K8 or K-bZIP, a structural and positional homologue of EBV ZTA. However, 
unlike EBV ZTA, K-bZIP is unable to activate lytic transcription from latency (30). K-bZIP 
shows strong trans-repression of viral ORF50 (15) and cellular p53 (28) promoters. 
SUMOylation of K8 mediates its repression (14).  
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Studies on KSHV pathogenesis have been limited to latently infected PEL-derived B 
cell lines like BCBL-1, BC-2, JSC-1, BC-3 or BC-1. In these cell lines, latency can be 
disrupted by the addition of the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) or 
histone de-acetylase (HDAC) inhibitor, sodium butyrate (24, 32). However, the efficiency of 
reactivation as measured by viral particle production, is very low, peaking at approximately 
twenty percent (42). Moreover, studies of KSHV latency are complicated by the fact that, at 
any time, ~5% of these cells are undergoing spontaneous lytic reactivation. 
In an effort to enhance our understanding of KSHV pathogenesis, we focused our 
attention on Orf49, an uncharacterized open reading frame in the lytic switch locus. Orf49 is 
located adjacent to Orf50 and on the opposite strand. The gene encoded by Orf49 shows 
limited sequence homology to the EBV BRRF1 gene. EBV BRRF1 lies in the same relative 
orientation as KSHV Orf49 and is subject to a similar splicing event that omits the BRRF1 
sequence from the EBV RTA transcript (34).  
Here we describe the initial characterization of KSHV Orf49 and its encoded protein.   
We have identified the 5’ and 3’ ends of the Orf49 transcript using rapid amplification of 
cDNA ends (RACE) and have characterized its transcription kinetics. The Orf49-encoded 
protein by itself could not activate any of the KSHV promoters we tested by promoter 
reporter assays, but it was able to cooperate with KSHV Orf50 to activate a number of lytic 
promoters containing AP1 sites. We also found that Orf49 can activate the c-Jun and the 
JNK/p38 pathways. We suggest that Orf49-mediated activation of the p38/JNK pathway 
during lytic reactivation plays an important role in KSHV viral replication.  
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MATERIALS AND METHODS 
Cell culture: Cos-1, 293, and Hela cells were grown in Dulbecco modified eagle medium 
(DMEM) supplemented with 10% FBS, penicillin and streptomycin (P/S) and 1X Gluta-max. 
CV-1 cells were further supplemented with Non-essential amino acids. Rhesus fibroblasts 
(RhF) were cultured in DMEM with 10% Cosmic Calf serum, P/S and 1X Gluta-max. The 
BCBL-1 cell line was grown in RPMI 1640 media with 10% FBS, P/S and L-glutamine. The 
BC-1 cell line was further supplemented with Sodium Pyruvate. All cell lines were 
maintained at 37°C and 5% CO2. BCBL-1 and BC-1 cells were induced into lytic 
reactivation by treating with 25ng/ml phorbol-12-tetradecanoate-13-acetate (TPA) or mock 
treated with the carrier dimethyl sulfoxide (DMSO). Transient transfections were carried out 
with the Superfect (Qiagen) reagent according to manufacturer’s directions.  
Plasmids: KSHV Orf49 was PCR amplified from the DNA of BCBL-1 cells induced with 
TPA for 48 hrs using primers 5` gcggcggaattcatggactacaaggacgacgacaa gacatcgagaaggcccc 
and 3` cgccgcagatctacctttttattgtatactgaacaatgc. The 5` primer added a Flag epitope to the 
PCR product, which was subsequently cloned into the pSG5 vector (Stratagene). The Orf50 
cDNA plasmid was amplified with primers 5` cgccgcgaattcatggcgcaa-
gatgacaagggtaagaagcttcggcggtcc and 3` cgccgcagatctttaacacttgtcgtcgtcgtccttgtagtcgt-
ctcggaagtaattacgcc, tagged with Flag at the C-terminal end and cloned into pSG5. Orf50p, 
Orf57p, K8p, vIL-6p and vPolymerase promoter reporter constructs have been described 
previously (16, 19-22) and encode a viral promoter, which drives expression of the firefly 
luciferase gene in the pGL3-Basic vector (Promega). Transcription factor plasmids, also 
described previously (13), encode Gal-4, ATF1, ATF2, CREB or c-Jun fused to the Gal-4 
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DNA-binding domain. The E1B-CAT reporter plasmid contains 5 copies of the Gal-4 DNA-
binding site upstream of the E1B TATA box and CAT gene.  
5` and 3` Rapid amplification of cDNA ends (RACE): Total RNA from TPA induced 
BCBL-1 cells was reverse-transcribed using the Smart RACE cDNA amplification kit 
(Clonetech) with random hexamer primers. The product was used as template in a PCR 
reaction with one of the following Orf49 specific primers (5`-1 cttgaccaaagccgcggaacctaggt, 
5`-2 ggaataagccaaattccgccctagccgc,  3`-1 tgtcgttcagatgtaccagcggtgca and 3`-2 
gtccgtcgccaccctcaatccagact). 5` and 3` PCR products were cloned into pCR2-TOPO vector 
(Invitrogen) and individual colonies were sequenced. 
RNA extractions and Northern Blots: Total cellular RNA extractions were performed with 
the RNA STAT-60 reagent (Tel-Test) according to manufacturer’s instructions. Ten 
micrograms total RNA per sample were electrophoresed in 1.5% agarose-formaldehyde gels 
and transferred to nitrocellulose membranes (Hybond N+; Amersham Pharmacia) by 
capillary transfer for 16-20 hours. Radioactive probes were made by random primed 
oligonucleotide labeling (Random Primed DNA-labeling kit, Roche) of gel purified PCR 
products with [γ-32P]dCTP (GE Healthcare). All hybridizations were performed using 
Quickhyb solution (Stratagene) for 16-20 hours at 60°C in a rotating hybridization oven. 
Membranes were washed twice in 2X SSC (1X SSC is 0.14M NaCl plus 0.015 soduim 
citrate)-0.1% sodium dodecyl sulfate (SDS) for 15 min at room temperature and once with 
0.1X SSC-0.1% SDS for 30 min at 60°C. Membranes were then analyzed with a 
PhosphorImager (Molecular Dynamics). 
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Western Blots: Transfected cells in 100mm dishes were washed twice with PBS harvested 
with 200ul radioimmunoprecipitation (RIPA) buffer (150mM NaCl, 1% NP40, 50mM Tris 
[pH 6.8], 0.5% sodium deoxycholate, 0.1% SDS) and freeze/thawed three times. Cell debris 
was spun down and the supernatant quantitated by Bradford assay (Biorad). Cell lysates were 
incubated with SDS gel loading buffer at 95°C for 5 min, on ice for 1 min and submitted to 
SDS-polyacrylamide gel electrophoresis (8). For glycosylation experiments Tunicamycin 
(Sigma) was added to cells to a final concentration of 20ng/ml or mock treated with an equal 
volume of carrier and harvested after 48 hours for Western blot analysis. Phosphatase 
treatments of whole cell lysates were performed following incubation with monoclonal anti–
Flag antibody (Sigma) for 1 hour at room temperature and immuno-precipitation for 16 hours 
at 4°C with AG beads (Santa Cruz). Beads were spun down and resuspended in 100ul NEB 
buffer 3 and three microliters of Calf Intestinal Phosphatase (New England Biolabs) or PBS 
followed by incubation for one hour at 37°C. Electrophoresed gels were transferred to 
nitrocellulose membranes (Hybond, Amersham) in a semi-dry transfer apparatus (Biorad) at 
constant 20V for 1 hour and blocked in 5% dry milk, 1% Tween-20 Tris Buffered Saline 
(TBSt) for 1 hour at room temperature. Peroxidase-labeled antibody to Flag epitope (Sigma), 
total and phosphorylated c-Jun, Beta-Actin (Cell Signaling) and total and phosphorylated 
JNK antibodies (Upstate) were used at 1:1000 dilutions in TBSt or 5% milk-TBSt. 
Membranes were washed 3 times for 5 min and immunoblots detected with the SuperSignal 
Chemiluminescent substrate (Pierce).  
Fractionation assays transfected cells were washed twice with 1X PBS and 
trypsinized for 5 minutes at 37°C. Trypsin was inactived by adding an equal volume of 
complete growth media (5% serum) and kept on ice. Cells were washed with PBS, 
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supernatants removed and cells resuspended in 500 microliters cytosolic lysis buffer (5mM 
Pipes, pH 8.0, 85mM KCl, 0.5% NP40) followed by a 5 minute incubation on ice. Nuclei 
were spun down and the cytosolic fraction removed. The nuclear fraction was washed with 
PBS, spun down and lysed with RIPA buffer. Finally, both fractions were freeze-thawed 
thrice and cleared by cenrtifugation. 
Immuno-fluorescence Assays: Cos-1, CV-1, and RhFs were seeded in 6 well plates and 
transfected with 4µg DNA per well. Forty-eight hours post transfection cells were washed 
twice with 1X TBS and fixed in 1:1 methanol:acetone at room temperature for 1 min. Cells 
were washed 4 times with TBS and incubated with 1:1000 anti-Flag Cy3 (Sigma) in TBS for 
1 hour at room temperature. DAPI in PBS was added for 10min followed by 2 more washes 
in TBS. Fluorescence was assayed in a Zeiss Axiovert 200 inverted microscope. 
Promoter Reporter Assays: Six well plates seeded with CV-1 cells were co-transfected 
with 1.5µg promoter reporter construct and 1.5µg of pSG5, pSG5-Orf49, or pSG5-
Orf50cDNA. One microgram β-galactosidase (β-gal) was co-transfected into each sample to 
normalize for transfection efficiency. Each sample was analyzed in duplicate in at least 2 
experiments. Forty-eight hours post-transfection cells were washed once in cold 1X PBS and 
lysed by freeze-thawing in 1X Reporter Lysis Buffer (Promega). Lysates were analyzed for 
Luciferase activity with the Luciferase assay system (Promega) and for β-gal activity with 
the Galacto-Star Kit (Tropix) in a FLUOstar plate reader (BMG labtech). 
Chloramphenicol Acetyl-Transferase Enzyme-linked Immunosorbent Assays  
(CAT-ELISA): CV-1 cells were seeded in 6-well plates and co-transfected with 1.2µg E1B-
CAT, 1.2µg of transcription factor reporter and 1.2µg pSG5 or pSG5-Orf49. 0.6µg β-gal was 
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added to each sample to normalize for transfection efficiency. Forty-eight hours post-
transfection cells were washed 3 times in cold 1X PBS and lysed. Cell lysates were spun 
down and incubated in CAT-ELISA kit (11) microwell plates according to manufacturer’s 
recommendations. CAT expression was assayed using a FLUOstar plate reader (BMG 
labtech). 
RT-PCR: c-Jun N-terminal Kinase (JNK) inhibitor SP600125 or p38 inhibitor SB202190 
(Sigma Aldrich) was added to a final concentration of 20μM to BCBL-1 cells and 
simultaneously induced with TPA or mock induced with DMSO. RNA was harvested 24 
hours post induction using the RNA STAT-60 reagent (Tel-Test) according to 
manufacturer’s instructions and equal amounts were reverse transcribed with the Reverse 
Transcription System kit (Promega). The product was diluted ten to fifty fold and used as 
template for PCR reactions with primers to vGPCR, Orf57 (MTA), Orf49, LANA and 
cellular GAPDH. 
RESULTS 
Identification of the Orf49 transcript: In an effort to identify the Orf49 transcript we 
performed 5’ and 3’ rapid amplification of cDNA ends (RACE). Total RNA was isolated 
from TPA-induced BCBL-1 cells and used as template for an initial reverse transcription 
step. Gene-specific primers were then used to amplify, clone and sequence Orf49 cDNA. We 
designed Orf49-specific primer sets to amplify the 5’ and 3’ ends of Orf49 cDNAs and 
produce a 200bp region of overlap between them enabling the alignment of the 5’ and 3’ 
clone sequences (Fig.1A). The PCR products (Fig.1B) were cloned into the TOPO 2.1 vector 
(Invitrogen). Since the length of Orf49 is about 930bp we were able to produce sequence 
alignments of the full-length Orf49 transcript including a short 5’ untranslated region (UTR) 
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and the 3` poly-adenosine tail (Fig. 1C). As depicted in Fig.1C, the full-length Orf49 
transcript is not spliced and the coding sequence is identical to the genomic open reading 
frame.  
Kinetics of expression of Orf49: In order to map the expression kinetics of Orf49 we 
induced BCBL-1 cells with 25ng/ml TPA or vehicle (DMSO) and harvested total RNA at 12, 
24, 36, 48 and 72 hours post-induction. Ten micrograms of total RNA per sample was 
electrophoresed on an agarose-formaldehyde gel and the resolved RNAs were transferred to 
nitrocellulose.   
Northern blot analysis was performed with an Orf49 probe. Fig. 2 (upper panel) 
shows that Orf49 RNA is only transcribed in TPA-induced cells and not in the DMSO-
treated cells. Orf49 was observed in two different transcripts; 3.6 and 1.2 Kb in size. The 1.2 
kb transcript is very close in size to the predicted size of Orf49 while the 3.6 Kb band likely 
represents a poly-cistronic transcript. The Orf49 transcripts were readily detectable at 12 hrs 
post-induction indicating that this gene is transcribed with early kinetics. The signal peaked 
between 24 and 36 hrs post-induction and remained high at the 48 and 72 hour timepoints. A 
Northern blot with Orf50-specific probe was included (middle panel) 
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Figure 1. Delineation of the full-length Orf49 transcript. A) RT-PCR design. Schematic 
representation of the Orf49 coding region (top) and location of RT-PCR primers designed for 
5` and 3` RACE (arrowheads). B) Molecular cloning of RT-PCR products. Ethidium 
Bromide visualization of RT-PCR products. Marker band sizes are provided on the right. 
Lanes 5’-1, 5’-2 yielded products of ~900 and ~350 basepairs (bp) respectively. Lanes 3’-1, 
3’-2 yielded products of ~340 and ~850bp respectively. Lane M: marker, Lane + : primers 
5`-1 and 3`-2 yield an internal fragment of  750bp, Lane - : negative control (no reverse 
transcriptase).C) Sequence of the full-length Orf49 transcript with 5’ and 3’ UTRs. RT-PCR 
products were cloned, sequenced and aligned.  A short 5’ UTR and a 3` poly-A tail were 
identified. The transcript is not spliced and therefore identical to the genomic coding 
sequence. 
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in order to demonstrate efficient reactivation.  The lower panel in Fig. 2 shows the agarose 
gel with equal loading of the individual RNA samples. Orf49 thus encodes a lytic protein that 
is transcribed with early kinetics and to high levels.  
Characterization of the Orf49 protein: The cDNA for KSHV Orf49 was PCR amplified 
and a Flag epitope was inserted at the N-terminus of the protein. The PCR product was then 
cloned into the pSG5 (Stratagene) vector and transfected into Cos-1 cells. As shown in Fig. 
3A, Orf49 ran as a 30kD protein on SDS-PAGE.  Sequence analyses of Orf49 suggested 
several possible N-linked glycosylation and phosphorylation sites but no significant 
similarity to other known proteins or cellular localization signals. The glycosylation state of 
Orf49 was determined by treating cells with tunicamycin, an inhibitor of N-glycosylation, for 
48 hours and performing an Orf49 Western blot. Tunicamycin treatment did not change the 
electrophoretic profile when compared to mock treatment suggesting that Orf49 is not N-
glycosylated (data not shown).         
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Figure 2. Expression Kinetics of Orf49. BCBL-1 cells were induced into lytic reactivation 
with 25ng/ml TPA or mock treated with DMSO. Total RNA was harvested at 12, 24, 36, 48 
and 72 hours post-induction and 10g RNA loaded per well of a formaldehyde-agarose gel. 
Northern blot analysis with an Orf49-specific probe reveals two Orf49 transcripts (Upper 
panel), a longer, 3.6 Kb transcript and a shorter 1.2 Kb species. Middle panel: Northern Blot 
with a Orf50-specific probe to demonstrate reactivation. Lower panel: loading control as 
visualized by Ethidium Bromide staining of the formaldehyde-agarose gel prior to transfer 
onto nitrocellulose membrane. 
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In order to identify the phosphorylation state of the Orf49 protein we transiently 
transfected Cos-1 cells with Orf49-Flag plasmid and immunoprecipitated the lysates with 
anti-Flag monoclonal antibody. Lysates were either treated with phosphatase or mock treated 
with PBS followed by Western blot with anti-Flag antibody. There was no difference in 
migration between phosphatase treated versus mock treated cell lysates suggesting that the 
protein may not be phosphorylated (data not shown). However it is possible that if 
phosphorylated, the protein is either resistant to CIP treatment or the mobility shift is too 
small to be detected by conventional SDS-PAGE. 
We next determined the intracellular localization of the Orf49-encoded protein. Cos-1 
cells and Rhesus fibroblasts (RhFs) were transfected or mock transfected with Orf49 
plasmid. Cos-1 cells were harvested using a cell fractionation method in order to separate the 
cytoplasmic and nuclear fractions of lysates. The nuclear, cytoplasmic and a non-
fractionated, total protein sample were subjected to Western Blots with Flag antibody. As 
shown in Fig.3, the flag-tagged Orf49 protein is detectable in the nucleus of Cos-1 cells as 
well as in the cytoplasm. We used the cytoplasmic marker GRP-78 (35) as a control for the 
stringency of the cell fractionation method to show that there was no detectable cytoplasmic 
contamination in the nuclear fraction.  
For immuno-fluoresence we chose RhF cells because of their elongated shape and 
clear demarcation of the nucleus and cytoplasm. 48 hours post-transfection RhFs were 
subjected to immuno-fluorescence assays using an anti-Flag antibody conjugated to Cy-3 
dye, and DAPI, a nuclear stain. We found that Orf49 was present in both the cytoplasm and 
nucleus. Fig.4 shows immunofluorescence of Orf49 in the RhF cells. Panels a and e show 
bright field images of the cells, panels b and f represent staining while panels 
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Figure 3. Cell fractionation of Orf49-transfected cells.   Cos-1 cells were transfected with 
Orf49-Flag and separated into nuclear and cytoplasmic fractions. Equal amounts of protein 
were loaded onto SDS-PAGE gels, transferred to nitrocellulose and the blots were probed 
with Flag antibody. The upper panel shows Orf49-Flag expression in the nucleus and the 
cytoplasm. The lower panel shows expression of GRP-78, a bonafide cytoplasmic marker. 
60 
 
 
 
61 
 
Figure 4. Cellular localization of Orf49. Rhesus fibroblasts (RhF) were transfected with an 
expression vector encoding a Flag-tagged Orf49 protein. 48 hours later, cells were fixed and 
stained with the nuclear DAPI stain (blue) and a Cy-3-conjugated antibody to the Flag 
epitope (red). Orf49 is readily detected in both the nucleus and cytoplasm of the cell.  Panels 
a and e: phase contrast, panels b and f: Cy-3, panels c and g: DAPI, panels d and h: merge 
DAPI and Cy-3 stains. Panels a-d at 40X magnification and panels e-h at 100X 
magnification. 
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c and g represent nuclear staining with DAPI. A merged view of Orf49 and nuclear staining 
is shown in panels d and h. We observed similar cellular localization profiles for Orf49 in 
CV-1 and 293 cells (data not shown).  
Orf50-mediated activation of key lytic promoters is enhanced by Orf4: Since Orf49 was 
expressed with early kinetics and appeared to be both nuclear and cytoplasmic, we attempted 
to determine if it could activate expression from a number of KSHV lytic promoters. We co-
transfected a set of promoter-luciferase reporter constructs including Orf57p, vGPCRp, and 
K8p with cDNA expression plasmids for either, Orf50, Orf49 or both. Although Orf49 was 
in itself unable to achieve high levels of activation of any of the promoters tested, we 
observed a cooperative effect of Orf49 with Orf50 on the activation of Orf57p, vGPCRp, and 
K8p (Fig. 5). Orf49 could augment Orf50-mediated transactivation of these promoters. It is 
important to note that Orf50-mediated induction of these promoters ranged from 50 to 300 
fold over that of empty plasmid arguing for a strong enhancing effect by Orf49 over an 
already high level of expression. (Fig.5). There was no cooperation with Orf50 on the 
induction of the vIL-6, Orf50, Pan (nut-1), and viral DNA polymerase promoters by Orf49 
(data not shown). Closer inspection of the promoter sequences cooperatively activated by 
Orf50 and Orf49 revealed that they all contain AP-1 sites, raising the possibility that Orf49 
may augment Orf50 transcription in an AP1-dependent manner. 
Orf49 can enhance c-Jun transcriptional function: In order to determine if Orf49 could 
activate transcription factors through the activation of AP-1 sites, we performed 
chloramphenicol acetyl-transferase (CAT) reporter assays with a c-Jun reporter plasmid. We 
examined whether Orf49 could augment the function of ATF-1, ATF-2, CREB or c- 
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Figure 5. Orf49 enhances Orf50-mediated induction of K8, Orf57 and vGPCR lytic 
promoters. Promoter reporter assays: empty vector (pSG5), Orf50, Orf49 or Orf50 plus 
Orf49 expression constructs were co-transfected into CV-1 cells with plasmids in which the 
vGPCR, K8 and Orf57 lytic promoters drive luciferase expression. 48 hours post-
transfection, promoter activity was determined by luciferase assay. Luciferase activities were 
normalized to beta-galactosidase and expressed as fold induction over empty plasmid. Fold 
activation values are indicated above each bar along with the standard error. Each experiment 
was performed in duplicate and the experiment was repeated several times. 
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Jun fusion proteins linked to the Gal4 DNA binding domain. Orf49 was co-transfected with 
ATF-1, ATF-2, CREB-1, and c-Jun Gal4 protein fusion expression plasmids into CV-1 cells 
and the activation of a reporter plasmid containing five copies of the Gal4 DNA binding site 
upstream of the CAT gene was measured by a CAT ELISA.  As shown in Fig. 6, Orf49 was 
unable to activate transcription through the ATF1, ATF2 and CREB transcription factors. 
However, there was a dose-dependent, ~5 fold induction of the c-Jun transcription factor 
over that of empty plasmid. Since the DNA binding activity in this experiment was mediated 
through the Gal4 DNA binding domain of the individual fusion proteins, these results suggest 
that Orf49 activates promoters by enhancing c-Jun transcriptional function. Moreover, the 
selective activation of c-Jun but not other transcription factors could explain why Orf49 was 
able to enhance Orf50 induction of only those promoters with AP1 sites, given that c-Jun is 
one of the strongest activators of AP1 elements. 
Orf49 is capable of inducing c-Jun phosphorylation: The activation of c-Jun is attributed 
to the phosphorylation of serine residues 63 and 73 (34, 36). In order to confirm that c-Jun 
was activated in cells expressing Orf49, we transfected CV-1 cells with an Orf49 expression 
plasmid and harvested protein lysates in the presence of phosphatase inhibitors. Western Blot 
analyses were performed using antibodies against total c-Jun or phosphorylated c-Jun at both 
serine residues 63 and 73 to determine the phosphorylation and activation state of c-Jun in 
the presence or absence of Orf49. Figure 7A shows that the c-Jun phosphorylation is greatly 
increased in the presence of Orf49 as compared to empty vector control.  
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Figure 6. Orf49 enhances c-Jun transcriptional function.  pSG5 empty vector or Orf49 
expression plasmids were co-transfected into CV-1 cells with plasmids encoding five copies 
of the Gal4 binding site upstream of the CAT gene and Gal4-protein fusions of ATF1, ATF2, 
CREB and c-Jun. Orf49 enhanced c-Jun-mediated transcription in a dose-dependent manner, 
but did not affect ATF-, ATF-2 or CREB-dependent transcription function. 
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c-Jun phosphorylation is mediated by c-Jun N-terminal kinase (JNK). We transfected 
293 cells with an Orf49 expression plasmid and performed Western blots to determine if JNK 
kinase was activated in the presence of Orf49. JNK activation can be measured by the 
phosphorylation status of threonine 183 and tyrosine 185 residues (18). We found that Orf49 
was in fact able to induce the phosphorylation of JNK in 293 cells (Fig. 7B), leading to the 
activation of c-Jun and c-Jun–mediated transcription. In addition, p38 kinase, another 
member of the mitogen-activated protein (MAP) kinase family was also phosphorylated and 
activated in Orf49 expressing cells as compared to the vector control (Fig. 7B).  
In order to ascertain if JNK and p38 are indeed activated in the more physiologically 
relevant context of reactivation of latently-infected B cells, we used a BCBL-1 cell line in 
which the lytic switch RTA is inducible by Tetracycline (26). In these cells RTA expression 
is tightly regulated by Tetracyclin (or Doxycyclin) and upon induction follows the strict 
pattern of gene expression characteristic of herpesviruses. Western blots for phospho-JNK 
and phospho-p38 were performed on lysates from the RTA-TREX BCBL-1 cells and the 
negative control pcDNA-TREX BCBL-1 cells, with or without a 24 hour Doxycyclin 
induction (final concentration of 1μg/ml). Western blots for RTA were also performed to 
demonstrate the Dox-mediated induction of RTA. As shown in figure 7C, both JNK and p38 
are activated after induction of RTA-TREX BCBL-1 cells, but not pcDNA-TREX BCBL-1 
cells, thus demonstrating that RTA-induced lytic reactivation does induce 
phosphorylation/activation of JNK and p38 kinases and that our results are not an artifact of 
TPA-induction or transient transfection.  
 
69 
 
 
 
 
70 
 
Figure 7. Orf49 induces phosphorylation of c-Jun by activation of JNK and p38. 
A) CV-1 cells were transfected with EGFP vector or an Orf49 expression plasmid and cells 
were harvested and lysed 48 hours post transfection. Phospho-c-Jun levels increased in the 
presence of Orf49 (first panel) while total c-Jun levels (second panel) remained comparable. 
The third panel shows expression of Orf49. Actin expression is also shown in the bottom 
panel to indicate equivalent loading.  B) Both JNK and p38 pathways are activated by Orf49. 
CV-1 cells were transfected with pSG5 vector or Orf49 expression plasmids, serum starved 
for 24 hours and harvested 48 hours post transfection. Lysates were subjected to Western blot 
analysis with anti-phospho-JNK (pJNK) and anti-phospho-p38 (pp38) antibodies. Cells 
expressing Orf49 (as determined by western blot with anti-Flag) showed vastly increased 
levels of phospho-JNK and phospho-p38 compared to the empty vector control. Actin 
expression is also shown in the bottom panel to indicate equivalent loading.  C) JNK and p38 
are activated during reactivation. pcDNA-TREX-BCBL-1 cells carrying pcDNA (empty) 
vector or RTA-TREX-BCBL-1 cells carrying a Doxycylin-inducible RTA were treated with 
1 microgram/ml Doxycyclin or untreated for 24 hours. Lysates were harvested and Western 
blots for phospho-JNK, phospho-p38 and Orf50 were performed. Doxycyclin-induced RTA-
TREX BCBL-1s showed increased levels of both phospho-JNK and phospho-p38, while 
pcDNA-TREX BCBL-1s cells showed no activation of JNK or p38. Orf50 expression was 
only induced in the RTA-TREX BCBL-1 cells as expected. 
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Figure 8. JNK and p38 activation is necessary for lytic gene expression. A) Reverse 
transcriptase-PCR (RT-PCR) of total RNAs from TPA-induced or mock-treated BCBL-1 
cells treated for 24 hours with JNK inhibitor SP600125 or p38 inhibitor SB202190 was 
performed. PCR reactions using vGPCR and Orf57 primers revealed that expression levels of 
these early genes are inhibited by JNK and p38 inhibitors. However, expression of the Orf49 
gene product was not inhibited by the presence of JNK or p38 inhibitors. In addition, levels 
of the latency gene, LANA, were not affected by the JNK or p38 inhibitors. The human 
GAPDH transcript was used as a loading control.  B) JNK and p38 inhibition hinder late 
protein synthesis. BC-1 cells were induced with TPA (or mock induced with DMSO) and 
JNK or p38 inhibitor. Cell lysates were harvested and equal amounts of total protein 
analyzed by Western blots using antibody directed against the late protein, Orf62/mCP. The 
bottom panel shows an actin loading control. 
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Taken together these results define the mechanism by which the Orf49 protein 
activates c-Jun-mediated transcriptional activation, namely by eliciting the phosphorylation 
and activation of JNK/p38 MAP kinases.  
JNK/p38 activation is necessary for the expression of lytic proteins: In order to determine 
the effect of JNK/p38 on KSHV lytic reactivation and replication, BCBL-1 cells were 
induced with TPA and simultaneously treated with the JNK inhibitor, SP600125 or p38 
inhibitor, SB202190. Total RNA was harvested at 24 hours post-induction and reverse 
transcribed. The RT product was then diluted 10-50 fold and used as template in a PCR 
reaction with primer sets for the early lytic genes vGPCR, Orf57 and Orf49 as well as KSHV 
LANA and human GAPDH controls. Figure 8A shows the PCR products from these 
reactions. Both inhibitors seemed to decrease the levels of lytic expression of the vGPCR and 
Orf57 transcripts. The Orf49 transcript was unchanged in the presence of inhibitors 
suggesting that Orf49 expression is not refractory to JNK and p38 inhibition. The LANA and 
GAPDH controls were stable regardless of treatment or replicative state.  
 We also performed Western blots to examine the expression of late lytic proteins.  
Cell lysates were harvested 24 hours after treatment and equal amounts of protein were 
analyzed by Western blot with anti-KSHV Orf62 antibody. Orf62 is also called minor capsid 
protein (mCP) or TRI-1(27). As shown in Figure 8B, treatment with both JNK and p38 
inhibitors suppressed lytic reactivation as measured by expression of Orf62 protein. In 
summary, these results support a functional role for the JNK and p38 pathways in lytic 
reactivation.  
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DISCUSSION 
We report here the first characterization of KSHV Orf49 located in between the two exons 
coding for Orf50 and on the opposite strand. We performed 5’ and 3’ RACE to identify ends 
of the Orf49 transcript and found it to be unspliced. The Orf49 transcript was ~1000 base 
pairs long, containing the expected coding sequence of over 900 bases plus a 15 nt 5` UTR 
and a 67 nt 3’ UTR including the poly-A tail.  Northern blot analyses revealed that Orf49 
transcripts were highly expressed during lytic reactivation with early kinetics and throughout 
the length of TPA treatment. Two transcripts were detected with a Orf49-specific probe, one 
of 1.2Kb and a second of 3.6Kb. The 1.2Kb transcript corresponds closely to our full-length 
cDNA clone. However, it is possible that there are longer, possibly bi-cistronic, transcripts 
that we did not detect via RACE. Expression levels peaked at 36 hours post TPA induction 
by Northern blot analyses. These results are similar to those reported by others (29) and 
personal communication with Dr. Dirk Dittmer  who found that Orf49 expression peaks 
between 24 and 48 hours using microarray analyses.  
The cDNA encoded by Orf49 expressed a protein of ~30 kilodaltons in size. We 
determined that the Orf49-encoded protein is not N-glycosylated nor phosphorylated despite 
the presence of several possible glycosylation and phosphorylation sites in the coding 
sequence. However it is possible that the protein can be phosphorylated but is resistant to calf 
intestinal phosphatase. Additionally, the Orf49 protein was localized to both the nucleus and 
the cytoplasm of cells as observed by immunofluoresence and cell fractionation Western 
blots. 
We next assessed the role of Orf49 in viral transcription. We used promoter reporter 
assays to evaluate if Orf49 was in fact able to induce expression from lytic viral promoters. 
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Our results showed that Orf49 itself was not a potent transactivator but was able to cooperate 
with Orf50 to increase Orf50-mediated activation of the K8, Orf57 and vGPCR promoters. It 
is important to note that the activation of these promoters by Orf50 alone was already high 
ranging from 50-fold Orf57 to 350-fold (vGPCR) over that of empty vector. This strong 
activation of Orf57, vGPCR and K8 suggest that Orf49 synergizes with Orf50 to increase the 
efficiency of lytic reactivation. Indeed, Orf57 has been shown to bind Orf50 and induce 
expression from the Orf50 promoter (23) suggesting that, in vivo, induction of Orf57 could 
indirectly enhance Orf50 expression and thus lytic reactivation.  
The K8 protein binds the oriLyt and is essential for lytic replication (1), hence, the 
increase in K-bZip expression mediated by Orf49 could significantly enhance the efficiency 
of lytic reactivation initiated by Orf50. Finally, the constitutively activated viral G protein-
coupled receptor, vGPCR, is an early lytic gene that plays important roles in angiogenesis. 
Thus, cooperative induction of these three viral promoters by Orf49 and Orf50 has tangible 
biological consequences for host cells undergoing lytic replication as well as the surrounding 
environment.  
We have also identified a mechanism by which Orf49 induces expression of K8, 
Orf57 and vGPCR. These promoters all share AP-1 sites in addition to RTA-responsive 
elements (RREs). Using CAT-reporter assays we demonstrated that Orf49 can augment c-
Jun-mediated transcriptional activation and that this activation was dose-dependent. These 
results were further validated by assessing phospho-c-Jun levels in the presence or absence of 
Orf49. Expression of Orf49 increased phospho-c-Jun levels as compared to the vector 
controls. Orf50 has been shown to increase the levels of total c-Jun in DG75 cells, however it 
did not induce c-Jun phosphorylation (40). Together these findings could suggest a 
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mechanism by which Orf50 increases total c-Jun protein, and Orf49 induces phosphorylation 
and activation of c-Jun thus enhancing the total c-Jun transcriptional activation potential in 
the cell. 
Since c-Jun activation is dependent on c-Jun N-terminal Kinase (JNK), we also 
performed anti-phospho-c-Jun N-terminal kinase (JNK) Western blots and found that Orf49 
can indeed activate JNK. These results could indicate that c-Jun-mediated transcriptional 
activation is induced by Orf49 through JNK activation.  Interestingly, Orf49 also induced 
phosphorylation/activation of the p38 kinase. Both JNK and p38 pathways are activated by 
stress, growth factors and cytokines. They are activated by the same mitogen activated 
protein kinase kinase kinase (MAP3Ks), share the MAP2K (mitogen activated protein kinase 
kinase) MKK4, and are often co-activated (43). Signaling through both pathways can result 
in proliferation, differentiation or apoptosis although p38 activation is also involved in 
development, inflammation and stress responses.  
KSHV vGPCR has also been shown to trigger the activation of JNK and p38 (2) 
underscoring the significance of these pathways during lytic replication. Because of the 
wide-ranging effects of these pathways we wanted to assess the contribution of each pathway 
to lytic reactivation. JNK and p38 inhibitors blocked TPA-induced expression of early genes 
like vGPCR and Orf57 as well as late genes like Orf62/mCP. There was a marked decrease 
in the total amount of Orf62/mCP detected in both JNK and p38 inhibitor–treated, lytically 
reactivated cell lysates indicating that signaling through both pathways can influence, at 
least, the amount of late structural proteins produced.  
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KSHV Orf49 is the positional homologue of the EBV BRRF1 gene encoding the Na 
protein. Na has been shown to encode a 34 kD protein with early kinetics that is induced by 
ZTA (34). Hong et al. reported that EBV Na functions in the reactivation of latent EBV, by 
inducing lytic promoters and increasing the amount of viral progeny released (13). They 
further showed that the BRRF1 promoter was induced by ZTA through a CRE motif (ZII) 
and that Na enhanced EBV RTA’s ability to induce ZTA, thus creating a self-reinforcing 
loop. EBV Na was also shown to activate c-Jun-mediated transcription. These findings led to 
the identification of Na as a transcription factor that activates ZTA expression through the 
activation of c-Jun and cooperates with RTA (BRLF1) in reactivation of EBV from latency. 
However, since KSHV K8, the EBV ZTA homolog, cannot by itself reactivate the virus from 
latency, it seems likely that the main function of KSHV Orf49 is to augment Orf50 
transactivation of a sub-set of early promoters. 
Thus, Orf49 represents an important member in the lytic reactivation cascade that 
enhances transcription from key Orf50-responsive promoters through the transcriptional 
activation of c-Jun and also activates the JNK/p38 kinase pathways, which are necessary for 
KSHV viral reactivation from latency as well as viral replication. 
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ABSTRACT 
   Kaposi’s sarcoma-associated herpesvirus (KSHV) is etiologically linked to Kaposi’s 
sarcoma, primary effusion lymphomas and multicentric Castleman’s disease. Like other 
herpesviruses, KSHV can exist in either a lytic or a latent phase during its lifecycle. We 
report that the lytic protein encoded by KSHV open-reading frame 64 (Orf64) is a viral 
deubiquitinase (DUB) enzyme capable of deubiquitinating cellular proteins in vitro and in 
vivo. Orf64 deubiquitinase activity is effective against lysine 48 (K48) and lysine 63 (K63) 
linked ubiquitin chains. Orf64-encoded DUB activity lies within the first 205 residues of the 
protein and deubiquitination is dependent on a cysteine at position 29, since mutation of this 
residue ablated this activity. Cell fractionation studies revealed that the N-terminus and the 
full-length protein localized to both the nuclear and cytoplasmic compartments. Promoter 
reporter assays showed that Orf64 could synergize with the lytic switch protein, RTA, to 
enhance transcription from RTA-dependent lytic promoters. The function of Orf64 was 
tested by siRNA knockdown studies on latently infected cells that were induced into lytic 
replication. These experiments indicated that Orf64 plays a role in lytic replication since 
transcription and expression of lytic proteins was decreased in cells with reduced Orf64 
levels. In sum, KSHV Orf64 encodes a robust deubiquitinase, which is unique in at least two 
respects. First, it does not show specificity towards K48 or K63 ubiquitin linkages. Second, 
Orf64 appears to enhance RTA-mediated transactivation of KSHV lytic genes. Altogether, 
these characteristics suggest a novel role for Orf64, a tegument protein, in the KSHV 
lifecycle.  
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INTRODUCTION 
Kaposi’s sarcoma-associated herpesvirus (KSHV) also known as human herpesvirus 
8 (HHV-8) is the most recently discovered human herpesvirus and the only human 
rhadinovirus [1]. KSHV is the etiological agent of Kaposi’s sarcoma (KS), as well as the 
lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric 
Castleman’s disease (MCD) [2,3,4]. KSHV is consistently found in all clinical forms of KS, 
PEL, and MCD. Moreover, KS is the most common neoplasm in the HIV-positive population 
and is an AIDS-defining illness [5]. Although KS lesions most frequently develop on the 
external skin, they can also be found on internal organs and in the oral cavity. KS is a highly 
angiogenic complex lesion that is comprised of endothelial cell-derived spindle-shaped cells 
and inflammatory cells that have migrated to the lesion [6].  
Like all herpesviruses, KSHV exhibits two distinct phases in its lifecycle: a lytic 
phase and a latent phase. De novo infection of endothelial cells results in temporary lytic 
replication [7,8]. Lytic replication is characterized by the transcription of the entire 
complement of viral genes (immediate early, early, and late) in a temporal fashion. Viral 
replication and virion assembly is followed by the release of infectious progeny from the 
infected cell. In contrast, during latency, only a few viral proteins are expressed and the viral 
genome remains in an episomal state. Neither mode of existence is in itself capable of 
sustaining neoplastic growth, as each state seems to make distinct contributions that are 
necessary for the development of KSHV-associated malignancies [9]. Thus, lytic and latent 
proteins modulate the environment of the host cell to the advantage of the virus. The role of 
ubiquitination in KSHV replication, transformation or pathogenesis has been examined to 
some extent. During the lytic cycle, KSHV expresses three E3-like ubiquitin ligases 
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[10,11,12] encoded by open reading frames (Orfs) K3 (MIR 1), K5 (MIR2) and RTA 
(Orf50). Both K3 and K5 target MHC class I molecules for degradation in order to hinder 
presentation of viral antigens. The lytic switch protein, RTA, targets IRF-7 for degradation in 
order to preclude induction of the interferon-mediated antiviral state [12].  
Ubiquitin (Ub) is a 76-amino acid molecule that is widely conserved and can be post-
translationally conjugated to specific target proteins through different linkages. The host cell 
utilizes Ub to control cellular processes such as protein expression, apoptosis, cell cycle 
regulation, receptor trafficking, DNA repair, and signal transduction [13,14]. Moreover, 
antigen presentation of pathogen-derived proteins requires ubiquitin-mediated proteosomal 
processing [15]. The ubiquitin pathway consists of a single E1 protein that activates and 
transfers Ub to one of several conjugating enzymes known as the E2 adaptor proteins in an 
ATP-dependent fashion. The E2 protein subsequently engages an E3 ligase bound to a 
specific target protein. The Ub moiety is then covalently linked to the target protein through a 
lysine residue by the E3 ubiquitin ligases [16].  
Proteolysis, however, is not the only outcome of ubiquitination. Typically, poly-
ubiquitination through the lysine 48 residue of ubiquitin results in the degradation of the 
target protein, whereas mono- and di-ubiquitination through lysine 63 is associated with 
cellular transport or functional modulation of the target protein (reviewed in [17]). Poly-
ubiquitination has also been demonstrated to occur through other lysine residues of ubiquitin 
such as lysine 29, although these linkages do not appear to be frequently used [18]. In 
addition, mono-ubiquitination has been shown to be involved in endocytosis, histone 
regulation and retrovirus budding (reviewed in [19]). Thus, ubiquitin modification represents 
a regulatory mechanism for multiple functions in the cell.  
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Besides KSHV, other herpesviruses such as HSV-1 and MHV-68 also encode E3 
ubiquitin ligases [20,21]. In a parallel, but opposing fashion, herpesviruses have also pirated 
deubiquitinase enzymes. Deubiquitinase (DUB) proteins cleave Ub molecules from either the 
E3 ligase, or the target protein, thereby pre-empting ubiquitin-mediated regulation. DUBs 
have been identified in several herpesviruses [22]. The multifunctional, large tegument 
protein encoded by UL36 in Herpes Simplex virus-1 (HSV-1) and Pseudorabies virus (PRV) 
(α-subfamily) are DUBs, as is the homologous UL48 protein in human Cytomegalovirus (β-
subfamily) [23]. 
Although the targets and direct effects of the herpesviral deubiquitinases are not 
known, studies of HSV-1 mutants indicate that the HSV UL36 plays a role in virion transport 
through microtubules [24], release of the viral genome into the nucleus [25,26], 
tegumentation and envelopment [27] as well as virion egress [28]. DUB activity of HSV 
UL36 appears to be important as a DUB-null mutant displayed a 3-log decrease in titers and 
a 50% reduction of egressing capsids from neurons [29]. Null mutations for PRV UL36 are 
lethal in vitro [30] and delay neuroinvasion in the mouse model [31]. Moreover, specifically 
mutating the DUB catalytic domain reduces titer and plaque size [32]. Recently, it was 
shown that a DUB mutant of Marek’s disease virus was severely impaired in its ability to 
induce lymphomagenesis [33].  
We report the first description of a viral DUB encoded by KSHV Orf64. Not much is 
known about KSHV Orf64 except that it has recently been identified as a lytic protein that is 
present in the tegument of the virion, and appears to act as a scaffold protein during 
tegumentation [34]. We found that KSHV Orf64 encoded a powerful deubiquitinase activity 
as measured by in vitro deubiquitination assays. Additionally, KSHV Orf64 was also able to 
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deubiquitinate cellular proteins when expressed in various cell types. The DUB activity was 
limited to the N-terminal domain of KSHV Orf64 and unlike other herpesviral DUBs, which 
show specificity for K48 ubiquitin linkages [23,35], KSHV Orf64 appears to deubiquitinate 
both K48- and K63-linked ubiquitin chains. KSHV Orf64 also appeared to modulate RTA-
mediated transactivation of RTA-responsive promoters in reporter assays. We found that 
siRNA knockdown of KSHV Orf64 resulted in decreased reactivation from latency and 
decreased viral replication.  
MATERIALS AND METHODS 
Cell Culture: HeLa, CV-1 and HEK-293 cell lines were maintained in complete media: 
Dubelcco’s Modified Eagle Media (DMEM) (Cellgro) with 10% fetal bovine serum (FBS), 
L-glutamine, and penicillin plus streptomycin. The rKSHV.219-Vero [41] (a kind gift from 
Dr. Jeff Vieira) were maintained in complete media with 5µg/ml puromycin. KSHV-293 
cells were established by overlaying supernatants from reactivated rKSHV.219-Vero on 
naive 293 cells followed by puromycin selection at 1μg/ml. All cells were grown in a 37°C 
incubator, with 5% CO2. 
Plasmids: The N-terminus of Orf64 (Orf64N) was constructed by PCR amplification of the 
first 615 nucleotides of Orf64 with a C-terminal Flag epitope and cloned into the EcoRI and 
HindIII sites of the pcDEF3 vector with forward primer “cgccgcgaattcgacatggcagcccagcctct-
gtacatggaggg” and reverse primer “cgccgcaagctttcacttatcgtcgtcatccttgtagtcgtagtcatgtgggata-
aagtaaaggaagc”. The Orf64N fragment was also sub-cloned into pGEX6p-1 (Amersham) to 
construct a GST fusion of Orf64N (GST-Orf64N). Site-directed mutagenesis of Orf64N was 
conducted to change the cysteine residue at amino acid 29 to a glycine residue (C29G) 
generating the plasmid, Orf64N-C29G and GST-Orf64N-C29G. The full-length Orf64 (Orf64FL) 
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was PCR amplified and cloned into the pcDEF3 vector with a C-terminal Flag epitope using 
the enzymes EcoRI and Not I with primers “cgccgcgaattcgacatggcagcccagcctctgtacatggaggg” 
and “cgcgcggcggccgctcacttatcgtcgtcatccttgtagtccaagtaccact-tcttttaactgtcaacgc”, respectively. 
PCR products were digested with the appropriate enzymes and ligated into pcDEF3. Five 
microliters of the ligation reaction was transformed into Stbl2 (Invitrogen) bacteria. The 
bacteria were grown at 30°C overnight on LB plates with 50μg/ml ampicillin. Clones were 
screened by enzymatic digestion and sequencing.  
Luciferase Assay: Orf50, Pan (nut-1), glycoprotein B (gB), vGPCR and DNA-Binding 
protein (DBP) promoter-reporter constructs have been previously described [47,48,49]. 
Orf64FL or empty expression vector was cotransfected with β-Gal, the indicated promoter-
reporter constructs, and an RTA expression plasmid into HEK-293 cells. Forty-eight hours 
post-transfection, cells were washed in cold PBS and lysed with Reporter Lysis Buffer 
(Promega) for 5 minutes at room temperature. Cells were frozen and thawed once and 
centrifuged at 3500 rpm for 5 minutes. Samples were analyzed for luciferase activity with the 
luciferase assay system (Promega) and for β-Galactosidase with the Galacto-Star kit 
(Tropix). Luciferase activity was normalized to β-Gal and expressed as fold induction over 
empty vector. Luciferase assays were performed in triplicate and each experiment was 
repeated at least four times.  
GST-Orf64N protein purification: BL21 (DE3) cells were transformed with plasmids 
pGEX-6p-1 (control vector), pGEX-6p-Orf64N or pGEX-6p-Orf64N-C29G. The bacteria were 
then grown in 2XYT broth with 50μg/ml ampicillin and 34μg/ml chloramphenicol to an 
OD600 of 0.6 as per the manufacturer’s directions and induced with 1mM IPTG for two hours 
at room temperature. Cells were spun down, and resuspended in lysis buffer (200mM NaCl, 
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50mM Tris-HCl, 0.5mM EDTA, 5% Glycerol, 0.5% NP40 plus Complete protease inhibitor 
cocktail [Roche]) followed by sonication. Triton-X was added to the lysates to a final 
concentration of 1% and the samples were rocked for 30 minutes followed by centrifugation 
at 13,000 rpm for 10 minutes. Supernatants were transferred to new tubes and incubated with 
a 50% slurry of glutathione-sepharose beads in 1X PBS for one hour. The GST-tagged 
proteins were washed three times with 1X PBS and used for in vitro deubiquitination assays. 
In vitro deubiquitination (DUB) Assays: In vitro DUB assays were performed in DUB 
assay buffer containing 50mM Hepes, 0.01% Brij-35, and 3mM DTT [50]. Synthetic Lysine 
48 (K48) or Lysine 63 (K63) ubiquitin chains (Biomol) were added to purified GST-Orf64N 
purified protein or 40ng of purified Isopeptidase T (Biomol) (positive control), at 37°C for 3 
to 4 hours. The sample was subsequently loaded onto a 10% SDS denaturing gel, 
electrophoresed and transferred to nitrocellulose. Western blots were performed with an anti-
ubiquitin antibody (Sigma).  For the in vitro fluorescence DUB assays, the Ubiquitin C-
terminal 7-amido-4-methylcoumarin (Ub-AMC) substrate (Biomol) was added to GST-
Orf64N purified protein in AMC Buffer containing 50mM Hepes, 0.5mM EDTA, 1mM DTT 
and 0.1mg/ml BSA. The samples were then pre-treated or mock-treated with the suicide 
inhibitor ubiquitin aldehyde (Ub-Al) (Santa Cruz). After incubation at room temperature at 
the indicated times, fluorescence (excitation at 380nm, emission at 460nm) was measured 
using the Fluostar machine (BMG). 
In vivo deubiquitination assay: Deubiquitination assays were also performed in transfected 
cells. HeLa, HEK-293, CV-1 and rKSHV.219-Vero cells were transfected with 2µg WT-Ub, 
K48-Ub or K63-Ub expression plasmids (kind gift of Dr. Vishva Dixit [39]) and 8µg 
pcDEF3-Orf64N, pcDEF3-Orf64FL or empty vector pcDEF3. Forty-eight hours post-
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transfection, cells were lysed with NP40 lysis buffer and equal amounts of protein lysate was 
loaded into 10% SDS-PAGE gels for Western blot analysis with anti-HA-HRP antibody. 
Cell fractionation assay: 293 cells in 100mm plates were transfected with pcDEF3-Orf64N 
or empty vector, pcDEF3. Cells were harvested 48 hours later by trypsinization for 5 minutes 
at 37°C. Complete media was added to neutralize trypsin, followed by washing twice with 
cold PBS. The plasma membrane was disrupted with 500μl cytosolic lysis buffer [5mM 
PIPES, 85mM KCl and 0.5% NP40 with complete (Roche) protease inhibitors] and incubated 
on ice for 5 minutes. Nuclei were spun down and the cytosolic fraction was transferred to a 
fresh tube. The nuclei were washed three times with 1X PBS, then lysed in 250µl 
radioimmunoprecipitation (RIPA) buffer (150mM NaCl, 1% NP40, 50mM Tris [pH 6.8], 
0.5% sodium deoxycholate, 0.1% SDS with complete protease inhibitors (Roche)) and 
freeze/thawed three times. Cell debris was spun down and the supernatants quantitated by 
Bradford assay (Biorad). 
Western blot analysis: Cells in 100mm dishes were transfected using Superfect reagent 
(Qiagen). Cells were harvested 48 hours post-transfection, washed twice with PBS, and lysed 
with 400µl Nonidet P-40 buffer (150mM NaCl, 1% NP40, 50mM Tris [pH 6.8], with 
complete protease inhibitors (Roche)). Cell debris was spun down and the supernatant 
quantitated by Bradford assay (Biorad). Cell lysates were incubated with SDS gel loading 
buffer at 65°C for 5 minutes, and subjected to SDS-polyacrylamide gel electrophoresis. 
Electrophoresed gels were transferred to nitrocellulose membranes (Hybond, Amersham) by 
wet transfer (20V for 16 hours) and blocked in 5% non-fat dry milk (NFDM), 1% Tween-20 
Tris Buffered Saline (TBSt) for 30 minutes at room temperature. Flag-HRP antibody 
(Bethyl) was used at 1:10,000 dilution in 3% NFDM-TBSt. HA-HRP antibody (Sigma) was 
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used at 1:10,000 dilution in 1% BSA in TBS-T. Goat anti-actin antibody (Cell Signaling) was 
used as a control at 1:1,000 dilution and the secondary peroxidase-conjugated anti-goat 
antibody (Dako) was diluted to 1:2,000, both in 5% NFDM. Rabbit anti-ubiquitin (Sigma) 
was used at 1:250 and secondary anti-rabbit peroxidase antibody (Amersham) was diluted to 
1:10,000, both in 5% NFDM. GRP-78 antibody (Santa Cruz) was used at 1:500 dilution in 
5% NFDM. Anti-tubulin (Sigma) was diluted to 1:10,000 and the anti-mouse peroxidase-
conjugated secondary antibody (Cell Signaling) was used at 1:2,000, both in NFDM. 
Membranes were washed for 30 minutes with TBST and Western blots were incubated in 
SuperSignal Chemiluminescent substrate (Pierce). 
Viral reactivation and replication assay: KSHV-293 cells in 100mm plates were either 
mock induced with 1:1 serum-free DMEM:SF9 medium or induced with 1:1 serum-free 
DMEM:Bac50 in SF9 medium for one hour at 37°C. The inoculum was removed and 
replaced with complete medium in the mock-induced set, or complete medium with 1.7mM 
Sodium Butyrate in the induced set. Twenty-four hours post-induction, cells were transfected 
with siRNAs against luciferase (Luc) or siRNAs against Orf64 in duplicate. Both sets were 
incubated for 48 hours post-transfection, at which point the supernatants and cells were 
harvested. The cell sample was split into two fractions to isolate both RNA and protein. Total 
cell RNA extractions were performed with the RNeasy Plus Kit (Qiagen) according to 
manufacturer’s instructions followed by RNase-free DNase treatment at 37°C for 1 hour. An 
additional step to remove enzyme and digested DNA was performed with the RNeasy 
miniprep kit (Qiagen). One microgram total RNA was used in a reverse-transcription 
reaction (Promega). Each reaction volume was brought up to 120µl and used as template in 
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PCR reactions. For cell extracts, cells were lysed with NP40 lysis buffer as described above 
and Western blots were performed as described above with anti-vIL6 antibody (ABI). 
RESULTS 
Clustal alignment of KSHV Orf64 homologs in other herpesviruses. HSV-1 UL36 and 
EBV Orf BPLF-1 were aligned with KSHV Orf64 using the Clustal W sequence alignment 
tool. Figure 1 shows the first 500 amino acid (aa) residues of these homologs, which display 
a low degree of identity and similarity. Notably, several short, well-conserved motifs emerge. 
The cysteine, histidine, and aspartic acid residues in HSV-1 (amino acid positions 66, 197 
and 199) and KSHV Orf64 (amino acid positions 29, 159, and 161) are conserved. These 
three amino acids represent a catalytic triad that constitutes the catalytic core for 
deubiquitinase activity [36]. These residues are conserved in other human herpesvirus 
homologs as well [35], thus providing strong indication that these residues constitute the 
catalytic core of the DUB. 
Orf64 protein expression and intracellular localization. The full–length Orf64 (Orf64FL) 
and N-terminus fragment of Orf64 (Orf64N) encoding the first 205 amino acids were each 
tagged with the Flag epitope and cloned into the pcDEF3 [37] mammalian expression vector.  
In order to determine the molecular size of these proteins, the individual plasmids were 
transfected into HEK-293 cells. Forty-eight hours post- 
95 
 
 
 
Figure 1. Sequence analysis predicts a deubiquitinase in KSHV Orf64. Clustal W 
alignment of the amino terminal 500 amino acid residues of KSHV Orf64 and homologs 
from EBV (Orf BPLF1) and HSV-1 (UL36) reveal key conserved amino acids shown in red. 
Red arrows indicate components of the putative catalytic core of the cysteine protease. 
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transfection, cells were harvested and lysed, and subjected to Western blot analysis using a 
Flag-HRP antibody. As depicted in Fig. 2A, the N-terminus of Orf64 ran at a mobility of 
30kDa while the full-length Orf64 (Orf64FL) protein ran at a much higher mobility of 
approximately 300kDa. The predicted size for the full-length, 2636 amino acid protein is 279 
kD, which closely correlates with the observed size. 
 To determine the cellular localization of KSHV Orf64, we transfected the pcDEF3-
Orf64N and pcDEF3-Orf64FL expression plasmids into HEK-293 cells. Forty-eight hours 
post-transfection, cells were lysed and either separated into cytosolic and nuclear fractions, or 
harvested as whole cell lysates. As shown in Figure 2B and Figure 2C, the Flag-tagged 
Orf64N and Orf64FL proteins were detected in both nuclear and cytosolic fractions. The 
integrity of the cytosol-nuclear separation was confirmed by blotting for the ER cytoplasmic 
protein, GRP-78. The signal for GRP-78 was only detectable in the cytoplasmic fraction and 
the whole cell lysate validating the integrity of the fractionation. These results suggest that 
both the N-terminus and full-length Orf64 proteins may be found in the cytoplasm and 
nucleus of the cell. 
In vitro deubiquitination Assays. As shown in Figure 1, KSHV Orf64 appears to contain a 
conserved deubiquitinase domain. In order to determine whether the predicted catalytic core 
of the Orf64 DUB was functional, we sub-cloned the Orf64N fragment into pGEX6p-1 to 
fuse it to GST and express it in vitro. GST-Orf64N was expressed in BL21 bacteria and 
purified using a GST column to high purity (Fig. 3A). The GST-Orf64N protein was 
subsequently used in two different in vitro deubiquitinase assays.  
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Figure 2. Expression and intracellular localization of Orf64. A) HEK-293 cells were 
transiently transfected with expression vectors for Flag-tagged N-terminal Orf64 (Orf64N) 
and full length (Orf64FL). Cells were harvested and the lysates subjected to Western blot 
analysis with an anti-Flag antibody. Orf64N displayed a mobility of ~30kD and Orf64FL 
displayed a mobility of ~300kD. B) Transiently transfected cells expressing Orf64N were 
subjected to cellular fractionation. The N-terminus of Orf64 was present in both the 
cytoplasm and the nucleus. Expression of the cytoplasmic marker GRP-78 (lower panel) 
served as a control for the fractionation. C) Transiently transfected cells expressing Orf64FL 
were subjected to cellular fractionation. The full-length Orf64 protein is also detected in both 
cytoplasmic and nuclear compartments. Expression of the cytoplasmic marker GRP-78 
(lower panel) served as a control for the fractionation. 
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The first assay used a wild-type ubiquitin substrate. This assay involves the cleavage 
of the Ubiquitin-AMC substrate by a deubiquitinase to free a fluorophore capable of 
excitation and emission at 460nm. For this assay, wild-type GST-Orf64N or a mutant protein 
in which the cysteine at position 29 was mutated to a Glycine (GST-Orf64N-C29G) was 
incubated alone, in the presence of the Ubiquitin-AMC substrate, or with substrate and a 
DUB suicide inhibitor, ubiquitin aldehyde (Ub-Al). The samples were then assayed for 
fluorescence at a wavelength of 460nm. A graph of the fluorescence values obtained at 
different time points after treatment is shown in Figure 3B. There is a significant increase in 
fluorescence in the sample containing GST-Orf64N protein and Ubiquitin-AMC substrate as 
compared to GST-Orf64N without substrate, GST-Orf64N-C29G with Ubiquitin-AMC, or GST-
Orf64N /GST-Orf64N-C29G with Ubiquitin-AMC substrate and the Ub-Al suicide inhibitor 
(Fig. 3B). These data strongly demonstrate that the purified N-terminus of Orf64 is able to 
cleave synthetic Ub chains in vitro in the absence of other cellular proteins, and that the 
cysteine residue is critical for this activity. 
To confirm these findings, a second type of in vitro DUB assay was performed. We 
incubated synthetic, branched K48- or K63-Ub chains with either GST alone or the GST-
Orf64N fusion protein (Fig. 3C). The bonafide deubiquitinase, Isopeptidase T (IsoT) [38], 
was also used as a positive control in this assay. The samples were run on SDS-PAGE and a 
Western blot with an anti-ubiquitin antibody was performed. Lanes with Ub chains alone, or 
Ub chains plus GST protein displayed a laddered pattern corresponding to ubiquitin chains 
containing different numbers of ubiquitin linkages (Figure 3C).  The previously characterized 
deubiquitinase, IsoT, cleaved all the branched chains (either  
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Figure 3. The N-terminus of Orf64 encodes deubiquitinating (DUB) activity for both 
K48- and K63-linked ubiquitin chains in vitro. A) GST-Orf64N and GST-Orf64N-C29G 
(lanes 2 and 3) were expressed in BL21 (DE) cells with the control GST protein (lane 1). 
After purification, the proteins were electrophoresed by SDS-PAGE and the gel was stained 
with Coomasie blue dye. B) Purified GST-Orf64N protein was incubated with a wild-type 
ubiquitin fluorogenic substrate, AMC-Ub. Fluorescence generated from the cleaved AMC-
Ub substrate was recorded over time at 460nm.  Data from reactions including AMC-Ub with 
GST-Orf64N-C29G purified protein, GST-Orf64N plus ubiquitin aldehyde (Ub-Al), or Orf64 N-
C29G plus Ub-Al are also shown. C) Purified GST-Orf64N protein was used in another in vitro 
DUB assay with ubiquitin chains. Lysine 48 (K48)- and lysine 63 (K63)-linked chains are 
not cleaved by GST (lanes 1) or in the absence of GST-Orf64N (lane 4). Ub chains containing 
K48- and K63-linked ubiquitin moieties were completely cleaved by the positive control, 
IsopeptidaseT (IsoT, lane 5), as well as in the presence of Orf64N (lanes 2 and 3).  
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K48- or K63-linkages). Likewise, in the presence of the GST-Orf64N fusion protein, the 
K48- and K63-Ub chains were also completely cleaved (Fig. 3C). These results indicate that 
the N-terminus of Orf64 encodes DUB activity and can cleave both types of Ub linkages, at 
least as effectively as the IsoT positive control. 
In vivo deubiquitination Assays. We next determined whether full-length Orf64 (Orf64FL) 
functioned as a deubiquitinase in a cell-based assay. 2x106 HEK-293 cells were plated on 
100mm dishes and co-transfected with a plasmid encoding a HA-tagged ubiquitin named 
pcDNA3.1-3XHA-Ub (WT-Ub) [39], pcDEF3 empty vector, or pcDEF3-Orf64FL plasmids. 
Cells were harvested 48 hours post-transfection and subjected to Western blot analysis with 
an anti-HA antibody to detect all ubiquitinated cellular proteins. When pcDEF3-Orf64FL was 
co-transfected with the WT-Ub expression plasmid, there was very little accumulation of 
ubiquitinated cellular proteins compared to the control, suggesting that KSHV Orf64 FL can 
cleave ubiquitin moieties off cellular proteins (Fig. 4A). We also performed identical assays 
with Orf64N in HeLa, CV-1 cells and the KSHV-positive rKSHV.219-Vero cells, and found 
that Orf64N retained the deubiquitinating activity of Orf64 in all these cells lines, i.e. in the 
presence or absence of the viral genome (Fig. 4B). 
 In order to identify which ubiquitin linkage type is targeted by Orf64 in vivo, we co-
transfected Orf64FL or empty vector with HA-tagged WT-Ub, or a plasmid (K48-Ub) in 
which all lysines in ubiquitin were mutated except for lysine 48, or another plasmid (K63-
Ub)in which only lysine 63 was left intact. The latter two constructs produce ubiquitin chains 
that can only be polymerized through their K48 or K63 lysine residues, respectively. Cells 
were harvested forty-eight hours post-transfection and subjected to 
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Figure 4. Orf64 exerts DUB activity in vivo. A) Co-transfection of pcDEF3-Orf64FL and 
HA-tagged ubiquitin expression plasmids in HEK-293 cells. Cells were harvested 48 hours 
post-transfection and subjected to Western blot analysis with an anti-HA antibody. 
Expression of Orf64FL protein results in decreased levels of high molecular weight 
ubiquitinated cellular proteins as compared to the empty vector (pcDEF) control. Western 
blots for actin show equal loading of protein lysates and western blots with anti-Flag 
antibody show expression of the full-length Orf64 protein. B) Co-transfection of pcDEF3-
Orf64N and HA-tagged ubiquitin expression plasmids in HeLa, CV-1 and KSHV-positive 
rKSHV.219-Vero cells (KSHV-Vero). Cells were harvested 48 hours post-transfection and 
subjected to Western blot analysis with anti-HA antibody. Expression of Orf64N protein 
results in decreased levels of high molecular weight ubiquitinated proteins as compared to 
the empty vector (pcDEF) control.  Thus, the DUB activity is encoded within the N-terminal 
205 residues of Orf64. Western blots for actin show equal loading of protein lysates and 
western blots with an anti-Flag antibody show expression of Orf64N protein.  
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Western blot analysis with an anti-HA antibody to detect the presence of ubiquitinated 
proteins in the cell. We found that lysates from cells transfected with the different ubiquitin 
expression constructs and empty vector (pcDEF) showed accumulation of many 
ubiquitinated cellular proteins. However, full-length Orf64 (Orf64FL) exerted a significant 
deubiquitination effect on cellular proteins (Fig. 5A) and displayed a deubiquitinase 
preference (but not specificity) towards K48-mediated ubiquitin linkages. KSHV Orf64FL 
was able to deubiquitinate most of the K48-linked ubiquitinated proteins and a significant 
proportion of the K63-linked ubiquitinated proteins (Fig. 5A). 
 Next, we determined whether Orf64N displayed the same linkage-type specificity in 
vivo. Notably, both K48- and K63-linked ubiquitin chains were completely cleaved by 
Orf64N with no apparent preference in the HEK-293 transfected cells (Fig. 5B). We also 
transfected HEK-293 cells with WT-Ub and either the wild-type N-terminal Orf64 (Orf64N) 
or mutant N-terminal ubiquitin antibody to detect ubiquitinated proteins. We found that wild-
type Orf64N displayed deubiquitinase activity against cellular ubiquitinated proteins but that 
the mutant Orf64N-C29G protein, showed a loss of DUB activity compared to the wild type 
Orf64N protein (Fig. 5C). In addition, a full-length clone containing the C29G mutation 
(Orf64FL-C29G) also displayed inhibition of DUB activity compared to the wildtype full-length 
clone (Orf64FL) when introduced into cells expressing WT-Ub (Fig. 5D). These results 
indicate that the predicted N-terminal catalytic core of KSHV Orf64 is functional and the 
cysteine 29 residue is indeed required for the DUB activity of this protein.  
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Figure 5. Orf64 can effectively cleave both K48 and K63 ubiquitin linkages.  A) pcDEF3 or 
pcDEF3-Orf64FL expression plasmids were co-transfected with expression plasmids for WT-
Ub, K48-Ub, or K63-Ub. Cells were harvested 48 hours post-transfection and subjected to 
Western blot analysis with an anti-HA antibody. Orf64FL was able to deubiquitinate WT-, 
K48- and K63-linked ubiquitinated cellular proteins. Actin blots show equal loading of 
protein lysates and a Western blot with an anti-Flag antibody shows expression of Orf64FL 
protein. B) pcDEF3 or pcDEF3-Orf64N expression plasmids were co-transfected with 
expression plasmids for WT-Ub, K48-Ub, or K63-Ub. Cells were harvested 48 hours post-
transfection and subjected to Western blot analysis with an anti-HA antibody. The N-
terminal Orf64N protein was able to deubiquitinate WT-, K48- and K63-linked ubiquitinated 
cellular proteins. Western blots for actin show equal loading of protein lysates and a Western 
blot with an anti-Flag antibody shows expression of the Orf64N protein. show equal loading 
of protein lysates and a western blot with an anti-Flag antibody shows expression of both the 
Orf64N and Orf64N-C29G proteins. C) Co-transfection of pcDEF3, pcDEF3-Orf64N and 
pcDEF3-Orf64N-C29G with WT-Ub expression plasmids in HEK-293 cells. Cells were 
harvested 48 hours post-transfection and subjected to Western blot analysis with an anti-HA 
antibody. Orf64N can deubiquitinate cellular proteins but the deubiquitinase activity of 
Orf64N is ablated by the C29G mutation suggesting that this cysteine is essential for 
deubiquitination mediated by Orf64.  
 (Continued…) 
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D) Co-transfection of pcDEF3, pcDEF3-Orf64FL and pcDEF3-Orf64FL-C29G with WT-Ub 
expression plasmids in HEK-293 cells. 48 hours post-transfection lysates were blotted with 
an anti-HA antibody. Orf64FL can deubiquitinate cellular proteins but the deubiquitinase 
activity is dependent on the C29 residue as demonstrated by the C29G mutation suggesting 
that this cysteine is essential for deubiquitination mediated by Orf64. Western blots for actin 
show equal loading in all panels. 
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Thus, in summary, our data suggests that KSHV Orf64 is a potent deubiquitinase 
against ubiquitinated cellular proteins and that both K48- and K63-linked ubiquitinated 
proteins can be deubiquitinated by KSHV Orf64. Additionally, our data suggests that the first 
205 amino acids of KSHV Orf64 are sufficient for this activity.              
Effect of Orf64FL on KSHV lytic promoters. In an effort to functionally characterize 
KSHV Orf64 to a greater extent, and because this protein can localize to the nucleus (Figure 
2), we performed luciferase assays to identify any effects Orf64 may exert on lytic promoters 
of KSHV. HEK-293 cells were transfected with empty vector, pcDNA3-KSHV Orf50 
(RTA), pcDEF3-Orf64FL or both pcDNA3-KSHV Orf50 (RTA) and pcDEF3-Orf64FL 
plasmids in addition to individual lytic promoter-driven luciferase plasmids. The lytic 
promoters examined were vGPCR, glycoprotein B (gB) DNA-binding protein (DBP), RTA, 
LANA, and Orf57 as previously described [40]. The luciferase values were normalized to β-
galactosidase and expressed as fold induction over empty vector. As shown in Figure 6, 
full-length KSHV Orf64 does not directly affect transcription from viral lytic promoters. 
However, in the presence of KSHV RTA, Orf64 can enhance RTA-mediated induction of a 
subset of lytic promoters. For the gB, RTA, Orf57 and vGPCR promoters, Orf64 increased 
RTA transactivation approximately 2-3 fold over RTA levels, which were already in the 
range of 10- and 75-fold over empty vector (Fig. 6).  
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Figure 6. KSHV Orf64 can enhance RTA-mediated transcriptional activation of lytic 
promoters. Empty vector (pcDEF3), RTA, Orf64FL, or RTA plus Orf64FL expression 
constructs were cotransfected into HEK-293 cells with a ß-galactosidase expression plasmid 
and promoter-luciferase reporter plasmids in which the KSHV vGPCR, DBP, gB, RTA, 
LANA, and Orf57 lytic promoters drive expression of firefly luciferase. Forty eight hours 
post-transfection, promoter activity was determined by luciferase assay. Luciferase activities 
were normalized to ß-galactosidase and expressed as fold induction over empty plasmid. 
Each experiment was performed in triplicate and repeated at least four times.  
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Orf64 and lytic replication. Since Orf64 showed the capacity to enhance RTA-induced lytic 
promoter activation, we hypothesized that it may contribute to the early stages of the lytic 
replication cycle. In order to identify the contribution of Orf64 to the lytic cascade, we 
designed short interfering RNAs (siRNAs) targeting Orf64 for degradation via the RNA-
induced silencing complex (RISC). To test the specificity and effectiveness of the Orf64 
siRNA knockdown, we transfected HEK-293 cells with the pcDEF3-Orf64FL expression 
plasmid along with either an irrelevant siRNA directed against luciferase (LUC) or the 
Orf64-specific siRNA (Orf64FL siRNA) (Dharmacon). Figure 7A shows the extent and 
specificity of the Orf64-directed siRNA at knocking down Orf64FL protein levels as 
measured by a Western blot to detect the presence of Orf64. Using this Orf64 siRNA we 
were able to consistently achieve a robust knockdown of the exogenously expressed Orf64FL 
protein. Actin was used as a control and showed no difference in protein expression in all 
four lanes (Fig. 7A).  
 KSHV-infected latent 293 cells (KSHV-293) were made by infecting HEK-293 cells 
with the rKSHV.219 virus [41] and selecting with 1μg/ml puromycin. We subsequently 
induced the KSHV-293 cells into lytic reactivation by infecting with baculovirus encoding 
KSHV-Orf50 (Bac50) and 1.7mM sodium butyrate. A control mock induced sample was also 
included using media without Bac50 or sodium butyrate. Twenty-four hours post-induction, 
we transfected cells with either LUC- or Orf64-directed siRNAs. Cells were harvested for 
total RNA analysis as well as protein analysis at 48 hours post-transfection. The RNA was 
used in reverse-transcription (RT) reactions. The resulting cDNAs were then used as 
templates for PCR amplification with Orf64, Orf57 (early lytic gene) and GAPDH primers to 
measure viral transcript levels and  
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Figure 7. Knock-down of Orf64 affects transcription and protein expression of lytic genes. 
A) HEK-293 cells were transfected with pcDEF3-Orf64FL and either siRNA against Orf64 or 
siRNA against luciferase (LUC). Cells were harvested 48 hours post-transfection and 
subjected to Western blot analysis with an anti-Flag antibody to detect Orf64FL expression.  
Knockdown of exogenous Orf64FL in HEK-293 cells was observed when a siRNA specific to 
Orf64, but not luciferase (LUC siRNA), was co-transfected with the Orf64FL expression 
vector. An actin blot was performed to show equal loading of protein lysates. B) KSHV-293 
cells were induced (or mock-induced) into lytic replication with Bac50 and sodium butyrate, 
and 24h later transfected with siRNAs against Orf64 or luciferase (LUC). Total RNA was 
harvested 48h post-transfection and used in reverse-transcription PCR reactions. The upper 
panel shows knockdown of the Orf64 transcript while the middle panel shows a reduction in 
the levels of Orf57 transcript. A GAPDH amplification was also performed as a control 
(bottom panel). The reactions performed without reverse-transcriptase (-RT lanes), result in 
no detectable product demonstrating the absence of DNA contaminants in the RT-PCR 
reactions. C) Protein lysates from untreated, mock-induced, and induced cells were analyzed 
by Western blot for the levels of the KSHV lytic protein, vIL6. An actin blot was also 
performed to show equal loading of protein lysates. 
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determine levels of reactivation. As shown in Figure 7B, moderate knockdown of the 
endogenous Orf64 transcript resulted in decreased Orf57 transcription in the reactivated 
KSHV- 293 cells, while GAPDH transcript levels remained unchanged. This suggests that 
knockdown of Orf64 results in decreased lytic reactivation of KSHV.  
To confirm these findings, we also performed Western blot analysis with an anti-viral 
IL-6 (vIL6) antibody (Fig. 7C). We found that knockdown of Orf64 also resulted in 
decreased levels of vIL6, an early lytic protein, while cellular actin levels remained 
unchanged (Fig.7C).  
DISCUSSION 
Sequence alignments indicate that all known herpesviruses encode a large tegument protein 
which is often the largest open-reading frame in the whole genome. Studies on HSV-1, PRV 
and CMV have suggested several distinct roles for this herpesviral core protein. These roles 
include, but are not limited to, delivery of genomic DNA into the nucleus, egress from the 
nucleus, and scaffolding during tegument assembly [29,30,33]. One unifying role of the 
Orf64 homologs common to all herpesviruses studied thus far is the ubiquitin specific 
protease (USP) or deubiquitinase (DUB) activity encoded in the N-terminus of these 
proteins. This activity has been found to affect plaque size, titers, and neuroinvasiveness of 
PRV, but has been deemed non-essential in vivo for PRV, yet required in vitro [30,31]. In 
contrast, in the case of HSV-1, UL36 is indispensible for transport along microtubules. 
Despite these differences it is clear that UL36 homologs in the alpha herpesviruses play 
pivotal, if not required, roles in the lytic lifecycle. Furthermore, the targets for the herpesviral 
DUBs have not yet been identified. 
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We are the first to report the functional characterization of KSHV Orf64-encoded 
deubiquitinase. We found that the full-length Orf64 protein showed both nuclear and 
cytoplasmic localization indicating that Orf64 protein shuttles between both these cellular 
compartments. In two different sets of in vitro deubiquitinase assays, we found that a GST-
Orf64N fusion protein was efficiently able to cleave ubiquitin linkages and did not display 
preference for K63- or K48-linked ubiquitin chains. Furthermore, expression of both the N-
terminus and full-length Orf64 proteins in different cell types resulted in a marked reduction 
of high molecular weight ubiquitinated proteins, suggesting that Orf64 can deubiquitinate 
cellular proteins in vivo. Moreover, an N-terminal mutant Orf64 protein in which the putative 
cysteine catalytic residue was mutated to glycine (Orf64N-C29G) was devoid of DUB activity. 
In a similar fashion, a full-length Orf64 clone encoding the C29G mutation (Orf64FL-C29G) 
was also deficient in DUB activity compared to wild type full-length Orf64 (Orf64FL). The 
most likely explanation for the requirement of this single amino acid is that C29 is part of the 
catalytic core or catalytic triad that defines the cysteine protease active site as predicted by 
sequence analysis (Fig 1). In sum, our data suggest the following: First, KSHV Orf64 
encodes a robust deubiquitinase enzyme. Second, the DUB activity is encoded within the 
first N-terminal 205 residues. Third, the cysteine residue at position 29 is critical for DUB 
activity. Fourth, the KSHV Orf64 protein does not display marked specificity towards K48- 
or K63-linked ubiquitin chains, although the deubiquitination of K48-linked ubiquitin chains 
appears to be slightly favored. The ability of KSHV Orf64 to deubiquitinate both K48 and 
K63 linkages is unique, since all other herpesviral DUBs target K48 linkages specifically 
[36,42]. 
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The ability of KSHV Orf64 to enter the nucleus and its sequence homology with 
other herpesviral DUBs suggests a role in virion assembly and DNA packaging. 
Additionally, its presence in the nucleus suggested that it might affect viral transcription, 
although other herpesviral DUB homologs have not been tested for effects on transcriptional 
regulation. We performed promoter reporter assays and found no direct effect of Orf64 on 
lytic promoters. However, the Orf64-encoded protein was able to synergize with RTA/Orf50 
to increase the level of transcription from RTA-responsive promoters. The promoters for 
vGPCR, gB, RTA, and Orf57 showed increased activity in the presence of RTA and Orf64, 
compared to RTA alone. Glycoprotein B (gB) is a late protein which is present on the viral 
envelope and involved in viral entry [43]. Upregulation of this protein could enhance both 
the infectivity and amount of virions released. The vGPCR protein plays a role in promoting 
cellular proliferation and angiogenesis by inducing the release of vascular endothelial growth 
factor (VEGF) into the microenvironment [44]. Upregulation of transcripts for the RTA and 
Orf57 proteins, both of which can induce transcription from the RTA promoter [45,46], 
suggest a role for Orf64 in supporting lytic replication by positively regulating RTA, the lytic 
switch protein. Our data suggests that Orf64 could be synergizing with RTA to maintain the 
lytic state of replication. To our knowledge, this constitutes the first report of a herpesviral 
deubiquitinase exerting any effect on viral promoters. Furthermore, we found that siRNA 
knockdown of Orf64 in KSHV-infected 293s induced to enter the lytic cycle, resulted in 
decreased levels of Orf57 lytic transcripts as well as decreased expression of the lytic protein, 
vIL6. This suggests that Orf64 expression can enhance the KSHV lytic cycle, most likely 
through its deubiquitination function. 
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The identification of KSHV Orf64 as a robust deubiquitinase that can catalyze 
cleavage of both K48- and K63-linked ubiquitin sets it apart from all its known herpesviral 
homologs. Furthermore, the synergistic increase in lytic promoter activation indicates that 
Orf64 may play a novel role in enhancing lytic replication, distinct from its predicted roles in 
tegument and virion assembly. Moreover, Orf64 is present in the tegument of the incoming 
virion during de novo infection [34]. Thus, it is in a position to exert an effect on KSHV 
replication upon entry of the virus into the cell. This provides a window of opportunity 
whence Orf64 could help to modify the cellular environment in order to precipitate the onset 
of lytic replication, maximize its efficiency, or both. 
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ABSTRACT 
Ubiquitin-mediated regulation of cellular signaling pathways is emerging as a 
regulatory mechanism that rivals phosphorylation in its breadth and complexity. One 
signaling pathway known to be regulated by ubiquitination is the NF-κB pathway. Several 
reports implicate NF-κB signaling in both latency and lytic replication of KSHV-infected 
cells. We have recently described a deubiquitinase (DUB) encoded by KSHV Orf64. Given 
the potent deubiquitination potential of KSHV Orf64 and the requirement of ubiquitin 
regulation for NF-κB signaling, we asked whether Orf64 could deregulate NF-κB pathway 
signaling. KSHV Orf64 expression induced the degradation of IκB, an inhibitor of NF-κB 
signaling whose degradation triggers the activation of the pathway. In addition, lytic 
reactivation of KSHV-infected cells was also shown to reduce the levels of IκB, indicating 
that NF-κB signaling is activated upon lytic replication in endothelial cells. These results 
suggest that Orf64 may play a novel role in viral replication via the activation of NF-κB 
signaling. Because Orf64 is present in the incoming virion it is in a position where it could 
induce NF-κB activation before the onset of viral transcription, setting the stage for the 
successful establishment of viral infection. 
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INTRODUCTION 
As mentioned in the previous chapter, the Ubiquitin (Ub) system represents a protein 
regulatory mechanism of the cell. Ubiquitin is widely expressed and conserved. The ubiquitin 
molecule is post-translationally conjugated to specific target proteins to regulate their 
stability and function. Cells use Ub to manipulate a variety of cellular processes including 
protein expression, apoptosis, cell cycle regulation, receptor trafficking, DNA repair, and 
signal transduction and antigen presentation [1,2,3]. 
There is ample evidence that viruses have targeted the Ub system for subversion in 
order to forward the viral agendas of replication and survival. Herpesviruses in particular 
have usurped this mechanism by encoding Ub-regulatory molecules in their genomes. These 
include proteins that act as Ub conjugating molecules or E3 ligases as well as Ub-
deconjugating proteins or deubiquitinases (DUBs). The DUBs, in particular, are part of a set 
of genes that seem to have been encoded in herpesviral genomes for a long evolutionary time 
and are termed ‘core’ genes [4]. These genes have been shown to encode large, 
multifunctional tegument proteins decorating the viral capsid [5].  
As discussed in chapter 3, we have recently functionally described KSHV Orf64 as a 
robust deubiquitinase (DUB) as measured by in vitro as well as in vivo deubiquitination 
assays ([6], submitted). KSHV Orf64 encodes the DUB activity in the N-terminus and unlike 
other herpesviral DUBs, which show specificity for K48 ubiquitin linkages [7,8], KSHV 
Orf64 appears to deubiquitinate both K48- and K63-linked ubiquitin chains. Its ability to 
localize to both the nuclear and cytoplasmic compartments may be tied to another novel 
function of this DUB i.e. the capability to modulate transactivation of RTA-responsive 
promoters in reporter assays.  
129 
 
We also found that siRNA knockdown of KSHV Orf64 resulted in decreased 
reactivation from latency and decreased viral replication suggestive of an important role of 
Orf64 in replication. Moreover, the ability of KSHV Orf64 to deubiquitinate a wide array of 
cellular proteins provides the virus with a large number of potential DUB targets, including 
transcriptional activators, with previously unidentified effects on both viral replication and 
cellular signaling.  
Cellular responses to environmental stimuli are mediated by inducible transcription 
factors and are mediated to a significant extent through changes in gene expression. A key 
player in responding to environmental changes is nuclear factor (NF-κB), an evolutionarily 
conserved signaling molecule that plays a critical role in a variety of cellular processes. NF-
κB plays an important role in the immune system [9,10,11] but also regulates gene 
expression for other biological processes and can thus influence multiple aspects of both 
normal and disease states. 
There are five members in the NF-κB family, p50/p105 (NF-κB1), and p52/p100 
(NF-κB2), p65 (RelA), RelB, c-Rel. In resting cells they exist as cytoplasmic homo- or 
heterodimers. Proteins of the IκB (inhibitor of κB) family bind to NF-κB to form a complex 
that prevents NFκB translocation to the nucleus where it exerts its activity. NF-κB signaling 
is characterized as proceeding through either the classical or alternative pathway [9]. The 
classical or canonical pathway is activated by stimulation with pro-inflammatory cytokines, 
pathogenic stimuli or antigenic peptides. Stimulation of the classical pathway results in the 
activation of the β subunit of the IκB kinase (IKK) complex, which can phosphorylate IκB 
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proteins. The NF-kB p105 subunit is processed into p50 which can heterodimerize with RelA 
(p65) or form p50/p50 homodimers. 
In the alternative or non-canonical pathway, the α subunit (IKKα) is activated 
instead. IKKα can then phosphorylate p100. Phosphorylation of IκB proteins induces lysine 
48 (K48)-linked polyubiquitination by the Skp1–Cullin1– F-box (SCF)/-transducin repeat-
containing protein (TrCP) E3-ligase complex resulting in proteasomal processing by the 
proteosome. Ubiquitin/proteosome-mediated processing releases p50-, p65- and c-Rel-
containing heterodimers. The resulting subunits form NF-κB complexes which then 
translocate to the nucleus, where they bind to NF-κB-responsive sequences in the promoters 
of target genes to drive transcription (Fig. 1).  
The IκB family is made up of seven members: IκBα, IκBβ, IκBγ, IκBε, BCL-3, and 
precursor proteins p100 and p105. The degradation of IκB proteins is a tightly regulated 
process that starts with phosphorylation by the activated IKK complex. The large IKK 
(900kDa) complex has been shown to contain two kinase subunits, IKKα (IKK1) and IKKβ 
(IKK2), and a regulatory subunit, termed NEMO (NF-κB essential modifier) or IKKγ [12]. 
Several recent studies indicate that the Ub system may play a pivotal role during IKKs 
activation after tumor necrosis factor- (TNF-α), interleukin 1 (IL-1), lipo-polysaccharide 
(LPS) stimulation as well as antigen presentation. Indeed, IKKγ, considered the ‘molecular 
switch of NF-κB activation’, can be polyubiquitinated through lysine residues 399, 285, 277 
and 309 [13,14,15]. 
Purified IKK complex has been shown to require functional TRAF-6 (TNF receptor 
(TNFR)-associated factor 6), a lysine-63 (K63)-specific E3 ligase [16]. IL-1 receptor (IL-1R) 
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and Toll-like receptor (TLR) signaling are both dependent on TRAF-6 mediated, K63-linked 
polyubiquitination of IKKγ [17,18]. TRAF-2 can also catalyze K63-linked polyubiquitination 
of RIP (receptor-interacting protein) [19]. In TNF-α-stimulated cells RIP-1 is essential 
during receptor complex formation. Interestingly, a study with TRAF2/TRAF5 doubly 
deficient mice [20] showed a severe impairment in TNF receptor (TNFR)-induced NF-κB 
activation. This suggests that TRAF2 and TRAF5 function in TNF signaling in a similar 
fashion to TRAF6 during IL-1 activation.  
TGF-β-activated kinase 1 (TAK1) is recruited to TRAF6 on IL-1 signaling and 
activates the IKK/NFκ-B pathway [21]. TAK1-binding (TAB) proteins stimulate TAK1 
kinase activity by binding to it.TAB2 and TAB3 are the molecular receptors for K63-
modified substrates of TRAF2 and TRAF6 [18]. 
The K63-specific DUB CYLD was identified by screening for DUBs that would 
down-modulate NF-κB signaling and due to its association with IKKγ [22,23,24]. Mutations 
in the CYLD gene cause familial cylindromatosis, a rare autosomal-dominant disease. 
Patients who suffer from cylindromatosis develop benign tumors from the proliferative cell 
types of hair follicles or eccrine glands. Expression of CYLD is induced by NF-κB, exerting 
autoregulatory feedback loop that limits IKK activity [25]. CYLD interferes with IKK/NF-
κB signaling by selectively cleaving K63-linked Ub chains from TRAF2, TRAF6 and IKKγ, 
but not K48-linked Ub chains on IκB. CYLD can repress TNF and IL-1 -mediated NF-κB 
activation when overexpressed.  
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Figure 1. Diagram of the canonical and non-canonical NFκB signaling pathways and 
main components.  Several membrane receptors stimulate the canonical pathway via 
adaptors (e.g. TRAFs), which results in IKK complex activation. K63-linked, non-
degradative ubiquitination of TRAFs, RIP and NEMO/IKKγ, binding of ubiquitin chains by 
TABs define TABs or NEMO/IKKγ and phosphorylation of IKKα and β are required for 
IKK activation. Deubiquitinating enzymes (DUB) counter Ub-mediated regulation. The IKK 
complex phosphorylates IκBs and p105, which are modified with K48-linked Ub chains by 
SCFβTrCP and targeted to the proteosome. The result is heterodimers of p50 with p65, or p50 
homodimers. LTβ and BAFF can also trigger p100 processing by way of TRAFs, NIK kinase 
and IKKα-containing complexes. p100 is phophorylated, ubiquitinated and processed to p52. 
p52 heterodimerizes with RelB. The yellow circles represent K63-linked ubiquitin and the 
red circles denote K48-linked ubiquitin. (Taken from Scheidereit, 2006.)  
 
 
 
 
 
 
 
 respo
mech
chain
[19,2
ligase
degra
ident
Cezan
activa
 
pathw
with 
[29]. 
overe
κB ac
Addit
surfa
PEL c
infect
fibrob
that N
A20 is an
nses [26]. A
anisms. The
s from RIP 
7]. The C-te
 that can ca
dation [19,2
ified as two 
ne results i
tion. 
There are
ay activatio
Bay 11-7082
The same st
xpression o
tivation via
ionally, rep
ced [32] and
ells, contrar
ion was not
lasts are no
FκB is acti
other recent
20 has been
 N-terminal
and TRAF6
rminal cont
talyze the ub
7]. Recently
other potent
n downregu
 several con
n status. Ini
 (Bay-11) r
udy also fou
f p65. More
 interactions
orts of PEL 
 suggest tha
y to the afo
 ruled out in
t induced in
vated during
ly described
 shown to d
 domain of A
, blocking T
ains a zinc-f
iquitination
, Cezanne a
ial DUBs th
lation of NF
flicting repo
tially it was
esulted in in
nd that KSH
over, latentl
 with IKKγ
cells enterin
t NF- B act
rementioned
 this report.
to lytic reac
 lytic replic
134 
 DUB that in
ownregulate
20 encodes
NFR and TL
inger domai
 of RIP whi
nd TRAF-b
at may inter
-κB, indicat
rts on the ef
 reported tha
creased leve
V lytic pro
y infected ce
and [30,31]
g apoptosis 
ivity is nece
 reports. Ho
 Furthermor
tivation upo
ation in seve
terferes wit
 IKK activa
 DUB activ
R signaling
n that serve
ch directs it
inding doma
act with TR
ing that Cez
fects of KSH
t pharmaco
ls of lytic r
moter induc
lls express 
 activation o
upon treatm
ssary for sur
wever, apop
e, it has also
n inhibition 
ral cell type
h TNF-α-in
tion by two 
ity that can 
 to NF-κB, 
s as a K48-s
 towards pro
in (TRABI
AF6 [28]. O
anne may b
V infection
logical inhib
eactivation i
tion is inhib
v-FLIP whic
f the IKK co
ent with Ba
vival of KS
tosis due to
 been shown
of the NFκB
s tested [33
duced NF-κ
distinct 
cleave K63 
respectively
pecific Ub E
teasomal 
D) have bee
verexpressi
lock IKK 
 on the NF-
ition of NF
n PEL cells 
ited by 
h induces N
mplex. 
y-11 have a
HV-infected
 late stage v
 that human
 pathway a
]. 
B 
 
3 
n 
ng 
κB 
-κB 
F-
lso 
 
iral 
 
nd 
135 
 
These findings coupled with the dependence of the NF-κB pathway on Ub-mediated 
regulation led us to investigate whether KSHV ORF64 play a role in the regulation of NF-κB 
pathway activation on its own and during lytic reactivation. 
MATERIALS AND METHODS 
Cell Culture: HEK-293 cell lines were maintained in complete media: Dubelcco’s Modified 
Eagle Media (DMEM) (Cellgro) with 10% fetal bovine serum (FBS), L-glutamine, and 
penicillin plus streptomycin. KSHV-293 cells were established by overlaying supernatants 
from reactivated rKSHV.219-Vero on naive 293 cells followed by puromycin selection at 
1μg/ml. All cells were grown in a 37°C incubator, with 5% CO2. 
Induction of KSHV-293 cells (K293) was achieved by infecting with baculovirus 
encoding the Orf50 gene (RTA) of KSHV for one hour at 37°C. The inoculum was removed 
and replaced with complete medium in the mock-induced set, or complete medium with 
1.7mM Sodium Butyrate in the induced set. Seventy-two hours post-induction cell lysates 
were harvested as described below and subjected to western blot analysis. 
Western blot analysis: Cells in 100mm dishes were transfected using Superfect reagent 
(Qiagen). Cells were harvested 48 hours post-transfection, washed twice with PBS, and lysed 
with 400µl Nonidet P-40 buffer (150mM NaCl, 1% NP40, 50mM Tris [pH 6.8], with 
complete protease inhibitors (Roche)). Cell debris was spun down and the supernatant 
quantitated by Bradford assay (Biorad). Cell lysates were incubated with SDS gel loading 
buffer at 65°C for 5 minutes, and subjected to SDS-polyacrylamide gel electrophoresis. 
Electrophoresed gels were transferred to nitrocellulose membranes (Hybond, Amersham) by 
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wet transfer (20V for 16 hours) and blocked in 5% non-fat dry milk (NFDM), 1% Tween-20 
Tris Buffered Saline (TBSt) for 30 minutes at room temperature.  
Flag-HRP antibody (Bethyl) was used at 1:10,000 dilution in 3% NFDM-TBSt. HA-
HRP antibody (Sigma) was used at 1:10,000 dilution in 1% BSA in TBS-T. Goat anti-β-actin 
antibody (Cell Signaling) was used as a control at 1:1,000 dilution and the secondary 
peroxidase-conjugated anti-goat antibody (Dako) was diluted to 1:2,000, both in 5% NFDM. 
Rabbit anti-IKKγ, -IκBα, -NFκB-1, -RelB and -TRAF-6 (Cell Signaling) were used at 1:500 
and secondary anti-rabbit peroxidase antibody (Cell Signaling) was diluted to 1:2,000, both 
in 5% NFDM. Membranes were washed for 30 minutes with TBST and Western blots were 
incubated in SuperSignal Chemi-luminescent substrate (Pierce). 
 Immuno-precipitations were performed by pre-clearing protein lysates with 2.5ug 
normal mouse IgG and 50µl of a 50% AG bead:PBS slurry followed by incubation with in a 
nutator at 4ºC for 30 minutes. After spinning down pre-cleared lysates, 1µg monoclonal anti-
IκBα antibody (Cell Signaling) was added and incubated overnight at as before. Fifty 
microliters of a 50% AG bead:PBS slurry were added and incubated for another hour before 
washing with PBS thrice. After final spin down the beads were resuspended in 40µl load 
buffer and submitted to Western blot analysis as described above. 
 
RESULTS 
In order to identify the potential role of Orf64 in NFκB signaling we performed transient 
transfections of HEK-293 and stable KSHV-infected 293 cells (K293) with empty vector or a 
full-length clone of KSHV Orf64. Forty-eight hours post-transfection cell lysates were 
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harvested, pre-cleared and immune-precipitated (IP) with anti-IκBα antibody. The protein-
antibody conjugates in the IP reaction were pulled down with AG-beads and submitted to 
western blot analysis. We chose IκBα since it is poly-ubiquitinated (ref) and therefore a 
possible target for a DUB. IκBα plays a central role in the activation of the canonical NFκB 
pathway physically sequestering the nuclear factor in the cytoplasm where it is non-
functional. The originating lysate was also loaded as an input control for the expression of 
Flag-tagged Orf64. As shown in Figure 2, expression of Orf64 causes depletion of IκBα 
protein from the cell. This phenomenon was observed in both naive 293 and KSHV-infected 
293s.  
The degradation of a cellular protein by a recently described DUB seemed enigmatic 
since DUB activity generally correlates with protein stability. Thus, we decided to ask 
whether Orf64 had an effect on the signaling/regulatory molecules upstream of IκBα. We 
focused on the canonical pathway since it is induced by pro-inflammatory cytokines and 
pathogenic stimuli through tumor necrosis factor receptor (TNFR) and toll-like receptor 
(TLR) activation. HEK293 cells were transiently transfected for ectopic expression of Orf64 
or empty vector negative control. Lysates were loaded in replicates and subjected to Western 
blot analyses.  
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The previously observed IκBα degradation shown in Figure 2 was replicated. Our 
results, shown in Figure 3, indicate that in the presence of Orf64 the levels of multiple 
members of the NFκB signaling cascade were reduced. The reduction in total protein levels 
was marked for IκB and there was a small decrease in IKKγ and not much difference in 
TRAF-6 levels. TRAF-6 and IKKγ are both modified and indeed regulated through K48- and 
K63-linked ubiquitination, respectively. 
Since IκBα is being degraded, and because Orf64 is a lytic protein, these results led 
us to ask how the status of NFκB signaling changes during reactivation from latency in our 
KSHV-293 cell culture system. In order to address this question we plated and twenty-four 
hour later, induced KSHV-293 cells into lytic reactivation. Cells were incubated for 72 hours 
post infection to allow ample time for Orf64 expression. Lysates were harvested, total protein 
concentrations quantitated for equal loading and subjected to Western blot analysis.  
The resulting Western blots showed a specific increase in the level of NFκB-2 p100 
protein, suggesting that the NFκB-2 subunit is spared from degradation when compared to 
uninduced control. In contrast, a decreased amount of NFκB-1 p105 protein was present in 
the induced lane indicating the degradation of p105 and activation of the canonical NFκB 
pathway (Fig. 4). We also observed a modest decrease in the levels of IKKγ during lytic 
reactivation. A Western blot for the lytic protein v-IL6 was performed in order to verify the 
successful induction of the lytic state. 
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DISCUSSION 
 In light of the recent reports on the activation state of the NF-κB pathway during viral 
infection and the fact that several key members in this pathway are subject to ubiquitin 
regulation, we decided to test whether the Orf64 DUB of KSHV was involved in effective on 
both lysine 48 (K48) and lysine 63 (K63)-linked Ub chains expanding the list of potential 
targets of deubiquitination as compared to alpha- and beta-herpesviruses whose DUBs are 
limited to K48-linked Ub chains. 
For our initial approach we chose IκBα, a target of Ub-modification that also 
represents a junction where several pathway stimuli converge in the canonical pathway of 
NF-κB activation. The results from the immune-precipitation of IκB from Orf64-expressing 
cells indicate that Orf64 can somehow induce the degradation of IκB (Fig. 2). This effect 
would seem to be at odds with its DUB activity which could, in the context of K48-linked Ub 
chains, result in the stabilization of target proteins. IκBα is in fact ubiquitinated through K48 
linkages indicating that Orf64 does not act directly act on IκB but rather on a regulatory 
protein of IκBα that affects its stability, possibly a molecule working upstream in the 
signaling pathway. 
In order to better understand the effects of Orf64 expression on the NF-κB signaling 
pathway, we repeated the Orf64 vs empty vector transient transfection of HEK-293 cells. We 
then performed Western blot analyses on the protein lysates with an array of different 
antibodies specific for members of the NF-κB signaling pathway that lie upstream of IκBα. 
The resulting blots confirmed the degradation of IκBα in the presence of Orf64 and 
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identified IKKγ as an additional target of Orf64-induced degradation (Fig. 3). The degree of 
protein degradation was evident for IκBα and more modestly for IKKγ.  
The possible mechanism of Orf64-dependent decrease in IKKγ levels is intriguing. 
IKKγ, also termed NEMO, is known as the ‘molecular switch’ of NFκB activation due to its 
pivotal role in this pathway. Lysin 63-specific ubiquitination of IKKγ by TRAF-6 is required 
for activation of the IKK complex, which results in the phosphorylation and subsequent 
degradation of IκB allowing the p50/p65 heterodimer (or p50 homodimers) to move to the 
nucleus. TRAF-6 is an adaptor protein which translates stimuli from membrane receptors 
into IKK complex activation through its E3 ligase activity. This adaptor is a lysine-63 (K63)-
specific E3 ligase which can also be ubiquitinated via K48 linkages which allow for its 
regulation via proteosome-mediated degradation. The K48-ubiquitination of TRAF-6 can be 
reversed by the cellular DUB A20. A20 inactivates TRAF6 though its DUB activity but has 
not been implicated in regulating its stability [27]. CYLD is another cellular DUB that can 
deubiquitinate and thus inactivate TRAF-6 and IKKγ. Thus, Orf64 deubiquitination of IKKγ 
would have functional effects but should not interfere with its stability. 
Several groups have reported the activation of NF-κB signaling during various stages 
of infection (lytic and latent) [33,34,35,36]. Since Orf64 is expressed in the lytic cycle (see 
chapter 3, Fig. 7) we decided to test whether induction of lytic reactivation in KSHV-293 
cells resulted in activation of this pathway.   
KSHV-293 cells were plated and induced with baculovirus encoding the lytic switch 
RTA protein and incubated for one hour. After incubation the inoculum was replaced with 
complete media containing 1.7mM sodium butyrate. Seventy-two hours post induction cell 
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lysates were harvested for Western blot analysis. An antibody to the KSHV lytic protein v-
IL6 was used to ensure that the lytic cycle had been induced. We then probed membranes 
with antibodies to NF-κB-1 and NF-κB-2 in order to verify our data in Fig. 3. As predicted, 
the NF-κB-2 Western blot did not show an increase in degradation of the p100 subunit, 
whereas the NF-κB-1 blot showed a decrease in the levels of the p105 subunit. These results 
confirm that lytic reactivation in latently infected KSHV-293 induces activation of the 
canonical NF-κB pathway. IKKγ was marginally reduced (Fig. 3) in this context. The 
degradation of NF-κB -1 p105 subunit is mediated by K48-linked poly-ubiquitination. Upon 
phosphorylation by the IKK complex, IκBs and p105 are ubiquitinated with K48-linked 
chains by SCFβTrCP resulting in their proteosome-mediated degradation. 
One possibility is that Orf64 could be stabilizing the ubiquitin-conjugating enzymes 
responsible for the degradation of the NFκB p105 subunit. Another possibility is that Orf64 
could be inducing the degradation of an inhibitor of p105 processing. 
These results argue for an effect of Orf64 on the canonical NF-κB pathway and 
possibly its activation. Ectopic expression of Orf64 in the absence of the viral genome is 
sufficient for the degradation of IκBα. The ubiquitin-mediated degradation of this central 
member of NFκB signaling is required for activation. In addition, an IκBα mutant with 
ablated IKK phosphorylation sites (IκB super-repressor, IκBSR) has been reported that is 
refractory to degradation by the proteasome, resulting in blocked NFκB signaling and 
highlighting the key role if NFκB in this pathway. The immediate effects of IκBα 
degradation are well understood. However, the result of IKKγ down-modulation by Orf64 is 
less clear and will require further study.  
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The identification of signal modulating capabilities encoded by Orf64, adds to the 
body of functions of this multifunctional protein. There are a number of predicted roles in 
microtubule transport and delivery of DNA into the nucleus based on sequence homology to 
other herpesviral DUBs. However, KSHV Orf64 has only been reported to be involved in 
tegument assembly [5]. We have shown that Orf64 encodes DUB activity capable of cleaving 
both K48- and K63-linked Ub chains. Moreover, Orf64 can also synergize with RTA (Orf50) 
to increase transcription of lytic promoters. Lastly, we have shown here that Orf64 can also 
target IκBα for degradation and may additionally de-stabilize IKKγ, an upstream component 
of the canonical NFκB pathway (Fig. 4). These studies have identified a number of possible 
targets of Orf64 including IKKγ and IκBα. It is not yet clear that the DUB function is pivotal 
in this respect, however, the high degree of ubiquitin-mediated regulation in this pathway 
make this a likely scenario. Future goals will be to determine if the DUB function of Orf64 
plays a role in this pathway. 
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General conclusions 
Herpesviruses tend to co-speciate with their hosts. This makes infection of other 
species more difficult but, conversely, translates to a high degree of viral adaptation to the 
host. This phenomenon is evidenced by the predominantly asymptomatic infection of humans 
with most of the herpesviruses. A case could be made that a balance has been reached where 
the virus persists and the host is spared significant viral-induced pathogenesis. This dormant 
or ‘latent’ state of infection is a defining feature of herpesviruses. Only sparingly will HSV-
1, or HCMV reactivate from latency and cause a short-lived disease episode in the 
immunocompetent host. Lytic reactivation triggers the activation of the host immune system 
and controls viral replication by killing infected cells bearing viral antigens. 
The most recently discovered human herpesvirus, the Kaposi’s Sarcoma-associated 
Herpesvirus (KSHV or HHV8) (10) is also predominantly latent in the host and it has been 
identified as the etiological agent of a number of malignancies. KS, PEL and MCD are 
etiologically associated with KSHV (9, 29)and are most aggressive in the context of the 
immune-compromised host (17). A primary example is provided by the exponentially 
increased incidence of KS concordant with the nascent AIDS epidemic in the early 1980s (3). 
In these cases, the balance between the infectious agent and the host is perturbed by the onset 
of immune-suppression. The HIV virus targets, replicates in, and kills most of the host T 
cells resulting in immune-suppression and the development of AIDS. At this time the host 
immune system is unable to control herpesviral replication and associated pathologies. 
Latency is characterized by expression of a very limited set of genes that assist in 
episome maintenance. The latency associated nuclear antigen (LANA) tethers the viral 
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episome to the host chromosomes (11). This ensures that the episome is replicated by the 
host machinery and passed to daughter cells during mitosis. The latent state however, does 
not last indefinitely. Environmental stimuli like hypoxia can trigger the lytic phase of 
replication (12). Hypoxia induces expression of the hypoxia-inducible factor 1α (HIF-1α) 
(33). HIF-1α can bind the promoter for the lytic switch protein encoded by Orf50 and induce 
its transcription (8). The replication and transcription activator (RTA) encoded by Orf50 is 
known to be necessary and sufficient for entry into lytic replication (24, 32, 36). The highly-
ordered series of events that result in lytic replication begins with immediate early genes like 
RTA transactivating promoters for early genes. These initial steps require the establishment 
of self-sustaining positive feedback loops that amplify a starting signal into a cell-wide, 
coordinated virus production effort. One example of such a feedback loop is the induction of 
Orf57 by RTA. RTA can induce Orf57 transcription resulting in an increase in Orf57 levels 
(23). Orf57, in turn, can bind RTA and induce expression from the Orf50 promoter 
enhancing Orf50 expression and lytic reactivation (26).  
This example also illustrates the focus of this dissertation. We have examined 
additional herpesviral proteins that play important roles supporting RTA in its functions. We 
have identified two such proteins encoded by KSHV. The first protein we described is 
encoded by a gene in the lytic switch locus which also contains RTA and K8. The RTA 
transcript undergoes a splicing event that excludes a sequence of 1kb from the mature RNA 
(16). It is this sequence in the complementary strand that encodes Orf49. Because of its 
location in the Orf50 locus we hypothesized that Orf49 could be a previously undescribed 
member of the lytic cascade. The ends of the Orf49 transcript were identified by 5’ and 3’ 
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RACE and revealed it to be unspliced with over 900 bases of coding sequence, a 5’ UTR and 
a polyA tail. As expected, the Orf49 transcript was highly induced early during lytic 
replication peaking 36hrs post-induction and maintained at high levels for the duration of 
treatment. Northern blots for Orf49 identified a lytic, 1.2kb transcript that closely matched 
our full-length cDNA clone. 
Transient expression of an Orf49 clone into cells resulted in a protein of ~30 
kilodaltons capable of translocating to the nucleus. We showed this by both immuno-
fluorescence assays and cell fractionations followed by Western blot. This finding led us to 
ask whether the nuclear localization of Orf49 was tied to a potential transcriptional activation 
function. In order to test this hypothesis we performed viral promoter reporter assays. Orf49 
proved to be unable to transactivate promoters on its own. However, when combined with 
Orf50 we observed a synergestic increase in Orf50-mediated transcriptional activation (16). 
The K8, Orf57 and vGPCR promoters were induced several fold over Orf50-mediated 
induction levels which ranged from 50-fold for Orf57 to 350-fold for vGPCR over that of 
empty vector. The K8 or K-bZIP gene product is required for lytic replication since it binds 
the OriLyt (13). As discussed above, Orf57 transcription is induced by Orf50 and vice versa 
in a positive feedback loop. Thus, an increase in Orf57 transcription would translate into 
higher levels of Orf50. vGPCR, a constitutively-active G protein-coupled receptor has been 
implicated in transformation and the angiogenec process via its induction of vascular 
endothelial growth factor (VEGF)  (1, 37). The strong activation of Orf57, vGPCR and K8 
promoters suggest that synergy of Orf49 with Orf50 may result in the increased efficiency of 
lytic reactivation. Because Orf49 was unable to single-handedly induce promoters we 
hypothesized that it could instead activate a cellular transcription factor. In order to identify 
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the mechanism of action of the cooperative promoter activation we tested a panel of 
transcription factor reporter plasmids for activation in the presence of Orf49. We found that 
the c-Jun transcription factor was activated by Orf49 while ATF1, ATF2 and CREB were 
not. The induced viral promoters all share AP-1 sites in addition to RTA-responsive elements 
(RREs) that would respond to c-Jun activation.  
Increased phosphorylated c-Jun, JNK and p38 levels were observed upon ectopic 
expression of Orf49. Orf50 has been shown to increase the levels of total c-Jun in DG75 
cells, however it does not induce phosphorylation of c-Jun (34). Together these results 
suggest a mechanism though which Orf50 increases total c-Jun protein, and Orf49 induces 
phosphorylation and activation of c-Jun thus increasing c-Jun transcriptional activation 
potential in the cell. 
Cellular stress, growth factors and cytokines all activate JNK and p38 pathways. They 
share pathway components like the mitogen activated protein kinase kinase kinase 
(MAP3Ks), and MAP2K (mitogen activated protein kinase kinase) MKK4, and are often co-
activated (38). These pathways mediate proliferation, differentiation or apoptosis while p38 
activation is also involved in development, and inflammation. KSHV vGPCR expression can 
also activate JNK and p38 (14). The activation of a signaling pathway by more than one viral 
Orfs highlights the significance of these pathways to viral replication.  
We then set out to assess the involvement of these pathways in lytic reactivation. 
Pharmacological inhibitors of both JNK and p38 blocked TPA-induced expression of early 
genes like vGPCR and Orf57 and the late structural gene Orf62/mCP. These data indicate 
that signaling through both pathways is required for efficient lytic replication.  
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Taken together our data suggest that Orf49 can induce the activation of the JNK and 
p38 pathways in order to enhance transcription from key Orf50-responsive promoters. 
Furthermore, we showed that the activation of the JNK/p38 kinase pathways is essential for 
KSHV viral replication. 
The second gene we have described is that encoded by KSHV Orf64. This Orf is a 
core herpesviral gene present in all herpesviruses. It is usually the largest ORF of the 
herpesviral genome and encodes a tegument protein. Various roles of this protein have been 
reported for HSV-1, PRV and CMV, among them delivery of genomic DNA into the 
nucleus, egress from the nucleus, and scaffolding during tegument assembly (5, 22, 25). One 
function shared by all Orf64 homologs studied thus far is deubiquitinase (DUB) or ubiquitin-
specific protease (USP) activity. The DUB domain is usually encoded in the N-terminal ~300 
residues.  
DUB activity affects plaque size, titers, and neuroinvasiveness of PRV with 
mutations exerting different consequences in vitro and in vivo (6, 25). The HSV-1 homolog 
termed UL36, is essential for microtubule transport to and from the nucleus. These data 
suggest that UL36 homologs play important roles in the lytic replication cycle.  
It is intriguing that the actual targets of the DUB activity for most herpesviruses have 
not been identified. In a recent report, Whitehurst et al (35) described the identification of 
ribonucleotide reductase as the first known target of the EBV-encoded DUB termed BPLF-1. 
In our study of KSHV Orf64 protein, we found that it was present in both nuclear and 
cytoplasmic compartments. Using in vitro deubiquitinase assays, we were able to show that a 
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GST-Orf64N fusion protein was capable of cleaving K63- and K48-linked ubiquitin chains. 
In cell culture, expression of the N-terminus and full-length Orf64 proteins potently reduced 
the amounts of ubiquitinated proteins, suggesting that Orf64 can deubiquitinate cellular 
proteins in vivo and that this activity is encoded within the N-terminal 200 amino acids.  
We then mutated the cysteine 29 residue, a part of the predicted catalytic core of the 
DUB, in order to functionally identify the source of DUB activity. The resulting N-terminal 
mutant Orf64 protein (Orf64N-C29G) was devoid of DUB activity both in vitro and in vivo. 
From this we conclude that C29 is part of the catalytic core or catalytic triad that defines the 
cysteine protease active site as predicted by sequence analysis.  
KSHV Orf64 localized the nucleus, which is expected given the behavior of its 
homologs and their roles in virion assembly and DNA packaging. However, given the 
growing amount of evidence implicating ubiquitination (both destructive and non-
destructive) in controlling signaling pathways and transcription factors, we decided to test 
Orf64 for transcriptional regulatory effects. Herpesviral DUB homologs so far have not been 
shown to affect transcriptional regulation. We performed promoter reporter assays and found 
no direct effect of Orf64 on lytic promoters. Although not an effective inducer on its own, 
Orf64 boosted RTA/Orf50 levels of transcriptional activation several lytic promoters. 
vGPCR, gB, RTA, and Orf57 promoters were induced more strongly when co-transfected 
with both RTA and Orf64 versus RTA alone.  
Upregulation of Glycoprotein B (gB) which helps mediate entry could enhance both 
the infectivity and amount of virions released (15). As discussed above, the vGPCR protein 
promotes proliferation and angiogenesis by inducing the release of VEGF into the 
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microenvironment (2). The RTA and Orf57 proteins can both induce transcription from the 
RTA promoter (13, 28), suggesting that Orf64 may support lytic replication by inducing 
RTA expression.  
In order to test the significance of Orf64-induced, Orf50 upregulation we knocked-
down Orf64 expression by transfection of double stranded short-interfering RNAs (siRNAs). 
siRNA knockdown of Orf64 in KSHV-infected 293s induced into lytic replication resulted 
down-regulation of Orf57 lytic transcripts and reduced levels of the lytic protein, vIL6. These 
data suggest that Orf64 expression can enhance the KSHV lytic cycle, most likely through its 
induction of lytic gene expression including Orf50. It is unclear at this juncture if 
deubiquitination activity is required for this particular effect. 
The ability of KSHV Orf64 to catalyze cleavage of both K48- and K63-linked 
ubiquitin sets it apart from all its known alpha- and beta- herpesviral homologs. The 
upregulation of RTA-mediated lytic promoter activation suggests that Orf64 may play a 
novel role in enhancing lytic replication, in addition to roles in tegument and virion assembly 
predicted by homology. The Orf64 protein is contained in the tegument of the incoming 
virion during de novo infection (30) raising the possibility that it may be active upon entry. In 
this context, Orf64 is poised to modify the cellular environment to favor efficient viral 
replication before the onset of viral transcription and genome replication. 
Recently, reports have emerged implicating ubiquitin as a modulator of the NF-κB 
pathway. In addition, the activation state of the NF-κB pathway during KSHV infection has 
been called into question by conflicting reports involving cells of different lineages (18, 21). 
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Since several key members in the NF-κB pathway are subject to ubiquitin regulation, we 
asked if Orf64 affects the NF-κB signaling pathway.  
We chose the ubiquitination target IκBα as a starting point, convergence point for 
several pathway signals in the canonical arm of NF-κB pathway activation. During ectopic 
expression, Orf64-expressing cells showed degradation of IκB. This was contradictory to its 
DUB activity, which we predicted would result in stabilization of IκBα since it is the subject 
of K48-linked ubiquitination. This suggests that Orf64 DUB does not act directly on IκBα 
but instead may stabilize an IκBα regulatory protein operating upstream in the pathway. 
We also identified IKKγ or NEMO as an additional target of Orf64-induced 
degradation. IKKγ is referred to as the ‘molecular switch of NFκB activation’ because it 
plays a central role in the pathway. TRAF-6 ubiquitinates IKKγ through K63 linkages, which 
is required for activation of the IKK complex. Activation results in the phosphorylation and 
degradation of IκBα, freeing NF-κB dimeric subunits to translocate to the nucleus. The 
TRAF-6 adaptor molecule is a K63-specific E3 ligase that is also subject to K48-linked 
ubiquitination and degradation. Ubiquitinated TRAF-6 is a substrate of the cellular DUB 
A20. A20 deubiquitination of TRAF-6 inhibits its activity (4). TRAF-6 and IKKγ are also 
substrates of CYLD, a cellular DUB that can deubiquitinate and inactivate both.  
NF-κB signaling during lytic and latent stages of infection has been reported (18, 22). 
Because Orf64 is a lytic protein we asked whether lytic reactivation in KSHV-infected 293 
cells resulted in activation of this pathway. Our results indicate that lytic reactivation of 
latently infected KSHV-293 induces activation of the canonical NF-κB pathway since the 
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levels of the p105 (NF-κB-1) subunit were decreased. IKKγ levels were also reduced but to a 
lesser extent. NF-κB-1 p105 subunit degradation is K48-linked poly-ubiquitination 
dependent. The IKK complex phosphorylates IκBs and p105, which are then K48-
ubiquitinated by SCFβTrCP. This targets both proteins for processing by the proteosome. 
Orf64 could thus act to stabilize ubiquitin E3 ligases like SCFβTrCP which mediate the 
degradation of the NFκB p105 subunit by K48-mediated deubiquitination of these proteins. 
Alternatively, Orf64 may interfere with the activation of inhibitors of p105 processing by 
K48-mediated deubiquitination of these proteins.  
Our results suggest that Orf64 plays a role in activation of the canonical NF-κB 
pathway since expression of Orf64 results in the degradation of IκBα. This particular 
member of the NFκB pathway lies at a bottle neck where several different stimuli converge 
on IκBα to be either allowed to proceed or negated. A IκBα mutant with ablated ability to 
phosphorylate, and thus activate (IκB super-repressor, IκBSR) has been reported to block 
NFκB signaling (19). This mutant protein highlights the key role of IκBα in NFκB signaling. 
The Orf64-mediated down-modulation of IKKγ is intriguing and will require further study.  
NF-kB is activated during infection of HUVECs and blocking this activation results 
in cytotoxicity (18). EBV and KSHV positive B-cell lines are mainly latent and also have 
active NF-κB signaling (7, 20, 21, 39). These cells apoptose upon pharmacological inhibition 
of NF-κB, suggesting that this pathway is important in maintaining latency. Orf64 is present 
in the incoming virion during de novo infection and could initiate NF-κB activation before 
viral gene expression. This could enhance the avoidance of cytotoxicity by the action of pro-
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survival products of NF-κB and lytic replication by induction of viral promoters. In fact, 
KSHV vGPCR is a strong activator of the NF-κB pathway (27, 31) indicating that Orf64 may 
be able to induce NF-κB signaling by two routes; degradation of IκB and lytic promoter 
transactivation. 
The sum of the data presented here demonstrated that there are viral proteins that 
support the role of KSHV RTA during lytic replication by different mechanisms. In our 
studies we found two examples of this phenomenon. First, the early lytic protein encoded by 
Orf49 was shown to act as an activator of the JNK and p38 signaling pathways. We 
subsequently showed that activation of these pathways is crucial for effective lytic replication 
and virion production.  
A second example is the activation of the NFκB pathway by Orf64. The exact 
mechanism for NF-kB activation is not yet clear but it is reproducible. As discussed in 
chapter 3, proteosomal degradation is not the only outcome of ubiquitination. Functional 
regulation of proteins is widespread and K63-mediated regulation is of particular importance 
in the NFκB pathway. Thus, there is a large pool of potential targets of Orf64-mediated 
deubiquitination. Moreover, since Orf64 is present in the incoming virion it is possible that it 
could activate NF-κB signaling upon entry. Orf64 could also activate signaling during the 
late lytic phase where it is expressed (Fig. 1). 
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Figure 1. Model of signaling pathway induction by KSHV Orf49 and Orf64. Orf49 
activates JNK and the c-Jun transcription factor to induce transcription of both cellular and 
viral genes. JNK signaling activation is essential for the completion of the lytic cycle. Orf64 
targets IκBα and perhaps IKKγ for degradation inducing the activation of the canonical NF-
κB pathway. 
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The work discussed in this thesis documents the contributions of two previously 
undescribed KSHV proteins to RTA-mediated induction of lytic replication. We believe 
more examples of viral modulators of the RTA protein will emerge and further delineate the 
mechanisms through which RTA achieves the efficient induction of the lytic cycle. 
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